

1 IN THE UNITED STATES DISTRICT COURT
2 FOR THE NORTHERN DISTRICT OF OHIO
3 EASTERN DIVISION

4 IN RE NATIONAL PRESCRIPTION
5 OPIATE LITIGATION Hon. Dan A. Polster
6 THIS DOCUMENT APPLIES TO ALL MDL No. 2804
7 CASES No. 17-MD-2804

8 _____/

9 HIGHLY CONFIDENTIAL -
10 SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

11 -- -- --

12 THURSDAY, JANUARY 10, 2019

13 -- -- --

14 Videotaped Deposition of DONALD WALKER, held
15 at the Law Offices of COVINGTON & BURLING, One Front
16 Street, 35th Floor, San Francisco, California,
17 beginning at 8:57 a.m., before Sandra Bunch
18 VanderPol, FAPR, RMR, CRR, CALIFORNIA CSR #3032

19 -- -- --

20
21
22 _____
23 GOLKOW LITIGATION SERVICES
24 877.370.3377 ph | 917.591.5672 fax
25 Deps@golkow.com

APPEARANCES

ERIC KENNEDY, ESQ.
WEISMAN, KENNEDY & BERRIS CO., L.P.A.
101 W. Prospect Avenue
Midland Building, Suite 1600
Cleveland, OH 44115
(216) 781-1111
Counsel for the Plaintiffs

EMILY JOHNSON HENN, ESQ.
EMILY KVESELIS, ESQ.
COVINGTON & BURLING LLP
3000 El Camino Real
5 Palo Alto Square
Palo Alto, California 94306-2112
(650) 632-4715
ehenn@cov.com
ekveselis@cov.com
Counsel for Defendant McKesson and the
Witness

ABIGAIL G. URQUHART, ESQ.
JONES DAY
555 South Flower Street, 50th Floor
Los Angeles, CA 90071
(213) 243-2884
urquhart@jonesday.com
Counsel for Defendant Walmart

JOSEPH BUSHAR, ESQ. (Telephone/streaming)
WILLIAMS & CONNOLLY, LLP
725 Twelfth Street, N.W.
Washington, DC 20005
(650) 632-4715
jrbushar@wc.com
Counsel for Defendant Cardinal Health

(Appearances continued on next page)

1 APPEARANCES (Continued)

2 SAMANTHA L. ROCCHINO, ESQ.
3 REED SMITH LLP (Telephone/Streaming)
4 Three Logan Square
5 1717 Arch Street, Suite 3100
6 Philadelphia, Pennsylvania 19103
7 (215) 851 8100
8 srocchino@reedsmith.com
9 Counsel for Defendant AmerisourceBergen

10 SCOTT LIVINGSTON, ESQ.
11 MARCUS & SHAPIRA LLP
12 One Oxford Centre, 35th Floor
13 Pittsburgh, Pennsylvania 15219
14 (412) 338-4690
15 livingston@marcus-shapira.com
16 Counsel for Defendant HBC Company

17 ERIC SHAPLAND, ESQ. (Telephone)
18 ARNOLD & PORTER KAYE SCHOLER, LLP
19 44th Floor, 777 South Figueroa Street
20 Los Angeles, California 90017-5844
21 (213) 243-4120
22 eric.Shapland@arnoldporter.com
23 Counsel for Defendants Endo Pharmaceuticals,
24 Inc. and Endo Health Solutions, Inc.

25 CIERA LOGAN, ESQ. (Telephone)
FOX ROTHSCHILD LLP
1301 Atlantic Avenue
Midtown Building, Suite 400
Atlantic City, New Jersey 08401-7212
(609) 572-2236
clogan@foxrothschild.com
Counsel for Defendant Validus
Pharmaceuticals

(Appearances continued on next page)

APPEARANCES (Continued)

LINDA K. RURANGIRWA, ESQ. (Telephone/stream)
COLLINSON, DAEHNKE, INLOW & GRECO
2110 E. Flamingo Road, Suite 305
Las Vegas, Nevada 89119
(702) 979-2132
Linda.rurangirwa@cdiglaw.com
Counsel for Defendant C&R Pharmacy

JUSTIN C. TAYLOR, ESQ. (Video/realtime
stream)
BAILEY & WYANT, PLLC
500 Virginia Street East | Suite 600
Charleston, West Virginia 25301
(304) 720-0714
Jtaylor@baileywyant.com

JUSTIN MANN, ESQ. (Video/realtime stream)
ROPES & GRAY, LLP
1211 Avenue of the Americas
New York, New York 10036-8704
(212) 596-9175
Justin.mann@ropesgray.com
Counsel for Defendant Mallinckrodt

LUCY ONYEFORO, ESQ. (Video/realtime stream)
ALLEGAERT BERGER & VOGEL LLP
111 Broadway, 20th Floor
New York, New York 10006
(212) 616-7060
onyeforo@abv.com
Counsel for Defendant Rochester Drug
Cooperative

(Appearances continued on next page)

1 APPEARANCES:

2 CONOR B. O'CROININ, ESQ.
ZUCKERMAN SPAEDER, LLP
3 100 East Pratt Street, Suite 2440
Baltimore, Maryland 21202-1031
4 (212) 616-7060
cocroinin@zuckerman.com
5 Counsel for Defendant CVS Indiana, L.L.C.,
CVS Rx

6

7 Also Present:

8 BRIAN ASQUITH, Law Clerk
9 EVAN WOLFE, Technical Support
10 RYAN WONG, Videographer

11

12 Appearing Via Video/Realtime Stream:

13 AMY KENNEDY

14

--o0o--

15

16

17

18

19

20

21

22

23

24

25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
22

E X H I B I T S

[illegible]

E X H I B I T S

[illegible]

E X H I B I T S

[illegible]

E X H I B I T S

[illegible]

1

E X H I B I T S

2

[illegible]

1	E X H I B I T S		
2	MCK-WALKER	Description	Page
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

--o0o--

1 BE IT REMEMBERED that on Thursday, the 10th
2 day of January, 2019, commencing at the hour of
3 8:57 a.m. in the law offices of Covington & Burling,
4 One Front Street, 35th Floor, San Francisco,
5 California, before me, Sandra Bunch VanderPol, a
6 Certified Shorthand Reporter in and for the State of
7 California, personally appeared.

8 DONALD WALKER,
9 called as a witness (McKesson), who, having been duly
10 sworn, was thereupon examined and interrogated as
11 hereinafter set forth.

12 --oOo--

13 THE VIDEOGRAPHER: We are now on the record.

14 My name is Ryan Wong. I'm a videographer
15 for Golkow Litigation Services. Today's date is
16 January 10th, 2019, and the time is 8:57 a.m.

17 This video deposition is being held in
18 San Francisco, California, in the matter of National
19 Prescription Opiate Litigation, for the United States
20 District Court, Northern District of Ohio.

21 The deponent is Donald Walker.

22 Would counsel please identify themselves for
23 the record.

24 MR. KENNEDY: Eric Kennedy, on behalf of
25 plaintiffs.

1 MR. ASQUITH: Brian Asquith, plaintiffs.

2 MR. WOLFE: Evan Wolfe, tech support.

3 MS. URQUHART: Abigail Urquhart, on behalf
4 of Walmart.

5 MR. LIVINGSTON: Scott Livingston, on behalf
6 of HBC.

7 MR. O'CROININ: Conor O'Croinin, on behalf
8 of CVS.

9 MS. KVESELIS: Emily Kveselis, for McKesson
10 and the witness.

11 MS. HENN: Emily Henn, from Covington &
12 Burling, on behalf of McKesson and Mr. Walker.

13 THE VIDEOGRAPHER: On the phone?

14 MR. SHAPLAND: Eric Shapland, on behalf of
15 Endo and Par, at Arnold & Porter.

16 MR. BUSHAR: Joseph Bushar, of Williams &
17 Connolly, on behalf of Cardinal Health.

18 MS. RURANGIRWA: Linda Rurangirwa.
19 Collinson, Daehnke, on behalf of C&R Pharmacy.

20 MS. ROCCHINO: Samantha Rocchino, of Reed
21 Smith, LLP, on behalf of AmerisourceBergen Drug
22 Corporation.

23 THE VIDEOGRAPHER: The court reporter is
24 Sandy VanderPol, and she will now swear in the
25 witness.

1 THE REPORTER: Raise your right hand,
2 please.

3 Do you solemnly swear or affirm that the
4 testimony you are about to give in this proceeding
5 will be the truth, the whole truth, and nothing but
6 the truth, so help you God?

7 THE WITNESS: I do.

8 EXAMINATION

9 BY MR. KENNEDY:

10 Q. Sir, my name is Eric Kennedy. You
11 understand that I represent the plaintiffs in this
12 case?

13 A. I do.

14 Q. And could you please state your full
15 name for the record.

16 A. Donald Walker.

17 Q. And are you currently employed?

18 A. I am not.

19 Q. And your prior employer was McKesson;
20 would that be true?

21 A. That's correct.

22 Q. And so the jury understands where we
23 are today, we are in San Francisco; are we not?

24 A. Yes, we're in San Francisco.

25 Q. And San Francisco would be the

1 worldwide corporate headquarters of McKesson
2 Corporation; would that be true?

3 MS. HENN: Objection to form.

4 THE WITNESS: McKesson's corporate
5 headquarters is currently in San Francisco,
6 California.

7 BY MR. KENNEDY:

8 Q. And we are at the offices of your
9 attorney at this present time; yes?

10 A. Yes, we are.

11 Q. When did you begin your career with
12 McKesson?

13 A. I joined McKesson in 1987.

14 Q. And when you joined them, what was
15 your position?

16 A. My first position with McKesson was
17 as a Transportation Manager with one of the
18 subsidiary companies that McKesson had.

19 Q. Were your responsibilities in any way
20 involved with the regulatory affairs at that time?

21 A. No.

22 Q. And what was the next position that
23 you held with McKesson?

24 A. I held the position with the -- what
25 was then the McKesson Drug Company and

1 Transportation, and had responsibility for
2 transportation planning.

3 Q. And when did you take that position?

4 A. About 1991.

5 Q. Did that position have anything to do
6 with regulatory affairs of the distribution of
7 opioids?

8 A. No, it did not.

9 Q. What did that position basically
10 involve?

11 A. The transportation position that I
12 held was really a position of optimizing delivery
13 efficiencies for our distribution centers.

14 Q. What was your next position at
15 McKesson?

16 A. I was the Distribution Center Manager
17 of our Sacramento Distribution Center.

18 Q. When did you take that position?

19 A. My best recollection is about 1992.

20 Q. And what were your duties and
21 responsibilities then, as the manager of a
22 distribution center?

23 A. I had responsibility for oversight of
24 our daily distribution of pharmaceuticals to
25 pharmacies served by that distribution center.

1 Q. And that position would have involved
2 the distribution of opioids; would it not?

3 A. As part of our distribution, we did
4 distribute controlled substances to pharmacies.

5 Q. Did you have any responsibility at
6 that point in time with respect to the creation,
7 management or implementation of anti-diversion
8 regulations and policies at McKesson?

9 MS. HENN: Object to form.

10 THE WITNESS: No. At that time I was
11 executing against existing policies the company had
12 in place.

13 BY MR. KENNEDY:

14 Q. What were in place from 1992 to the
15 late '90s? What was the policy in place?

16 A. There were -- the policies we had
17 were contained in our Operations Manuals that
18 specified our responsibilities to comply to
19 regulations for handling and distribution of
20 controlled substances.

21 Q. We know about the existence of
22 Standard Operating Procedure 55. Are you familiar
23 with that?

24 A. Yes.

25 Q. Was that the policy and procedure

1 that was in place in the 1990s?

2 A. The Section 55 of our Operations
3 Manual covered the responsibilities with the handling
4 and distribution of controlled substances.

5 Q. Sir, that wasn't my question. I was
6 asking, was Standard Operating Procedure Section 55,
7 was that the policy in place in the 1990s?

8 A. My recollection is that Section 55
9 was the applicable policy in place during a period in
10 the 1990s.

11 Q. How long did you hold the position as
12 a Distribution Center Manager?

13 A. I recall it was approximately 18
14 months.

15 Q. So sometime in 1993/'94, you took on
16 a new position?

17 A. Yes. In 19 -- in that time frame, I
18 don't recall exactly when, I was promoted to a new
19 position of Vice President of Distribution Operations
20 for their Western Region.

21 Q. Western Region would be the western
22 part of the United States?

23 A. Yes.

24 Q. And what were your responsibilities
25 as VP of Distribution of the Western Region?

1 A. I had responsibility for the
2 operations staff in the distribution centers that
3 comprised the Western Region. So the distribution
4 center managers that operated those facilities
5 reported to me.

6 Q. And at that point in time -- how
7 long -- how long did you hold that position?

8 A. I held that position until about
9 1996.

10 Q. And in that position, did you have
11 responsibility -- other than the following of SOP 55,
12 did you have any duties, responsibilities, with the
13 creation and the management of anti-diversion
14 policies and procedures at McKesson?

15 MS. HENN: Objection to form.

16 THE WITNESS: In that role I had
17 responsibility for the distribution centers and their
18 execution of their responsibilities under Section 55
19 to the handling and distribution of controlled
20 substances.

21 BY MR. KENNEDY:

22 Q. You held that position till what
23 year, the VP of the Western Region?

24 A. Approximately 1996.

25 Q. And what position did you take in

1 1996?

2 A. In 1996 I was promoted to the Senior
3 Vice President of Distribution for McKesson
4 Pharmaceutical.

5 Q. Was that a new position also?

6 MS. HENN: Objection to form.

7 THE WITNESS: No. That position, I
8 succeeded an individual who retired from the company.

9 BY MR. KENNEDY:

10 Q. Is that the position you held until
11 the time of your retirement?

12 A. Yes, with the exception of a period
13 of time from approximately 2000 to 2005 where I was
14 responsible for our Six Sigma organization.

15 Q. And what is that?

16 A. Six Sigma is a process improvement
17 methodology that we introduced to the company at that
18 time, and I was the senior leader of our Six Sigma.

19 Q. Did the Six Sigma project in any way
20 relate to the distribution of opioids?

21 A. Not that I recall.

22 Q. From '96 to 2000, in this four-year
23 period, what are your responsibilities as a Senior VP
24 of Distribution as it related to the distribution of
25 opioids?

1 A. As the Senior Vice President of
2 Distribution, included in my responsibility was our
3 Regulatory Affairs Group. It was our overall
4 responsibility to ensure that we were complying with
5 regulations associated with the handling and
6 distribution of controlled substances.

7 Q. And would that be on a national
8 basis?

9 A. Yes.

10 Q. Then from 2000 to 2005, when you no
11 longer had your responsibilities as Senior VP of
12 Distribution, who took over your responsibilities
13 during this five-year period?

14 A. I recall there were two different
15 individuals that had responsibility during that time
16 frame, a Ron Bone and a Brian Magerkurth.

17 Q. And so they had taken over your
18 responsibilities as it related to McKesson's
19 responsibilities as a distributor relating to the
20 distribution of opioids?

21 A. During -- during that time they would
22 have had the responsibility for our Regulatory
23 Affairs, yes.

24 Q. And would their responsibility and
25 your responsibility, when you were acting as the

1 Senior VP, would that have related to the policies
2 and procedures of McKesson in relation to suspicious
3 order monitoring?

4 MS. HENN: Objection to form.

5 THE WITNESS: As part of our overall
6 policies, it did include reporting of suspicious
7 orders.

8 (Exhibit No. 690 was marked.)

9 BY MR. KENNEDY:

10 Q. I am going to show you what we have
11 marked as Plaintiffs' Exhibit 690, if you would,
12 please.

13 MS. HENN: Do you have a second copy for the
14 counsel over here? `

15 UNIDENTIFIED SPEAKER ON TELEPHONE: And if
16 it does have a Bates number, if that could be read
17 into the record, it would be appreciated.

18 MR. KENNEDY: The Bates number,
19 McKessonMDL00409116 -- that's the starting Bates --
20 to -73. To -173.

21 BY MR. KENNEDY:

22 Q. Mr. Walker, what is the date on this
23 document, if you look at the cover page?

24 A. The date is March 12th, 2014.

25 Q. Large capitals, "McKesson

1 Corporation"?

2 A. Yes.

3 Q. And the title would be the,
4 "Presentation to the U.S. Attorney's Office, Northern
5 District of West Virginia, and DEA." Do you see
6 that?

7 A. Yes.

8 Q. If you will -- if you will go to page
9 -122, the last three -- the last three numbers in the
10 bottom right-hand corner.

11 Is the title of this McKesson's Regulatory
12 Affairs team, Pre-Settlement"?

13 MS. HENN: Objection to form.

14 THE WITNESS: Yes.

15 BY MR. KENNEDY:

16 Q. Presettlement would be prior to 2008;
17 would that be true? There was a settlement between
18 McKesson and the DEA in 2008; do you recall that?

19 A. I recall the settlement in 2008, yes.

20 Q. And this is referencing a
21 pre-settlement; do you see that?

22 A. I see that.

23 Q. My question being, from 2000 to -- up
24 to 2008, the time of the settlement, would this have
25 been the regulatory team at McKesson?

1 MS. HENN: Objection to form.

2 THE WITNESS: Can you repeat.

3 BY MR. KENNEDY:

4 Q. In this time frame, prior to the
5 settlement, prior to 2008, would this presentation to
6 the government -- would this presentation to the
7 government accurately reflect the regulatory team at
8 McKesson?

9 A. The regulatory -- counsel, if your
10 question is if this was the regulatory team prior to
11 2008, yes.

12 Q. And --

13 A. I'm not familiar with this document.
14 So that's why I'm answering the question that way.

15 Q. I just thought I might help you with
16 recollecting back to this period of time.

17 And so my question is, Bruce Russell is one
18 of three of the regulatory team. Do you remember
19 when he was brought on at McKesson, prior to 2008 to
20 make up the regulatory team?

21 A. I don't recall specifically when he
22 was brought on. When I joined the company, Bruce was
23 already an employee of McKesson.

24 Q. All right. And do you know when he
25 took this position as part of the regulatory team?

1 A. I don't recall specifically. He held
2 several -- several different positions. I know that
3 it did include regulatory, but I don't know the
4 dates.

5 Q. And do you know when Mr. Hilliard was
6 brought on and made part of the regulatory team at
7 McKesson?

8 A. Again, I don't recall the specific
9 date. But Mr. Hilliard joined our regulatory team as
10 a result of our acquisition of Foxmeyer Corporation.

11 Q. And when we talk about a regulatory
12 team, can we be in agreement we are talking about the
13 team that managed -- managed and implemented the
14 policies in relation to the distribution of opioids;
15 would that be correct?

16 MS. HENN: Objection to form.

17 THE WITNESS: The regulatory team had
18 responsibility for ensuring the policies were current
19 and in compliance with the regulation, and provided
20 oversight and guidance to our distribution center
21 teams to ensure that all of our distribution centers
22 were in compliance.

23 BY MR. KENNEDY:

24 Q. And when we're talking about
25 compliance, we're talking about -- that would include

1 compliance as it relates to the distribution of
2 opioids; true?

3 A. It would include the distribution of
4 controlled substances, yes.

5 Q. Opioids; correct? They were a
6 controlled substance?

7 A. The -- we had responsibility for all
8 controlled substances.

9 Q. Okay. I want you -- it's just a
10 simple "yes" or "no" question.

11 Opioids are a controlled substance; are they
12 not? "Yes" or "no."

13 A. I understand narcotics are a
14 controlled substance, as defined by the DEA, but I
15 don't have the expertise to understand. We
16 understood them to be controlled substances.

17 Q. Well, let me ask you this. You were
18 in charge of regulatory; you worked at the
19 distribution center; you had a long career working
20 directly with the DEA; correct? Correct?

21 MS. HENN: Objection to form.

22 THE WITNESS: I had a long career with
23 McKesson that included interaction with DEA.

24 BY MR. KENNEDY:

25 Q. And are you saying that you have

1 never understood that opioids were a controlled
2 substance?

3 A. In the regulations, I understand
4 narcotics to be a controlled substance. And what I
5 can't answer for you is whether opioids specifically
6 are called out in the regulation.

7 We were responsible for the oversight and
8 control of controlled substances, including
9 narcotics.

10 Q. Okay. My question is very simple.
11 In your long career at McKesson -- and at the end of
12 the day you were the boss with respect to
13 regulation -- and are you saying that, as you sit
14 here today, you never understood that opioids were a
15 controlled substance that the federal government was
16 addressing when they put the Controlled Substance Act
17 into law in 1970? You never understood that; is that
18 your testimony, sir?

19 MS. HENN: Objection to form.

20 BY MR. KENNEDY:

21 Q. I'm asking you about opioids.

22 A. Again, I very specifically understood
23 narcotics, and I --

24 Q. And you didn't know about opioids?

25 A. And I don't recall opioids being in

1 the regulation.

2 Q. Let me ask you, did you recall, in
3 your long, long career, did you know whether or not
4 oxycodones were within the topic of controlled
5 substances that the DEA and Congress of the
6 United States were intending to be within the purview
7 of what they wanted regulated? Did you understand
8 oxycodones were a part of that?

9 MS. HENN: Objection to form.

10 THE WITNESS: I understood oxycodone to be a
11 Class 2 narcotic, yes.

12 BY MR. KENNEDY:

13 Q. A controlled substance that you had
14 the responsibility at McKesson to regulate; correct?
15 You understood that?

16 A. Yes.

17 Q. Did you understand that hydrocodones
18 were within the purview of controlled substances that
19 the government and the DEA and Congress intended to
20 be subject to their regulation and distribution?

21 A. Yes.

22 Q. The three folks that we see here
23 making up the regulatory team -- and, again, when I
24 say "regulatory team" or "Regulatory Affairs," we
25 could understand that what we are talking about are

1 the responsibilities of McKesson as it related to the
2 prevention of diversion of controlled substances; you
3 understand that?

4 MS. HENN: Objection to form.

5 THE WITNESS: I would describe our
6 regulatory team as having responsibility to ensure
7 that our distribution centers were complying with all
8 regulations, to which McKesson was obligated.

9 BY MR. KENNEDY:

10 Q. Well, tell me what regulations
11 McKesson was obligated to with respect to the
12 distribution of controlled substances, then, so maybe
13 we can communicate better. Tell me.

14 In this period prior to 2008, tell me the
15 regulations that you just referred to that McKesson
16 was responsible to follow.

17 A. At a high level, the responsibility
18 of our distribution centers was to ensure the safe
19 handling, security, recordkeeping associated with the
20 distribution and handling of controlled substances
21 and to -- specifically under the regulation, to guard
22 against diversion and report suspicious orders.

23 Q. And that was under this -- this
24 umbrella of Regulatory Affairs; correct?

25 A. Yes, under our Regulatory Affairs

1 Group, including our distribution centers, that was
2 our compliance responsibility.

3 Q. And prior to 2008, as you've
4 represented to the DEA in this slide presentation,
5 prior to 2008, these three folks, Mr. Walker,
6 Mr. Russell, Mr. Hilliard, they made up the
7 regulatory team; true?

8 MS. HENN: Objection to the form.

9 THE WITNESS: Prior to 2008, this was the
10 regulatory team.

11 BY MR. KENNEDY:

12 Q. So during this period prior to 2008,
13 I want to focus on 2005 to start with; all right?

14 A. Okay.

15 Q. 2005 there was an opioid crisis in
16 the United States; was there not?

17 MS. HENN: Objection to form.

18 THE WITNESS: I -- I don't have the specific
19 knowledge or recollection that there was an opioid
20 crisis in the United States at the time.

21 BY MR. KENNEDY:

22 Q. In 2005?

23 A. Correct.

24 Q. Let me ask you this. Is it just that
25 you don't remember back to 2005, or is it that you

1 believe that back in 2005 you weren't conscious of an
2 opioid crisis in this country?

3 A. I don't recall when the term --
4 basically, the public information associated with
5 what eventually was termed "the opioid crisis" first
6 was identified.

7 Q. Well, let me ask. In 2005 you
8 understood McKesson was selling more opioid narcotics
9 than any company in the United States? You knew
10 that, didn't you?

11 MS. HENN: Objection to form.

12 THE WITNESS: No, I don't have any specific
13 information or recollection that our quantities were
14 the largest in the United States.

15 BY MR. KENNEDY:

16 Q. As you sit here today, do you know
17 and do you understand that over the years McKesson
18 has been the largest distributor of opioids in this
19 country?

20 MS. HENN: Objection to form.

21 THE WITNESS: No, I don't have that
22 knowledge.

23 BY MR. KENNEDY:

24 Q. In 2005 McKesson was selling
25 oxycodones, were they not?

1 A. In 2005 I believe that McKesson
2 was -- oxycodone was one of the controlled substances
3 we sold.

4 Q. McKesson was selling hydrocodones;
5 were they not?

6 A. In 2005?

7 Q. Yes.

8 A. Yes.

9 Q. And if I were to tell you that with
10 respect to narcotics and controlled substances, by
11 2005 McKesson was probably selling over a billion
12 dollars worth of those narcotics, would that be
13 contrary to your memory and your belief of the level
14 of sales of McKesson in 2005?

15 MS. HENN: Objection to form.

16 THE WITNESS: I don't have any specific
17 knowledge in what our sales quantities of those
18 substances were at that time.

19 BY MR. KENNEDY:

20 Q. Let me ask you -- see if we can

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10 Q. That's not what I'm asking you. And
11 you -- you're the right guy, and you understand --
12 you heard my question; did you not?

13 MS. HENN: Counsel, could you just ask a
14 question, please.

15 BY MR. KENNEDY:

16 Q. Did you hear my question, sir?

17 A. I heard your question.

18 Q. Did you understand my question?

19 A. I understood your question.

20 Q. I'm going to ask it again, maybe in a
21 little different way.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10 Q. And I'm going to move to strike. And
11 I'm going to ask you again.

12 I want to know about your responsibility to
13 know. I don't want you to parrot something that you
14 want to say or have been prepared to say. I want you
15 to answer my question; all right?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

12 Q. So are you going to refuse to answer

13 that question? I want to know, and I will move on.

14 If you are not going to answer that question, I will

15 move on.

16 Are you refusing to answer my question?

17 MS. HENN: Counsel, please just pose

18 questions. He will answer them.

19 BY MR. KENNEDY:

20 Q. Are you refusing to answer my

21 question, sir?

22 MS. HENN: Objection to form.

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

[illegible]

[REDACTED]

18 Q. And I've written that accurately;
19 correct? Simple question. If I haven't, I will
20 rewrite it; I will write more.

21 Have I written that correctly with respect
22 to Mr. Walker's view as head of regulatory, your view
23 of McKesson's responsibility?

24 MS. HENN: Objection to form.

25 ///

1 BY MR. KENNEDY:

2 Q. Have I written that accurately, sir?

3 A. That appears to be what I said.

4 Q. Very good. All right.

5 So let's take a look at whether or not

6 McKesson fulfilled its responsibility --

7 all right? -- according to Mr. Walker's view of their

8 responsibility. All right?

9 A. Okay.

10 (Exhibit No. 801 was marked.)

11 MR. KENNEDY: If you can give me

12 Exhibit 688, please.

13 (Exhibit No. 688 was marked.)

14 BY MR. KENNEDY:

15 Q. So let's look at McKesson's

16 fulfilling of its responsibility, then, as you have

17 described it. This is Exhibit 688, Bates -00496859

18 to -875.

19 This is a memorandum. Do you see that up at

20 the top, it says, "Memorandum"?

21 A. Yes. Give me just a minute.

22 Yes.

23 BY MR. KENNEDY:

24 Q. And this is a Memorandum. This is a

25 DEA document; is it not? Do you see the DEA logo,

1 U.S. Department of Justice, Drug Enforcement

2 Administration? This is a memo from the DEA, from

3 their documents; true?

4 A. That's what's on the document, yes.

5 Q. Well, Mr. Walker, you have seen this

6 document before; have you not? This came from your

7 files.

8 A. Yes, I have seen this document.

9 MS. HENN: Objection to form.

10 BY MR. KENNEDY:

11 Q. When was the last time you saw this

12 document?

13 A. I believe the most recent was in

14 preparation for this deposition.

15 Q. All right. So this is a memorandum.

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

25 Q. And this is an internal memoranda

1 that Mr. Mapes, from the DEA, created for Joseph
2 Rannazzisi of the DEA; true? Is that true?

3 A. That would appear to be correct.

4 Q. And you know who Mr. Rannazzisi of
5 the DEA is, do you not?

6 A. Yes, I do.

7 Q. He held an important position with
8 the DEA; did he not?

9 A. Mr. Rannazzisi was the head of
10 diversion control.

11 Q. And that's an important position; is
12 it not?

13 A. I believe so.

14 Q. All right. Let's read the first

The diagram illustrates a 3D coordinate system with three axes: x, y, and z. The x-axis is horizontal, the y-axis is vertical, and the z-axis is diagonal. A point is marked in the 3D space, and its projections onto the axes are shown. The axes are labeled x, y, and z. The point is labeled with coordinates (x, y, z).

21 of reading).

22 He's from McKesson; right?

23 MS. HENN: Objection to form.

24 BY MR. KENNEDY:

25 Q. He's legal counsel at McKesson?

1 A. Mr. Gilbert is outside counsel for
2 McKesson.

3 Q. All right. A lawyer; right?

4 A. Yes, he's a lawyer.

5 Q. Ronald Bone, Senior Vice President,
6 Distribution Support. He's from McKesson; correct?

7 A. Yes.

8 Q. Gary Hilliard, Director of Regulatory
9 Affairs was present; right?

10 A. Yes.

11 Q. And as far as that -- the hierarchy,
12 the chain of command in Regulatory, he was right
13 underneath you or he was two down from you; correct?
14 We just looked at that.

15 A. At -- that's not accurate. At this
16 time I was not in the role of Senior Vice President
17 of Distribution. But ultimately he was.

18 Q. Okay. And Michael Mapes, from the
19 DEA, was at the meeting; true? Is that what it
20 indicates?

21 A. That's what the document indicates.

22 Q. Charles E. Trant, Office of Chief
23 Counsel, Diversion and Regulatory Litigation
24 Division, that was a lawyer from the DEA present at
25 the meeting; true?

1 MS. HENN: Objection to form.

2 THE WITNESS: Again, that's what the
3 document represents.

4 BY MR. KENNEDY:

5 Q. Jim Crawford, from the DEA, he was
6 also there; correct?

7 A. According to the document.

8 Q. Kyle Wright, from the DEA, was also
9 at the meeting, according to the document?

10 A. Yes, that's what's written.

11 Q. That last sentence in the first
12 paragraph states:

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

21 Q. And you understand that they said
22 they wanted to talk to you about source of supply.
23 That's McKesson, because McKesson is a source of
24 supply to pharmacies; true?

25 MS. HENN: Objection to form.

1 BY MR. KENNEDY:

2 Q. That's what they are talking about?

3 A. McKesson's role in the pharmaceutical
4 supply chain is to supply pharmacies.

5 Q. They are a source of supply? That's
6 what they are talking about in this memo; true?

7 MS. HENN: Objection to form.

8 THE WITNESS: I'm not sure what their intent
9 in writing the "source of supply." But McKesson does
10 supply pharmacies.

11 BY MR. KENNEDY:

12 Q. Are you telling me, you don't know
13 what they mean by "source of supply"? You don't know
14 what that means?

15 MS. HENN: Objection to form. Asked and
16 answered.

17 BY MR. KENNEDY:

18 Q. Is that your testimony?

19 MS. HENN: Same objection.

20 THE WITNESS: Again, I'm not sure
21 specifically what Mr. Mapes is intending or meaning
22 there. What I can assure you is that McKesson
23 supplies pharmacies.

24 BY MR. KENNEDY:

25 Q. All right. From your background,

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11 Q. Let me ask you, meetings like this
12 didn't happen every week with the DEA where lawyers
13 are involved, the DEA is bringing all these folks,
14 and McKesson is bringing all these folks? These type
15 meetings with the DEA did not happen every week;
16 would that be true?

17 A. Meetings at DEA headquarters were
18 not, you know, frequent.

19 Q. This didn't even happen every month,
20 where this many people from McKesson were brought in
21 to meet this many people at DEA headquarters? It
22 didn't even happen once a month; did it?

23 A. Not that I recall.

[REDACTED]

[REDACTED]

[illegible]

[illegible]

The diagram consists of 16 horizontal gray bars of varying lengths and positions, each preceded by a small square icon. The bars are arranged in a vertical sequence, with some starting at the left margin and others indented. The lengths of the bars vary, with some being full-width and others being shorter. The overall structure suggests a list or a sequence of items, possibly representing a process flow or a set of data points.

18 Q. McKesson, when they provided us with
19 this document, put a black box. Do you know why that
20 black box is there?

21 MS. HENN: Objection to form.

22 THE WITNESS: No, I do not.

23 BY MR. KENNEDY:

1. **Identify the main components of the system.**
 2. **Define the objectives and scope of the project.**
 3. **Develop a detailed project plan.**
 4. **Implement the plan and monitor progress.**
 5. **Evaluate the results and make adjustments.**

Age Group	Male (%)	Female (%)
18-24	50	50
25-34	50	50
35-44	50	50
45-54	50	50
55-64	50	50
65+	50	50

12 Q. Now, you have reviewed this document
13 within the last few weeks; true?

14 A. Yes, I believe so.

15 Q. And you clearly would have seen this
16 document back in 2005, 2006? We got it out of your
17 files; correct? You saw it back then; right?

18 MS. HENN: Objection to form.

19 THE WITNESS: I don't recall seeing this
20 document, this internal DEA document, prior to the
21 review with counsel.

22 BY MR. KENNEDY:

Category	Percentage
Category 1	10%
Category 2	20%
Category 3	30%
Category 4	40%
Category 5	50%
Category 6	60%
Category 7	70%
Category 8	80%
Category 9	90%
Category 10	100%

1	1	1	1
2	2	2	2
3	3	3	3
4	4	4	4
5	5	5	5
6	6	6	6
7	7	7	7
8	8	8	8
9	9	9	9
10	10	10	10
11	11	11	11
12	12	12	12
13	13	13	13
14	14	14	14
15	15	15	15
16	16	16	16
17	17	17	17
18	18	18	18
19	19	19	19
20	20	20	20
21	21	21	21
22	22	22	22
23	23	23	23
24	24	24	24
25	25	25	25
26	26	26	26
27	27	27	27
28	28	28	28
29	29	29	29
30	30	30	30
31	31	31	31
32	32	32	32
33	33	33	33
34	34	34	34
35	35	35	35
36	36	36	36
37	37	37	37
38	38	38	38
39	39	39	39
40	40	40	40
41	41	41	41
42	42	42	42
43	43	43	43
44	44	44	44
45	45	45	45
46	46	46	46
47	47	47	47
48	48	48	48
49	49	49	49
50	50	50	50
51	51	51	51
52	52	52	52
53	53	53	53
54	54	54	54
55	55	55	55
56	56	56	56
57	57	57	57
58	58	58	58
59	59	59	59
60	60	60	60
61	61	61	61
62	62	62	62
63	63	63	63
64	64	64	64
65	65	65	65
66	66	66	66
67	67	67	67
68	68	68	68
69	69	69	69
70	70	70	70
71	71	71	71
72	72	72	72
73	73	73	73
74	74	74	74
75	75	75	75
76	76	76	76
77	77	77	77
78	78	78	78
79	79	79	79
80	80	80	80
81	81	81	81
82	82	82	82
83	83	83	83
84	84	84	84
85	85	85	85
86	86	86	86
87	87	87	87
88	88	88	88
89	89	89	89
90	90	90	90
91	91	91	91
92	92	92	92
93	93	93	93
94	94	94	94
95	95	95	95
96	96	96	96
97	97	97	97
98	98	98	98
99	99	99	99
100	100	100	100

[illegible]

25 MR. KENNEDY: All right. Let's go four

1 months later. All right. Four months later. If we
2 could look at Exhibit 689, please.

3 (Exhibit No. 689 was marked.)

4 MR. KENNEDY: That's a Bates -00496876 to
5 -878.

6 Q. You have got a September 1 meeting,
7 2005. I want to talk about four months later. You
8 have seen this document; have you not?

9 A. Yes, I have.

10 Q. This is from your files.

11 A. Yes, I have seen this document.

12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. This is another -- this is another
15 DEA memo; is it not?

16 A. It would appear to be a DEA memo,
17 yes.

[illegible]

1 Q. Now, this is a DEA memo, again,
2 written to Mr. Rannazzisi; correct?

3 A. That's correct.

4 Q. Let's look to the first paragraph.

█ [REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

13 The second paragraph states:

14 (Reading) Representing McKesson

15 Corporation were Donald G. Walker" --

16 That's you; right?

17 A. Yes, it is.

18 Q. You're at the second meeting; right?

19 A. Yes, I was at this meeting.

20 Q. And that point you were Senior Vice

21 President of Distribution Operations; correct?

22 A. That is correct.

23 Q. So you're sitting on top of

24 Regulatory Affairs at that point; true?

25 A. Yes.

1 Q. Bill Mahoney, Distribution Center
2 Manager, Lakeland Distribution Center, Florida, was
3 there; right? McKesson employee; true?

4 A. Yes.

5 Q. Gary Hilliard, Director of Regulatory
6 Affairs, was there; right?

7 A. Yes.

8 Q. McKesson. He's from McKesson; right?

9 A. Yes, he was.

10 Q. And John Gilbert, one of McKesson's
11 lawyers was present; true?

12 A. That is correct.

13 Q. And it says -- next paragraph down it
14 outlines now who is there from the DEA. It says:

15 (Reading) Representing Drug
16 Enforcement Administration (DEA)
17 Office of Diversion Control (OD) were
18 Joseph Rannazzisi, Deputy Assistant
19 Administrator, Michael R. Mapes,
20 Chief, E-Commerce Section (end of
21 reading).

22 Another DEA person; true?

23 A. Yes.

24 Q. Kyle Wright, Chief E-Commerce
25 Operations from the DEA was present; right?

[illegible]

[illegible]

[illegible]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 BY MR. KENNEDY:

7 Q. The next bullet point down, "The
8 E-Commerce Section" -- that's the DEA -- "retrieved
9 ARCOS data" -- and that's a database where the DEA
10 can look at what McKesson is actually distributing
11 and selling; true? That's what the ARCOS data is?

12 A. The ARCOS data is data that we
13 provided -- that is required by the regulation. So
14 it is data of sales of controlled substances that are
15 required to be reported.

16 Q. So it states:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

A 20x20 grid of gray squares on a white background, representing a sparse matrix. The squares are distributed across the grid, with some appearing in single cells and others in small groups, indicating non-zero entries in the matrix.

22 Q. You know that at this point in time,
23 the DEA, their statistics in ARCOS, were showing that
24 the average monthly, average monthly distribution by
25 a distributorship of McKesson was 5,000 units of

1 hydrocodone? Do you remember that? Remember that
2 communication, all during this period?

3 MS. HENN: Objection to form.

4 THE WITNESS: I recall DEA indicating that
5 5,000 doses of controlled substances was average.

6 BY MR. KENNEDY:

7 Q. That's an average monthly dose;
8 right?

9 A. That's what I recall.

[REDACTED]

Service	18-24	25-34	35-44	45-54	55-64	65+
Smartphone	95%	90%	85%	75%	65%	55%
Internet	90%	85%	80%	70%	60%	50%
Video	85%	80%	75%	65%	55%	45%
Music	80%	75%	70%	60%	50%	40%
Smart TV	75%	70%	65%	55%	45%	35%
Smartwatch	70%	65%	60%	50%	40%	30%
Smart home	65%	60%	55%	45%	35%	25%
Smart car	60%	55%	50%	40%	30%	20%
Smart city	55%	50%	45%	35%	25%	15%
Smart office	50%	45%	40%	30%	20%	10%
Smart factory	45%	40%	35%	25%	15%	5%
Smart agriculture	40%	35%	30%	20%	10%	0%
Smart energy	35%	30%	25%	15%	5%	0%
Smart transportation	30%	25%	20%	10%	5%	0%
Smart infrastructure	25%	20%	15%	5%	0%	0%
Smart environment	20%	15%	10%	5%	0%	0%
Smart security	15%	10%	5%	0%	0%	0%
Smart health	10%	5%	0%	0%	0%	0%
Smart education	5%	0%	0%	0%	0%	0%
Smart industry	0%	0%	0%	0%	0%	0%

13 Q. Let me ask you this. Forget the
14 averages and forget everything else. You were
15 involved in this, sir, for how many years?

16 A. Probably 15 years in the role.

The diagram consists of 10 horizontal gray bars of varying lengths and positions, arranged in a sequence from top to bottom. The bars are set against a white background. The first bar is a single long bar. The second bar is a single long bar. The third bar is a single long bar. The fourth bar is a single long bar. The fifth bar is a single long bar. The sixth bar is a single long bar. The seventh bar is a single long bar. The eighth bar is a single long bar. The ninth bar is a single long bar. The tenth bar is a single long bar.

The image shows a horizontal bar chart with 25 rows. Each row consists of a small gray square on the left, followed by a long gray bar. The bars vary in length and position, with some starting at different horizontal offsets. The bars are arranged in a way that suggests a sequence or progression, with some bars being longer than others and some starting further to the right.

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

14 Q. -- you don't have any knowledge
15 whether these are correct? You were directly
16 involved with this memo from the beginning, and this
17 led to negotiations and a settlement, and McKesson
18 losing its license to distribute opioids and a
19 \$13 million fine; did it not? You were directly
20 involved with that; were you not?

21 MS. HENN: Objection to form.

22 THE WITNESS: I was directly involved in the
23 settlement with DEA and the penalties that were
24 associated with that.

25 ///

1 BY MR. KENNEDY:

[illegible]

A horizontal bar chart consisting of 20 rows. Each row features a small, dark gray square icon on the left, followed by a larger, light gray rectangular bar. The bars vary in their starting and ending horizontal positions relative to the chart's boundaries. Some bars start at the far left, while others are indented. The lengths of the bars also vary, with some extending nearly to the right edge and others being much shorter.

19 MR. KENNEDY: Could I have the Elmo, please.

20 MS. HENN: Counsel, we have been going over
21 an hour. Would this be a decent time for a five-,
22 ten-minute break?

23 MR. KENNEDY: Sure.

24 THE VIDEOGRAPHER: We are going off the
25 record. The time is 10:07 a.m.

1 (Recess taken.)

2 THE VIDEOGRAPHER: We are back on the

3 record. The time is 10:22 a.m.

4 BY MR. KENNEDY:

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ ■ [REDACTED]

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ ■ [REDACTED]

21 Q. Hydrocodone is a controlled

22 substance; right?

23 A. Yes, it is.

■ ■ [REDACTED]

■ [REDACTED]

The diagram consists of 24 horizontal bars arranged vertically. The bars vary in their starting and ending horizontal positions, creating a sequence of events or a timeline. The bars are colored in a light gray color. The sequence of bars is as follows:

- Bar 1: Starts at the left edge, ends at approximately 80% width.
- Bar 2: Starts at the left edge, ends at approximately 85% width.
- Bar 3: Starts at the left edge, ends at approximately 90% width.
- Bar 4: Starts at approximately 20% width, ends at approximately 70% width.
- Bar 5: Starts at the left edge, ends at approximately 30% width.
- Bar 6: Starts at approximately 20% width, ends at approximately 60% width.
- Bar 7: Starts at approximately 20% width, ends at approximately 80% width.
- Bar 8: Starts at the left edge, ends at approximately 25% width.
- Bar 9: Starts at approximately 20% width, ends at approximately 85% width, with a small square at the far right edge.
- Bar 10: Starts at the left edge, ends at approximately 85% width.
- Bar 11: Starts at the left edge, ends at approximately 95% width.
- Bar 12: Starts at the left edge, ends at approximately 85% width.
- Bar 13: Starts at the left edge, ends at approximately 85% width.
- Bar 14: Starts at the left edge, ends at approximately 75% width.
- Bar 15: Starts at the left edge, ends at approximately 85% width.
- Bar 16: Starts at approximately 20% width, ends at approximately 55% width.
- Bar 17: Starts at the left edge, ends at approximately 30% width.
- Bar 18: Starts at approximately 20% width, ends at approximately 80% width.
- Bar 19: Starts at approximately 20% width, ends at approximately 35% width, followed by a gap, then approximately 40% width to 55% width, followed by a gap, then approximately 60% width to 90% width.
- Bar 20: Starts at the left edge, ends at approximately 30% width.
- Bar 21: Starts at approximately 20% width, ends at approximately 70% width, followed by a gap, then approximately 75% width to 95% width.
- Bar 22: Starts at the left edge, ends at approximately 25% width.
- Bar 23: Starts at approximately 20% width, ends at approximately 35% width, followed by a gap, then approximately 40% width to 55% width, followed by a gap, then approximately 60% width to 90% width.
- Bar 24: Starts at the left edge, ends at approximately 35% width, followed by a gap, then approximately 40% width to 85% width.

[illegible]

20 BY MR. KENNEDY:

21 Q. Sir, you sat through the meetings,
22 the negotiations, the pleadings, and all of the legal
23 proceedings with respect to this event; did you not?

24 A. No, that's not accurate. I did not
25 sit through all the meetings and negotiations that

1 took place between counsels.

2 Q. Did you sign the agreement with the
3 DEA in relation to these violations, these sales of
4 hydrocodones? Did you sign the very settlement
5 agreement; sir?

6 A. I signed the 2008 memorandum
7 agreement, yes.

8 Q. Let me back up, because I just -- I
9 just want to be clear about it.

Category	Male (%)	Female (%)
1. Overall	50	50
2. Age 18-24	45	55
3. Age 25-34	48	52
4. Age 35-44	52	48
5. Age 45-54	55	45
6. Age 55-64	58	42
7. Age 65+	60	40
8. Male	50	50
9. Female	50	50
10. Education Level	48	52
11. High School	45	55
12. College	50	50
13. Postgraduate	55	45
14. Income Level	48	52
15. Low Income	45	55
16. Middle Income	50	50
17. High Income	55	45

[illegible]

[illegible]

24 BY MR. KENNEDY:

25 Q. And that means you're not going to be

1 able to sell narcotics to pharmacies: Right? If you
2 have got to give your registration back, that's what
3 that means?

4 A. If a registration is suspended or
5 revoked, then you're unable to sell controlled
6 substances.

■ ■ ██
■ ██
■ ██
■ ██
■ ██
■ ██
■ ██
■ ██
■ ■ ██
■ ██
■ ██
■ ██
■ ██

17 BY MR. KENNEDY:

18 Q. And you ended up surrendering your
19 registration; didn't you?

20 MS. HENN: Objection to form.

21 THE WITNESS: Counsel, that's not correct.
22 We had a limited suspension of certain controlled
23 substances from certain distribution centers, is the
24 result of the agreement with DEA.

25 ///

1 BY MR. KENNEDY:

2 Q. We will look at that specifically.

```
3   Let's go down to -- after some bullet points, I want
4   to go down to the paragraph that starts with
5   "Through."
```

```
6         Do you see this paragraph that starts with
7     "Through"?
```


[illegible]

1	1	1	1
2	1	1	1
3	1	1	1
4	1	1	1
5	1	1	1
6	1	1	1
7	1	1	1
8	1	1	1
9	1	1	1
10	1	1	1
11	1	1	1
12	1	1	1
13	1	1	1
14	1	1	1
15	1	1	1
16	1	1	1
17	1	1	1
18	1	1	1
19	1	1	1
20	1	1	1
21	1	1	1
22	1	1	1
23	1	1	1
24	1	1	1
25	1	1	1
26	1	1	1
27	1	1	1
28	1	1	1
29	1	1	1
30	1	1	1
31	1	1	1
32	1	1	1
33	1	1	1
34	1	1	1
35	1	1	1
36	1	1	1
37	1	1	1
38	1	1	1
39	1	1	1
40	1	1	1
41	1	1	1
42	1	1	1
43	1	1	1
44	1	1	1
45	1	1	1
46	1	1	1
47	1	1	1
48	1	1	1
49	1	1	1
50	1	1	1
51	1	1	1
52	1	1	1
53	1	1	1
54	1	1	1
55	1	1	1
56	1	1	1
57	1	1	1
58	1	1	1
59	1	1	1
60	1	1	1
61	1	1	1
62	1	1	1
63	1	1	1
64	1	1	1
65	1	1	1
66	1	1	1
67	1	1	1
68	1	1	1
69	1	1	1
70	1	1	1
71	1	1	1
72	1	1	1
73	1	1	1
74	1	1	1
75	1	1	1
76	1	1	1
77	1	1	1
78	1	1	1
79	1	1	1
80	1	1	1
81	1	1	1
82	1	1	1
83	1	1	1
84	1	1	1
85	1	1	1
86	1	1	1
87	1	1	1
88	1	1	1
89	1	1	1
90	1	1	1
91	1	1	1
92	1	1	1
93	1	1	1
94	1	1	1
95	1	1	1
96	1	1	1
97	1	1	1
98	1	1	1
99	1	1	1
100	1	1	1

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 Q. And tell the jury what generic
7 hydrocodones are.

8 A. In all pharmaceuticals or medicines,
9 as a brand drug comes to market, it stays brand for a
10 period of time, at which time a generic drug can be
11 manufactured that has the same pharmacological
12 characteristics as the brand medication. So it's
13 very common in pharmaceutical industry for generics.
14 Amoxicillin is probably the best example that
15 everybody would know.

16 Q. And, sir, the majority of
17 hydrocodones that McKesson was selling were generic;
18 were they not?

19 A. I do not know what quantities were
20 brand versus generic at that point in time.

21 Q. In a general sense, that has always
22 been true at McKesson? You sell more generics than
23 you do brand name controlled substances; hasn't that
24 always be true?

25 MS. HENN: Objection to form.

[illegible]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED]

7 BY MR. KENNEDY:

8 Q. Sir, McKesson had the duty since 1970
9 to identify and report suspicious orders of
10 controlled substances; did they not?

11 A. I don't know specifically when the
12 CFR was generated. It was in the early '70s. But in
13 the time that I was there, we had the responsibility.

14 Q. And that included generic
15 hydrocodones, did it not, that duty, that
16 responsibility?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 THE WITNESS: We were responsible to report
20 the sales of all pharmaceutical or controlled
21 substances that were reportable to the DEA.

22 MR. KENNEDY: Okay. I'm going to ask to
23 strike your answer. Could you read back my question,
24 sir. I want you to listen real careful, and I want
25 you to answer this question. Not what you want to

1 answer. I want you to answer what I'm asking this
2 point forward, if you could.

3 MS. HENN: Objection to form.

4 MR. KENNEDY: Could you read it back,
5 please.

6 (Record read as follows: QUESTION:
7 And that included generic
8 hydrocodones, did it not, that duty,
9 that responsibility?)

10 MS. HENN: Same objection. Lacks
11 foundation.

12 THE WITNESS: Hydrocodone -- all hydrocodone
13 was a reportable controlled substance.

14 BY MR. KENNEDY:

15 Q. Including generic hydrocodone; true?

16 A. Including generic hydrocodone, yes.

17 Q. Because generic hydrocodone, sir, is
18 just as addictive as brand-name hydrocodone; is it
19 not?

20 MS. HENN: Objection to form.

21 THE WITNESS: I have no expertise on
22 addiction rates or addiction. So I can't comment
23 whether -- one versus the other.

24 BY MR. KENNEDY:

25 Q. They weren't any different

1 chemically; were they?

2 MS. HENN: Objection to form.

3 BY MR. KENNEDY:

4 Q. Branded versus generic aren't
5 different chemically?

6 A. Generally, my understanding is that
7 they were very close, if not identical, in terms of
8 chemical makeup. But, again, I don't have the level
9 of expertise to testify absolutely that they were the
10 same.

11 Q. Generic hydrocodone, sir, your
12 understanding generic hydrocodone was just as likely
13 to cause an overdose and death as a named brand
14 hydrocodone; true?

15 MS. HENN: Objection to form.

16 THE WITNESS: My understanding is that
17 generic hydrocodone, as it's designed for medical
18 purposes, it was the same as brand hydrocodone.

19 BY MR. KENNEDY:

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

[REDACTED]

19 BY MR. KENNEDY:

20 Q. By 2005, though, you understood, did
21 you not, that hydrocodones were one of the major
22 causes of addictions in the United States? You knew
23 that by 2005; didn't you?

24 MS. HENN: Objection to form.

25 THE WITNESS: I don't recall, you know,

1 specifically having any awareness of hydrocodone
2 being a national issue in 2005.

3 BY MR. KENNEDY:

4 Q. By 2005, sir, didn't you understand
5 that hydrocodones were one of the most highly
6 diverted drugs in this country?

7 MS. HENN: Objection to form. Lacks
8 foundation.

9 BY MR. KENNEDY:

10 Q. Do you understand that by 2005?

11 MS. HENN: Same objection.

12 THE WITNESS: I don't -- I don't have any --
13 any recollection or knowledge of that.

14 BY MR. KENNEDY:

15 Q. So at this point in time, in 2005 to
16 early 2006, when you have this period where you sell
17 two million hydrocodones, are you saying that you did
18 not understand that hydrocodones were one of the most
19 highly diverted drugs in this country? You didn't
20 know that?

21 MS. HENN: Objection. Asked and answered.
22 Lacks foundation.

23 THE WITNESS: I had no knowledge or
24 understanding of addiction rates of hydrocodone.

25 ///

1 BY MR. KENNEDY:

2 Q. You had been selling hydrocodones for
3 a decade or more, making millions of dollars, and you
4 didn't understand that; is that your testimony?

5 MS. HENN: Objection. Asked and answered.
6 Lacks foundation.

7 THE WITNESS: In 2005 I had no knowledge and
8 don't recall.

9 MR. KENNEDY: I am going to give you
10 Exhibit 695.

11 (Exhibit No. 695 was marked.)

12 BY MR. KENNEDY:

13 Q. Sir, I'm going to show you --

14 MS. HENN: Counsel, this appears to have
15 been printed without Bates number or confidentiality
16 stamp. So we would just ask, for the record, that
17 those -- the number and the confidentiality
18 designation be read into the record, if you have it.

19 MR. KENNEDY: The Bates numbers?

20 MS. HENN: The Bates number, so the people
21 on the phone know what you're looking at.

22 MR. KENNEDY: These are not Bates numbered.
23 This comes from the U.S. Department of Justice, Drug
24 Enforcement Administration.

25 MS. HENN: Has it not been produced in this

1 litigation?

2 MR. KENNEDY: Well, I can't tell you I've
3 got a memory of all 20 million documents produced, so
4 I really don't know.

5 MS. HENN: Okay.

6 BY MR. KENNEDY:

7 Q. Do you see the DEA logo on
8 Exhibit 695, sir?

9 A. Yes, I do.

10 Q. Does it say, "U.S. Department of
11 Justice, Drug Enforcement Administration"; correct?

12 A. Yes.

13 Q. Do you see the Bates stamp there?
14 They are -- they are not Bates stamped, but a date
15 stamp of July 28, 2004; do you see that?

16 A. Yes.

17 Q. And you were just telling me you
18 don't think you had knowledge of -- with respect to
19 the diversion, the addiction of hydrocodones in 2005.
20 That's what we were talking about; right?

21 MS. HENN: Objection. Asked and answered.

22 BY MR. KENNEDY:

23 Q. Correct, sir? Is that what we just
24 were talking about, your knowledge in 2005; right?

25 A. That's correct.

1 Q. And then in 2005 you were the boss
2 with respect to McKesson's regulation, diversion of
3 controlled substances; correct?

4 MS. HENN: Objection. Lacks foundation.

5 THE WITNESS: In the latter part of 2005, I
6 assumed that responsibility.

7 BY MR. KENNEDY:

8 Q. All right. And this is July '04. So
9 this is -- this is even before that date; right? So
10 this is available before that date; all right?

11 MS. HENN: Objection to form.

12 BY MR. KENNEDY:

13 Q. Go to page 2. 132 at the bottom,
14 page 2 up at the top. The second sentence,
15 "Despite." Does it state:

16 (Reading) Despite their obvious
17 utility in medical practice, as stated
18 above, hydrocodone products are among
19 the most popular pharmaceutical drugs
20 associated with drug diversion,
21 trafficking, abuse and addiction (end
22 of reading)?

23 Is it your testimony you did not know that
24 in 2005?

25 A. Counsel, as I answered, I do not

1 recall having any specific knowledge of hydrocodone
2 or this issue. This is the first time I've seen this
3 document and had no other personal knowledge.

4 Q. Well, you're in charge of Regulatory
5 in 2005; right?

6 MS. HENN: Objection to form.

7 THE WITNESS: I assume --

8 BY MR. KENNEDY:

9 Q. Correct?

10 A. I assumed responsibility for
11 Regulatory in September of 2005.

12 Q. And McKesson is selling millions upon
13 millions of hydrocodones in 2005; are they not?

14 A. I don't know specifically the
15 quantities that we were selling. We sold hydrocodone
16 as one of the controlled substances we provided to
17 our licensed pharmacies.

18 Q. Look at the first bullet. And this
19 is a -- this is in a government available document.
20 Look at the first bullet, "Hydrocodone has an abuse
21 liability similar to morphine."

22 Did you know that?

23 MS. HENN: Objection to form.

24 BY MR. KENNEDY:

25 Q. Did you know that in 2005?

1 A. No, Counsel, I -- as I said, I don't
2 have and did not have any personal knowledge of, you
3 know, hydrocodone or its comparison to morphine.

4 Q. Look at the next bullet, first
5 sentence. Now you're in charge of making sure that
6 hydrocodones as a controlled substance are not being
7 diverted; correct?

8 A. We had the responsibility --

9 Q. I asked you about, were you in charge
10 of that responsibility?

11 MS. HENN: Objection to form.

12 Let the witness finish his answer, please.

13 THE WITNESS: I had responsibility for our
14 regulatory and our compliance, which included
15 guarding against and preventing -- guarding against
16 the diversion of controlled substances.

17 BY MR. KENNEDY:

18 Q. Does the next bullet point in this
19 DEA document say, "Hydrocodone products are
20 associated with significant diversion"? Does it
21 state that?

22 A. Paragraph 2, that's what the document
23 says. And DEA is alleging, yes.

24 Q. You say, "DEA is alleging." Is that
25 what you said? Did you say, "DEA is alleging"?

1 A. This is -- this is their document.

2 Q. When you say "allege," you didn't --
3 there's not much question about that. This is more
4 than an allegation. That's the truth in 2005, from
5 everything you know, sir? Fifteen years in this,
6 that's the truth; is it not?

7 MS. HENN: Objection to form. Lacks
8 foundation.

9 THE WITNESS: Counsel, again, I -- as I
10 stated, I do not remember having any specific
11 recollection around discussions either -- or
12 documents around hydrocodone's addictive and its
13 comparison to others.

14 BY MR. KENNEDY:

15 Q. I just want to go back.

16 A. I'm just simply looking at the
17 document and trying to answer your question.

18 Q. I just want to ask you real simple.
19 You used the words, "DEA alleges." Was the problem
20 in 2005 that you and McKesson thought that these were
21 just DEA allegations with respect to hydrocodones and
22 diversion? Did you think these were just
23 allegations?

24 MS. HENN: Objection to form.
25 Mischaracterizing the testimony and lacks foundation.

1 BY MR. KENNEDY:

2 Q. Is that what you thought in 2005,
3 sir?

4 A. Counsel, I was answering your
5 question specific to this document. I don't know.
6 And certainly I'm not sure I can answer the question
7 as you asked it.

8 Q. Next says -- next bullet, first
9 sentence, "Hydrocodone products are associated with
10 significant drug abuse."

11 Did you know that in 2005, as the person who
12 was in charge of Regulatory? Did you know that?

13 MS. HENN: Objection to form.

14 THE WITNESS: Again, I don't recall being
15 specifically aware of a hydrocodone drug abuse issue.

16 BY MR. KENNEDY:

17 Q. The next bullet:

18 (Reading) Poison control data, DAWN
19 medical examiner (ME) data and other
20 ME data indicate that hydrocodone
21 deaths are numerous, widespread and
22 increasing in number (end of reading).

■

[REDACTED]

■

[REDACTED]

■

[REDACTED]

[illegible]

█ [REDACTED]

█ [REDACTED] █ [REDACTED]

█ [REDACTED] █ [REDACTED]

█ [REDACTED]

█ [REDACTED]

6 (Exhibit No. 693 was marked.)

7 BY MR. KENNEDY:

8 Q. Showing you what has been marked as
9 Exhibit 693. 693, all right, which is No. -497154.

10 Go to the second page, if you would. And I
11 believe this is a document prepared by the DEA and
12 provided to us by McKesson.

13 Do you see the chart on page -155? Do you
14 see that?

15 A. Yes.

16 Q. Now, this is McKesson hydrocodone
17 sales and distributions from October 1, now, to
18 January 31, a four-month period. We've been talking
19 about just 11 days in October.

20 This is a four-month period; do you see
21 that?

22 A. Yes.

23 Q. This is in Florida, just Florida;
24 all right?

█ [REDACTED] █ [REDACTED]

[illegible]

23 BY MR. KENNEDY:

24 Q. You do know that the DEA gets its
25 numbers from ARCOS; correct? The ARCOS database,

[illegible]

Highly Confidential - Subject to Further Confidentiality Review

■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED] [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	■ [REDACTED]
■	[REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 BY MR. KENNEDY:

7 Q. And that included, number one,
8 identifying orders of unusual size; correct?

9 MS. HENN: Objection to form.

10 THE WITNESS: In the suspicious order
11 regulation, unusual size is called out.

12 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

23 Q. Absolutely. And that's more than
24 just making sure you're selling to a pharmacy that's
25 got a license; right? Correct?

1 A. And report to the DEA.

Response	Percentage
Yes, the U.S. should take action to reduce greenhouse gas emissions	92%
No, the U.S. should not take action to reduce greenhouse gas emissions	8%

Age Group	Percentage
18-24	10%
25-34	15%
35-44	20%
45-54	25%
55-64	30%
65-74	35%
75-84	40%
85+	45%

13 BY MR. KENNEDY:

14 Q. You don't remember that that is the
15 reason that you got fined \$13 million?

16 MS. HENN: Objection to form. Lacks
17 foundation.

18 BY MR. KENNEDY:

19 Q. You don't remember?

20 A. I don't remember or have any
21 independent knowledge of whether or not any of these
22 pharmacies ever reported to DEA during that time
23 frame.

24 Q. All right. Sir, I wrote down some of
25 the dates of what we have been talking about so we

1 can put it all together here, everything we have been
2 talking about.

A collection of 30 horizontal bars of varying lengths and positions, representing a data series. The bars are arranged in a vertical stack, with some starting at the left edge and others indented. The lengths vary significantly, with some bars spanning most of the width and others being very short. The bars are a solid gray color.

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

[illegible]

Category	Percentage
1	99%
2	99%
3	99%
4	95%
5	1%
6	15%
7	1%
8	95%
9	99%
10	95%
11	1%
12	15%
13	1%
14	95%
15	99%
16	95%
17	1%
18	15%
19	1%
20	95%
21	99%
22	95%
23	1%
24	15%
25	1%
26	95%
27	99%
28	95%
29	1%
30	15%
31	1%
32	95%
33	99%
34	95%
35	1%
36	15%
37	1%
38	95%
39	99%
40	95%
41	1%
42	15%
43	1%
44	95%
45	99%
46	95%
47	1%
48	15%
49	1%
50	95%

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11 (Exhibit No. 802 was marked.)

12 MR. KENNEDY: Well, sir, let's -- let me
13 show you Exhibit 686.

14 (Exhibit No. 686 was marked.)

15 BY MR. KENNEDY:

16 Q. 686 does not have Bates numbers.

17 Sir, you indicate you don't have any knowledge of
18 McKesson -- McKesson sending massive amounts around
19 the country of hydrocodone -- excuse me,
20 hydrocodones. This is a Settlement Agreement. Look
21 at that first sentence.

22 (Reading) This is a Settlement
23 Agreement entered into on April 30th,
24 2008, between the United States
25 Department of Justice, through the

1 United States Attorney's Office, for
2 the Districts of Maryland, Middle
3 Florida, Southern Texas, Colorado,
4 Utah, and Eastern California (end of
5 reading).

6 Do you see that?

7 A. I see that.

8 Q. And the Settlement Agreement is with
9 McKesson Corporation; true?

10 A. Yes.

11 Q. You signed this document; did you
12 not?

13 A. Yes, I did.

14 Q. And that's why I'm asking, why is it
15 that you didn't have any knowledge that this was
16 going on across the country? You signed this
17 document; didn't you?

18 MS. HENN: Objection to form.

19 THE WITNESS: I signed this document,
20 Counsel.

21 BY MR. KENNEDY:

22 Q. Let's go to the next page, down to
23 No. 8 on the next page. See where it says, on No. 8,
24 paragraph 8, "The Covered Conduct shall mean the
25 following alleged conduct"? Do you see that?

1 A. Yes.

2 Q. "A: Within the District of
3 Maryland" -- and that's not Florida; right? Can we
4 agree that's not Florida?

5 A. Maryland is not Florida.

6 Q. (Reading) -- from January 2005?
7 through October 2006,
8 McKesson-Landover sold approximately
9 three million dosage units of
10 hydrocodone to New Care Pharmacy in
11 Baltimore and failed to report these
12 sales as suspicious orders to DEA when
13 discovered, as required by and in
14 violation of 21 C.F.R 1301.74(b), and
15 21 U.S.C. 842 (a)(5) (end of reading).

16 Do you see that?

17 A. Yes.

18 Q. That's 150,000 hydrocodones a month,
19 if I did the math right. Do you see that? That
20 would be 30 times the national average?

21 MS. HENN: Objection to form.

22 BY MR. KENNEDY:

23 Q. The DEA national average; right? If
24 I did my math right.

25 MS. HENN: Objection to form.

1 BY MR. KENNEDY:

2 Q. Do you see that?

3 A. Again, if using DEA's average, which
4 I can neither support or refute, and the dosage units
5 here, that your math is correct.

6 Q. That's Maryland; right? So let's
7 go -- No. B, that's the Middle District of Florida,
8 and that's probably what we've been talking about;
9 correct?

10 A. Yes.

11 Q. And then go to C. Now we're in the
12 Southern District of Texas; right? And does it
13 state:

14 (Reading) from February to December of
15 2007, McKesson-Conroe sold
16 approximately 2.6 million dosage units
17 of hydrocodone to Mercury Drive
18 Pharmacy and Maswoswe's Alternative
19 Pharmacy and failed to report those
20 sales as suspicious orders to DEA when
21 discovered (end of reading).

22 Did I read that right?

23 A. Yes, you read that correctly.

24 Q. And that's over eight months. And
25 that would be about 150,000 a month, if I did my math

1 right; correct?

2 A. If you divide what that says, that
3 would be correct for the two pharmacies.

4 Q. And, again, if the DEA was correct,
5 and that the national average is about 5,000 a month,
6 what's this? About 30 times? 30 times the national
7 average; right?

8 MS. HENN: Objection to form.

9 BY MR. KENNEDY:

10 Q. Correct?

11 A. Are you referring to the Texas
12 pharmacies?

13 Q. We're on Texas, yes, sir.

14 A. If the math -- but, again, it would
15 be -- there's two pharmacies involved. But your math
16 would be correct.

17 Q. And not one order was reported to the
18 DEA; was it?

19 MS. HENN: Objection to form. Lacks
20 foundation.

21 BY MR. KENNEDY:

22 Q. Is that right?

23 A. I don't have any specific knowledge
24 of what was or wasn't reported to DEA.

25 Q. What does it state here. "Failed to

1 report these sales as suspicious orders to the DEA";
2 does it say that?

3 A. That's what it says. That was the
4 allegation.

5 Q. Did you sign this?

6 A. I did.

7 Q. Let's go to D on the next page. This
8 is Colorado now. It states:

9 (Reading) With respect to Colorado,
10 from September 2005 through November
11 of 2007, McKesson-Aurora sold large
12 quantities of hydrocodone to three
13 Colorado pharmacies (end of reading).

14 Is that what it states with respect to
15 Colorado?

16 A. That is correct.

17 Q. E, now we're in Utah:

18 (Reading) From January 2005 through
19 October 2007, McKesson-Salt Lake City
20 sold approximately 825,000 dosage
21 units of hydrocodone, oxycodone,
22 Fentanyl and Methadone to the
23 Blackfeet Clinic in Browning, Montana
24 (end of reading).

25 Does it state that?

1 A. Yes, that's what it states.

2 Q. And, again, failed to report any of
3 these to the DEA as suspicious orders; true?

4 MS. HENN: Objection to form. Lacks
5 foundation.

6 BY MR. KENNEDY:

7 Q. Correct?

8 MS. HENN: Same objections.

9 THE WITNESS: What is written is that
10 allegation.

11 BY MR. KENNEDY:

12 Q. You signed the document; right?

13 A. I signed the agreement.

14 Q. And, again, just to backtrack a
15 second. The responsibility of McKesson, with respect
16 to suspicious orders, included identifying orders of
17 unusual size; true? Is that true?

18 A. As part of the regulation, size is a
19 factor.

20 Q. Part of your responsibility, is to
21 identify unusual orders of size; correct?

22 MS. HENN: Objection to form.

23 THE WITNESS: We were responsible for
24 reporting suspicious orders, which included unusual
25 size.

1 BY MR. KENNEDY:

2 Q. Sir, I asked you a "yes" or "no"
3 question. And we have a limited amount of time here.
4 And I know you've been instructed to repeat my
5 question in your answer to take up time. But if I
6 asked you a "yes" or "no" question, I want you to
7 answer it "yes" or "no" so we can move forward with
8 this and not waste time having you repeat my question
9 in every answer, as you've been instructed to.

10 All right?

11 MS. HENN: Counsel, I don't appreciate the
12 kind of --

13 MR. KENNEDY: But it's the truth.

14 MS. HENN: -- allegation you're making.

15 MR. KENNEDY: It's the truth, and you know
16 that.

17 MS. HENN: You don't know that. And you're
18 just arguing with the witness and wasting time.

19 MR. KENNEDY: Are you going to deny that
20 that's the truth?

21 MS. HENN: I am --

22 MR. KENNEDY: Are you going to deny that
23 that is the truth of how he has been prepared?

24 MS. HENN: Counsel, you know you have no
25 right to know anything about how he has been

1 prepared. He is here to answer your questions and
2 has been doing that in good faith, and I suggest you
3 move on and ask the question.

4 MR. KENNEDY: Absolutely. Because you know
5 I have no right to know how you have prepared the
6 witness, you know --

7 MS. HENN: Counsel --

8 MR. KENNEDY: -- you can get away with
9 instructing him to repeat my question and every
10 answer to waste our seven hours.

11 MS. HENN: Counsel, you have no basis and no
12 right to make these allegations and waste time in the
13 deposition.

14 Mr. Walker has come from retirement to spend
15 time answering your questions, and he's doing a
16 good-faith job of that. And I suggest we move on
17 from this tantrum and --

18 MR. KENNEDY: It's not a tantrum.

19 MS. HENN: -- pay attention to the job at
20 hand.

21 If you would like to call the Special Master
22 and have him review this transcript, I think he will
23 agree that the witness is doing a fine job of
24 responding to your argumentative questions, and will
25 continue to do that throughout the day.

1 MR. KENNEDY: Nobody answers questions in
2 that fashion unless they are told to do so. I
3 don't -- I don't blame him one bit. He's a gentleman
4 coming here from his retirement and having to answer
5 these questions because of the company that he worked
6 for and what they did to this country.

7 What I am objecting to is the way you have
8 instructed this witness to waste our time.

9 MS. HENN: Counsel --

10 MR. KENNEDY: That's what I am objecting to.
11 So let's be clear.

12 MS. HENN: Are you done with your speech now
13 so we can move on?

14 MR. KENNEDY: I all am done, so let's move
15 on.

16 MS. HENN: Thank you.

17 MR. KENNEDY: I hope, I just hope that he
18 ceases and stops what he is doing.

19 MS. HENN: He's not doing anything of the
20 sort. And I suggest we focus on the task at hand.

21 BY MR. KENNEDY:

22 Q. Sir, let's now go to California, if
23 we could. Does this Settlement Agreement, in
24 California state, that:

25 (Reading) From October of '07 through

1 June of '07, McKesson-West Sacramento
2 suffered the theft of significant loss
3 of controlled substances on 28
4 separate occasions and failed to
5 timely submit required theft and loss
6 reports to the DEA (end of reading)?

7 Is that what it states here? Now, this is
8 California.

9 A. That's what it states.

10 MR. KENNEDY: I want you to look at
11 Exhibit 688.

12 I'm sorry, 687.

13 (Exhibit No. 687 was marked.)

14 MR. KENNEDY: 687 Exhibit starts with Bates
15 -00574724 and ends with -4744.

16 Q. Mr. Walker, have you seen this
17 document before?

18 A. Yes, I have.

19 Q. And this would relate to a meeting of
20 "Directors of Regulatory"? Is that what it says?

21 A. Yes.

22 Q. This would have been in Dallas, March
23 5-6, 2008; true?

24 A. Yes.

25 Q. Do you remember who was present at

1 this meeting?

2 A. I don't remember specifically all the
3 participants. I know that our newly-hired Director
4 of Regulatory Affairs and my Regulatory staff was
5 there. But I don't know who else might have been
6 there.

7 Q. And the purpose of the meeting was
8 what?

9 A. As I recall, the purpose of the
10 meeting was to review with the Regulatory staff and
11 then expanded the overview of the Memorandum of
12 Agreement that we were moving forward with. We
13 hadn't signed it yet, but we were very close. So we
14 had the components.

15 Q. That was the Memorandum of Agreement
16 that we just talked about with the DEA, with the
17 Department of Justice?

18 A. Yes, the same memorandum.

19 Q. And it was signed by you, and it was
20 also signed by Mr. Hammergren, that agreement with
21 the DEA; was it not?

22 A. I'd -- I'd have to look.

23 Q. Let me ask you this. Where -- in
24 relation to the company in 2008, where were you with
25 respect to -- Mr. Hammergren was the CEO?

1 A. Yes, he's the CEO.

2 Q. Where did you sit in relation to the
3 CEO in your responsibility as with the VP of
4 Distribution and Operations? Where did you sit in
5 relation to Mr. Hammergren?

6 A. Probably best described as not very
7 close. But it was several levels, you know, down in
8 the organization.

9 Q. Would you interact with him? You
10 were both in San Francisco; right?

11 A. There were occasions that I
12 interacted with Mr. Hammergren.

13 Q. What committees did you sit on? I
14 know that -- we know your title. But were you a part
15 of any management committees at McKesson? And I'm
16 talking about the '08 period.

17 A. Yes. So in that time frame in my
18 role, I was part of the -- I will use your term --
19 management committee that oversaw -- oversaw the
20 pharmaceutical business.

21 Q. Okay. So the management committee
22 that oversaw the pharmaceutical business. And a
23 significant part of McKesson's business was the
24 pharmaceutical business, I assume?

25 A. Yes.

1 Q. And when -- who all was on the
2 management committee of pharmaceuticals?

3 MS. HENN: Objection to form.

4 BY MR. KENNEDY:

5 Q. And, again, we're on the 2008 period.

6 A. At a -- at a high level, the
7 president of U.S. Pharma and then individuals that
8 had leadership positions in sales, inventory,
9 vendor-manufacturer relationships, HR, and marketing,
10 I.T. I mean, sort of --

11 Q. Ten members? Twenty members?

12 A. My best recollection is about ten.

13 Q. And their responsibility was -- was
14 what this management committee of U.S. -- this is
15 U.S. pharmaceuticals?

16 A. Yes. U.S. pharmaceuticals.

17 Q. And what was the responsibility of
18 this management committee that you sat on?

19 A. Again, at a high level, it was really
20 to collaborate to provide overall guidance and
21 direction. And there was, you know, the normal
22 planning/budgeting processes that we went through.

23 Q. All right. Let's -- let's go back to
24 this meeting, then, that was -- that was held in 2008
25 with the Directors of Regulatory.

1 If you can go to page -- the Bates in the
2 bottom of -4733. Did you run this meeting?

3 A. Yes, I did.

4 Q. Did you prepare these slide
5 presentations?

6 A. Looking at it, I don't specifically
7 put in the slide presentation. But it was consistent
8 with one that I would do.

9 Q. All right. Well, let's look, then,
10 at this page of the 2008 slide presentation. And
11 this is talking about the 2008 Settlement Agreement
12 that is reached with the Department of Justice and
13 the DEA; correct?

14 A. Correct.

15 Q. And this is in relation to what we
16 have been talking about for the last hour; true?

17 A. Yes.

18 Q. And does this slide presentation
19 state that -- the first -- the first bullet, "Six
20 different McKesson facilities involved"; right?

21 A. Yes.

22 Q. And we went over those six different
23 facilities, I think. Florida, Maryland, Texas, Utah;
24 correct? Those are the ones we went through?

25 A. That's correct.

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 Q. And does it state, Conroe DC -- that
7 would be Texas, Conroe?

8 A. Yes.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

23 BY MR. KENNEDY:

24 Q. Sir, at this point in time, these
25 allegations, which are 2004, 2005, 2006, at that

1 point in time were the suspicious order monitoring
2 policies of McKesson national?

3 A. Yes. It was a single system. So the
4 answer is, yes.

5 Q. So the policies and the procedures
6 that led at least to what you considered to be the
7 allegations of these extraordinary sales, those
8 policies and procedures were the same in Maryland,
9 Ohio, West Virginia, Utah, Florida; would that be
10 true?

11 A. Yes.

12 Q. And as the person in charge, sitting
13 on the top of this, did you make every effort to make
14 sure that the implementation of the policies and
15 procedures relating to suspicious order monitoring,
16 that they were being implemented uniformly across the
17 country?

18 MS. HENN: Objection to form.

19 THE WITNESS: Yes, we had a system in place
20 that was reporting regularly to DEA suspicious
21 orders.

22 BY MR. KENNEDY:

23 Q. So the answer would be, yes, you, as
24 the boss, made an effort to make sure that your
25 policies with respect to suspicious orders were being

1 implemented uniformly across the country; true?

2 A. Yes.

3 Q. You didn't want somebody doing
4 something different in California than they were
5 doing in Maryland; did you?

6 A. The system was one system. So the
7 uniform reporting and report generation was the same
8 across the country.

9 Q. And would I be correct that you had
10 meetings amongst the Directors of Regulatory Affairs
11 from different regions, you had meetings and calls to
12 make sure that the policies with respect to
13 suspicious order monitoring were being implemented
14 and used by them uniformly; true?

15 MS. HENN: Objection to form. Lacks
16 foundation.

17 THE WITNESS: Can you clarify the time frame
18 you're referring to.

19 BY MR. KENNEDY:

20 Q. Again, let's -- the entire time that
21 you were the head of -- excuse me. You were the head
22 of Regulatory. You would have meetings and
23 conference calls in an attempt to make sure that your
24 policies with respect to suspicious order monitoring
25 were being implemented uniformly across the country;

1 right?

2 A. Generally I would answer that
3 question, yes, Counsel. The reason I asked you the
4 question about the time frame is at this point this
5 was the initial meeting that I had with newly-hired
6 directors. So prior to that meeting, they would not
7 have been involved in any of the suspicious orders.
8 So I want to be accurate in my response to you.

9 Q. Okay. But from '08 forward, while
10 you were in charge, again, you would have meetings,
11 you would have memos, you would have calls in an
12 attempt to make sure that your policies were being
13 implemented uniformly across the country; true?

14 MS. HENN: Objection to form. Compound.
15 Lacks foundation.

16 THE WITNESS: So subsequent to the 2008
17 agreement with the regulatory team, we had regular
18 conference calls, regular discussions to ensure that
19 we were executing our regulatory responsibilities
20 uniformly across the country; so yes.

21 BY MR. KENNEDY:

22 Q. You don't want Mr. Oriente in the
23 East doing something different from Mr. McDonald in
24 the West, doing something different than Mr. Gustin
25 in the Midwest; true?

1 A. Generally that would be accurate.

2 MS. HENN: Counsel, we have been going about
3 an hour and ten minutes. Take another break.

4 MR. KENNEDY: I about to switch to a new
5 topic. That's good.

6 THE VIDEOGRAPHER: We are going off the
7 record. The time is 11:31 a.m.

8 (Recess taken.)

9 THE VIDEOGRAPHER: We are back on the
10 record. The time is 11:49 a.m.

11 BY MR. KENNEDY:

12 Q. All right. Mr. Walker, it's still
13 Eric Kennedy after our break. I know you might be
14 disappointed, but it's still me.

15 I'm going to switch gears. I want to talk
16 about the 2008 CSMP, the Controlled Substances
17 Monitoring Program. You remember that program?

18 A. Yes.

19 Q. That was a program that McKesson
20 developed and put into place in 2008; is that true?

21 A. Yes, that is correct.

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ ■ [REDACTED]

Row	Bar Length (approx. %)
1	90
2	85
3	25
4	80
5	95
6	90
7	10
8	30
9	70
10	20
11	80
12	90
13	95
14	100
15	20
16	30
17	80
18	100
19	45
20	80
21	90
22	95
23	30

22 Q. Let me -- let me show you
23 Exhibit 672. And if you keep this exhibit in front
24 of you even after this series of questions, because
25 we're going to refer back to this quite a bit,

1 all right?

2 A. That would be fine.

3 (Exhibit No. 672 was marked.)

4 BY MR. KENNEDY:

5 Q. This is the McKesson's 2008
6 Controlled Substance Monitoring Program; is it not?

7 A. What this document is, is a -- the
8 Operations Manual entry and documentation of how to
9 execute against the Controlled Substance Monitoring
10 Program. That's probably the best way to describe
11 it.

12 Q. Was there any document that McKesson
13 has that is more comprehensive and detailed with
14 respect to your suspicious order monitoring system
15 than this document from the period of 2008 to, let's
16 say, 2014? Any document other than this that is more
17 comprehensive?

18 A. Probably this would be the most
19 comprehensive document.

20 MS. HENN: Counsel, just to clarify the
21 record. You had referred to this as the 2008
22 program, but I see it as a 2013 version. I just want
23 to make sure the record is clear on that.

24 BY MR. KENNEDY:

25 Q. Okay. This is the revised version

1 that comes into play in 2008; correct? The original
2 version is 2008?

3 A. Just a moment, Counsel.

4 MR. KENNEDY: I was -- this is when it's
5 printed, 2013. When it's printed.

6 MS. HENN: If you look on one of the last
7 pages, it will show you the revisions history.

8 MR. KENNEDY: All right.

9 MS. HENN: And the last revision I see is
10 from 11-29-2013.

11 MR. KENNEDY: All right.

12 MS. HENN: Sorry. March 20th, 2013.

13 BY MR. KENNEDY:

14 Q. And this program came into place, as
15 I said before, in 2008; did it not?

16 A. That is correct.

17 Q. And it was revised various times, as
18 we have seen, up through '13; correct?

19 A. Yes.

20 Q. And if I make reference to something
21 here in my questioning that wasn't in existence in
22 2008, you will let me know; all right?

23 MS. HENN: Objection to form.

24 THE WITNESS: I will let you know.

25 ///

1 BY MR. KENNEDY:

2 Q. All right. So this is the program
3 that comes into place, the Controlled Substances
4 Monitoring Program, in 2008; would that be correct?

5 A. Yes. This is the Controlled
6 Substance Monitoring Program overview that we would
7 put in our Operations Manual.

8 Q. And we were talking about this
9 threshold system. And do you see where it says,
10 "Purpose"?

11 A. Yes.

Age Group	Percentage
18-24	10%
25-34	15%
35-44	20%
45-54	25%
55-64	30%
65-74	35%
75-84	40%
85+	45%



■ [REDACTED] [REDACTED]
■ [REDACTED]
■ [REDACTED] [REDACTED]
■ [REDACTED]

5 MR. KENNEDY: We will take a look.

6 (Exhibit No. 755 was marked.)

7 BY MR. KENNEDY:

8 Q. Showing you Exhibit 755, Bates
9 -409289 to -299. Is this the Settlement and Release
10 Agreement and Administrative Memorandum and Agreement
11 between McKesson and the Department of Justice and
12 the DEA?

13 A. I understand this to be that, yes.

14 Q. And if you will go to Attachment 6,
15 or Bates No. -298 down at the bottom. Do you see --
16 under the -291, is what we're looking for.

17 And, again, you were a signatory on this
18 agreement? Thank you. Is that correct?

19 A. Yes, I was.

20 Q. And -291, on Bates -291, if you will
21 go to that. And do you see the section, "Obligations
22 of McKesson"?

23 You might want to look at the first four
24 lines. "Obligations of McKesson." And these are the
25 obligations under the agreement that McKesson agreed

1 to with the Department of Justice and DEA; right?

2 Does it state:

3 (Reading) McKesson agrees to maintain
4 a compliance program designed to
5 detect and prevent diversion of
6 controlled substances as required
7 under the CSA and applicable DEA
8 regulations. This program shall
9 include procedures to review orders
10 for controlled substances. Orders
11 that exceed established thresholds and
12 criteria will be reviewed by a
13 McKesson employee (end of reading).

14 Do you see that?

15 A. Yes.

16 Q. So the agreement with the DEA
17 mentions thresholds; correct?

18 A. Yes.

[REDACTED]

25 Q. And it states that you're going to

1 make informed decisions at McKesson based upon these
2 established thresholds; true? That's what your
3 program states?

4 MS. HENN: You're referring to Exhibit 672?

5 MR. KENNEDY: Yeah, I'm talking about the
6 program. We're not talking about the --

7 MS. HENN: It's a different exhibit.

8 THE WITNESS: Okay. Okay. Can you
9 repeat --

10 BY MR. KENNEDY:

11 Q. Yes, my question is --

12 A. I'm sorry. I was still --

13 Q. -- your agreement with the DEA talked
14 about thresholds; true?

15 A. Correct.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8 Q. All right. And McKesson -- if we
9 look at this program and how it's divided up, there
10 were basically two different groups of customers.
11 One, the big chain pharmacies, the RNAs, the regional
12 national accounts; correct?

13 A. That's one large customer group.

14 Q. And the other major customer group
15 that's defined in your monitoring program were the
16 ISMCs, or the independent small, medium chains;
17 correct?

18 A. That was also included. But that
19 wasn't the totality of every registrant that we
20 provided controlled substance to. So the two groups
21 that you mentioned in addition to that, would be what
22 we called our hospital or MHS group. So these were
23 hospitals, institutions, surgery centers. And then
24 probably the fourth big category was the federal
25 government.

1 Q. All right. I'm going to talk about
2 the two. I want to talk about the big chain
3 pharmacies, the RNAs; all right? And I want to talk
4 about the smaller chains, the independents and the
5 small; all right?

6 A. Yes.

A horizontal bar chart consisting of 20 rows. Each row begins with a small, solid gray square icon. To the right of each icon is a horizontal gray bar. The bars vary in their starting and ending horizontal positions across the rows, creating a staggered effect. The background is a light gray, and the bars themselves are a darker gray.

[illegible]

■ [REDACTED] [REDACTED]

■ [REDACTED]

3 (Exhibit No. 676 was marked.)

4 BY MR. KENNEDY:

5 Q. Let me show you Exhibit -- you
6 were -- you don't think that's accurate, but you
7 were -- you were the boss at this point in time in
8 '08; correct?

9 A. Yes.

10 Q. I'm going to show you Exhibit 676.
11 And that's Bates -542108 to -110.

12 This is an email from Tom McDonald. Do you
13 see that? The first page.

14 A. Yes.

15 Q. And who was Tom McDonald in this time
16 period of 12 -- or excuse me, 2012? Who was he?

17 A. Tom McDonald was the Director of
18 Regulatory Affairs for the Western part of the
19 United States.

20 Q. And so he was, what, one of four
21 directors; true? Or one of five at that point?

22 A. I don't recall specifically whether
23 we had four or six at the time. But one of four or
24 six.

25 Q. And he's sending an email to an

1 extraordinarily large group of people. Can you --
2 are you able to kind of look through that and say
3 this is -- who this group is?

4 A. Based on the names here, this is a
5 combination of our sales and operations teams in the
6 West Region.

7 Q. And you're copied on this; right?
8 Donald Walker, CC.

9 A. Yes, I am.

10 Q. So you would have gotten this; right?

11 A. Yes.

12 Q. Subject, "Ongoing due diligence, new
13 questionnaires and dispensing data." Do you see
14 that?

15 A. Yes.

16 Q. It says high -- importance is high;
17 right?

18 A. Yes.

19 Q. Look to the next page, if you would,
20 -109, all the way toward the bottom, the paragraph
21 that starts with, "Additionally."

22 A. Can I have a moment just to review
23 the rest of the document?

24 Q. Sure.

25 A. I'm not --

1 (Witness reviewing document.)

2 A. Okay.

3 Q. Look at the paragraph. This is
4 Mr. McDonald. You're copied on this. The paragraph
5 that starts, "Additionally."

6 He states:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8 BY MR. KENNEDY:

9 Q. And tell the jury, dispensing data
10 from a pharmacy, what is that?

11 A. The data that a pharmacy may or may
12 not provide was data around the quantities of a given
13 pharmaceutical or medicine that they would dispense.
14 So it was a summary document.

15 Q. So dispensing data is going to tell
16 McKesson how much the CVS store on Main Street, how
17 much Oxycontin they are selling; right? That's what
18 it would tell McKesson; correct?

19 A. I can't answer that accurately,
20 Counsel, because your example of a CVS store would
21 not be an example of that.

22 Q. All right. Okay. Take CVS out.

23 A. I'm trying to answer you accurately.

24 Q. Let's talk about an independent
25 pharmacy on Main Street. They provide you with

1 dispensing data. It's going to tell McKesson how
2 much Oxycontin that they are selling, actually
3 dispensing, filling prescriptions and dispensing;
4 that's what dispensing data is?

5 MS. HENN: Objection to form.

6 THE WITNESS: Dispensing data should
7 represent that, yes.

8 BY MR. KENNEDY:

9 Q. So Mr. McDonald, head of the Western
10 Region, in this email he says:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11 BY MR. KENNEDY:

12 Q. I understand. We know that to be
13 true, because we're reading the document. I'm asking
14 about your opinion. You were the boss. You were
15 above Mr. McDonald. You were the one that was in
16 charge of the implementation of the policies and
17 procedures at McKesson.

18 Do you agree, Mr. Walker, as being the boss?
19 Do you agree with his statement?

20 MS. HENN: Objection to form.

21 BY MR. KENNEDY:

22 Q. And he states:

[REDACTED]

[REDACTED]

[REDACTED]

Category	Percentage
1	100%
2	100%
3	100%
4	100%
5	100%
6	100%
7	100%
8	100%
9	100%
10	100%
11	100%
12	100%
13	100%
14	100%
15	100%
16	100%
17	100%
18	100%
19	100%
20	100%
21	100%
22	100%
23	100%
24	100%
25	100%
26	100%
27	100%
28	100%
29	100%
30	100%
31	100%
32	100%
33	100%
34	100%
35	100%
36	100%
37	100%
38	100%
39	100%
40	100%
41	100%
42	100%
43	100%
44	100%
45	100%
46	100%
47	100%
48	100%
49	100%
50	100%
51	100%
52	100%
53	100%
54	100%
55	100%
56	100%
57	100%
58	100%
59	100%
60	100%
61	100%
62	100%
63	100%
64	100%
65	100%
66	100%
67	100%
68	100%
69	100%
70	100%
71	100%
72	100%
73	100%
74	100%
75	100%
76	100%
77	100%
78	100%
79	100%
80	100%
81	100%
82	100%
83	100%
84	100%
85	100%
86	100%
87	100%
88	100%
89	100%
90	100%
91	100%
92	100%
93	100%
94	100%
95	100%
96	100%
97	100%
98	100%
99	100%
100	100%

A horizontal bar chart with 25 rows. Each row features a small gray square on the left, followed by a long gray bar. The bars vary in length and are positioned at different vertical levels, creating a fragmented, abstract pattern. The bars are distributed across the rows as follows:

Row	Bar Start (approx. %)	Bar End (approx. %)
1	28	82
2	28	77
3	28	87
4	23	92
5	9	89
6	23	69
7	23	84
8	9	20
9	9	33
10	23	68
11	28	85
12	28	77
13	28	68
14	23	87
15	9	90
16	9	87
17	9	42
18	23	69
19	9	33
20	23	68
21	28	87
22	9	89
23	9	87
24	9	42
25	28	82

[illegible]

Category	Percentage
1	75%
2	85%
3	25%
4	15%
5	10%
6	15%
7	85%
8	90%
9	95%
10	95%
11	80%
12	25%
13	15%
14	10%
15	85%
16	90%
17	85%
18	45%
19	15%
20	15%
21	85%
22	15%
23	15%
24	15%
25	15%
26	15%
27	15%
28	15%
29	15%
30	15%
31	15%
32	15%
33	15%
34	15%
35	15%
36	15%
37	15%
38	15%
39	15%
40	15%
41	15%
42	15%
43	15%
44	15%
45	15%
46	15%
47	15%
48	15%
49	15%
50	15%
51	15%
52	15%
53	15%
54	15%
55	15%
56	15%
57	15%
58	15%
59	15%
60	15%
61	15%
62	15%
63	15%
64	15%
65	15%
66	15%
67	15%
68	15%
69	15%
70	15%
71	15%
72	15%
73	15%
74	15%
75	15%
76	15%
77	15%
78	15%
79	15%
80	15%
81	15%
82	15%
83	15%
84	15%
85	15%
86	15%
87	15%
88	15%
89	15%
90	15%
91	15%
92	15%
93	15%
94	15%
95	15%
96	15%
97	15%
98	15%
99	15%
100	15%

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

7 Q. And he's in charge -- Mr. McDonald is
8 in charge of the Western Region. How many states did
9 that include? What states?

10 A. If there were just four of the DRAs
11 at the time, he would have had the western states,
12 and from Colorado, north to Wyoming, south to
13 Arizona -- I can't remember -- New Mexico west.

14 Q. California?

15 A. California.

16 Q. Arizona?

17 A. California, Arizona, Oregon,
18 Washington, Colorado, New Mexico.

19 Q. He's in charge of thousands of
20 pharmacies, thousands of customers; is he not?

21 A. There -- there were a lot of
22 pharmacies in the west.

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

6 BY MR. KENNEDY:

7 Q. All right. We will look at documents
8 in a minute. But I'm going to write that down.
9 All right.

10 So I wrote dispensing -- I wrote your name,
11 Mr. Walker, "Dispensing data does not include cash
12 payment information." Is that your -- is that your
13 testimony?

14 MS. HENN: Objection to form.

15 THE WITNESS: That was not my testimony.
16 What I said is your question statement was not
17 accurate.

18 BY MR. KENNEDY:

19 Q. If you get dispensing data from a
20 pharmacy, you're going to be able to see cash
21 payments; are you not, sir?

22 A. Not necessarily.

23 Q. In many instances will you be able to
24 see that, sir?

25 A. If -- if the pharmacist chooses to

1 enter a cash payment in their pharmacy terminal
2 system where this data originates, then, yes, it will
3 show up.

4 Q. All right.

5 A. If he chooses not to do that, it
6 won't show up.

7 Q. All right. And so you're getting
8 dispensing data. And if the pharmacist is putting
9 cash payments in, all right, you're going to be able
10 to see cash payments -- correct? -- from what you
11 just said, if the pharmacist is entering it; true?

12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. True?

15 A. If the pharmacist enters it into the
16 pharmacy terminal system, we would see that.

17 Q. And a certain percentage of cash
18 payments for opioids for narcotics is evidence of
19 diversion; is it not?

20 MS. HENN: Objection to form.

21 THE WITNESS: The DEA identified cash
22 payment percentage as a potential indicator.

23 BY MR. KENNEDY:

24 Q. All right. And if you get dispensing
25 data, as indicated in this memo, it's going to tell

1 you who the prescribing doctors are; is it not?

2 MS. HENN: Objection to form.

3 THE WITNESS: If the data is complete, we
4 would see the doctors -- generally see the doctors in
5 the dispensing data.

6 BY MR. KENNEDY:

7 Q. And that would allow McKesson to
8 determine whether a small group of doctors is
9 prescribing a large amount of opioids; correct? You
10 would be able to do that if you had the dispensing
11 data; true?

12 MS. HENN: Objection to form.

13 THE WITNESS: I'm not sure I can answer that
14 accurately. Generally, if the physicians are in
15 there and the data was complete, not -- our challenge
16 was, is the data wasn't always complete. So I'm
17 reluctant to say that that is accurate.

18 BY MR. KENNEDY:

19 Q. If you have accurate prescribing
20 data, McKesson would be able to determine whether a
21 small group of doctors is ordering a large percentage
22 of the opioids from that pharmacy; correct? You're
23 able to do that?

24 A. If the data was accurate, yes.

25 Q. And the DEA told you back in '06 that

1 that's one of the things that you should look for;
2 true? Back in '06 they told you?

3 MS. HENN: Objection to form. Lacks
4 foundation.

5 THE WITNESS: Repeat your question, Counsel.
6 BY MR. KENNEDY:

7 Q. And the DEA told you back in 2006
8 that's one of the things you should look for, a small
9 number of doctors ordering a large percent of the
10 opioids from a pharmacy? That's one of the things
11 you should look for?

12 A. My recollection of the document, the
13 documents state that is one of the areas that they
14 outlined.

15 Q. And if you had the doctor's name from
16 the prescribing -- or the prescribing data, you
17 could -- McKesson could research as to whether or not
18 this physician was having problems with any medical
19 board; couldn't you?

20 MS. HENN: Objection to form.

21 BY MR. KENNEDY:

22 Q. If you had that data?

23 A. I believe, Counsel -- I didn't
24 specifically make any type of inquiries myself, but
25 my understanding was, is that we -- you had the

1 ability to identify any doctors if, in fact, there
2 was documentation on state medical board sites.

3 Q. And if you got the dispensing data,

4

5 you can now actually see if a pharmacy is purchasing
6 opioids from other distributors, other than just
7 McKesson; correct?

8 MS. HENN: Objection to form. Lacks
9 foundation.

10 THE WITNESS: I don't recall that we had the
11 ability or felt we had the ability to determine
12 multiple distribution -- distributors supplying a
13 pharmacy through dispensing data.

14 BY MR. KENNEDY:

15 Q. Let me ask you this. If the
16 dispensing data says that a particular pharmacy is
17 dispensing, selling 1,000 Oxycontin in a month, and
18 your records say you're selling them only 500, then
19 you can reasonably conclude that they are getting
20 Oxycontin from somebody other than just McKesson;
21 right?

22 MS. HENN: Objection. Calls for
23 speculation.

24 THE WITNESS: Counsel, there are so many
25 variables in pharmacy behavior, in terms of inventory

1 management, again, it's very difficult for me to
2 answer accurately whether that could take place.

3 BY MR. KENNEDY:

4 Q. If you have the dispensing data,
5 McKesson would be able to determine the percentage of
6 controlled substances against total prescriptions?
7 They would be able to calculate that, wouldn't they?

8 MS. HENN: Objection. Lack of foundation.
9 Speculation.

10 THE WITNESS: Counsel, I'm having a
11 difficult time answering the question. I think it's
12 an oversimplification of analysis of the value of
13 this dispensing data.

14 As I stated, it was a very valuable tool to
15 us, but it was a single tool. We had other data
16 points that we needed to understand.

17 BY MR. KENNEDY:

18 Q. Isn't that exactly one of the things
19 that the DEA told McKesson in 2006 you ought to be
20 looking to, the percentage of controlled substances
21 that a pharmacy was selling against its total
22 prescription sales? Isn't that one of the specific
23 items that DEA informed you in 2006 you should be
24 looking at?

25 MS. HENN: Objection. Lack of foundation.

1 BY MR. KENNEDY:

2 Q. Correct?

3 A. My recollection, was that the
4 percentage of controlled substance sales were a point
5 of indication.

6 MR. KENNEDY: All right. So we've got

■ [REDACTED]

■ [REDACTED]

9 look to another region, all right? Let's look to
10 Exhibit 680.

11 (Exhibit No. 680 was marked.)

12 MS. HENN: Thank you.

13 BY MR. KENNEDY:

14 Q. Exhibit 680 is -492821 to -492823.
15 This is an email from Dave Gustin; correct?

16 A. Yes.

17 Q. Tell the jury who Dave Gustin was?

18 A. Dave Gustin was the Director of
19 Regulatory Affairs, DRA, for the Central Region.

20 Q. And the Central Region, how many
21 states are in the Central Region?

22 A. I don't know specifically the number
23 of states going from memory here, but it's basically
24 the Midwest, stretching down into Kentucky. So Iowa,
25 Nebraska, Minnesota, Illinois, Indiana.

1 Q. Well, between Mr. McDonald now and
2 Mr. Gustin, they probably account for more than half
3 of the country; would that be right?

4 A. Certainly half the geography.

5 Q. Thousands of pharmacies; right?

6 A. There would be a large number of
7 pharmacies in that area.

8 Q. And Mr. Gustin -- now, this is
9 1-16-12. This is about the same time of McDonald's
10 email talking about dispensing data. And can you
11 tell us who's this large group of people that he
12 seems to be sending this email to?

13 A. This appears to be the North Central
14 Region Sales and Operations teams.

15 Q. Look at the next page, if you would.
16 See on the next page, a January 5, 2012, email from
17 Dave Gustin?

18 A. Yes.

19 Q. Another large group of people?

20 A. Yes.

21 Q. In the first paragraph does he state:

■ [REDACTED]
■ [REDACTED]
■ [REDACTED]
■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. So he's talking about requirements,
10 and he's talking about the Controlled Substances
11 Monitoring Program of 2008; true?

12 A. Yes.

13 Q. And that program applied nationally;
14 did it not?

15 A. Yes, it did.

16 Q. Look at the next page, if you would,
17 page -23. In big capital letters, "Dispensing data."
18 Do you see that?

19 A. Yes.

20 Q. Now, this is Mr. Gustin, and he is
21 the Director of Regulatory Affairs for the entire
22 North Central Region of the United States; true?

23 A. Yes.

24 Q. And he states, and he seems -- maybe
25 he's parroting Mr. McDonald. But now he is writing

1 to his region:

Response	Percentage
U.S. should take action	85%
U.S. should not take action	15%

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

7 BY MR. KENNEDY:

8 Q. All right. Well, look at -- look at
9 your Controlled Substances Monitoring Program, if you
10 would, the program you put in place in 2008, which is
11 Exhibit 672? Back to 672, if you could.

12 MS. HENN: The 2013 version?

13 MR. KENNEDY: Yes.

14 THE WITNESS: I see it.

15 BY MR. KENNEDY:

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

1 BY MR. KENNEDY:

2 Q. Let's go back, then, if we could, to
3 Exhibit 680. This is Mr. Gustin, from the North
4 Central Region; correct?

5 A. Yes.

6 Q. And he's writing his region. And if
7 we look to bullet point 2, he states:

█ [REDACTED]

█ [REDACTED] █

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

[illegible]

A collection of 25 horizontal bars of varying lengths and positions, representing a stylized barcode or data visualization. The bars are arranged in a vertical sequence, with some starting at the left edge and others indented. The bars vary in length, with some spanning most of the width and others being much shorter. The bars are a solid dark gray color against a light gray background.

24 MR. KENNEDY: Let's look at 681,
25 Exhibit 681.

1 (Exhibit No. 681 was marked.)

2 BY MR. KENNEDY:

3 Q. Showing you what has been marked as
4 Exhibit 681, which is -490953 to -54. Now, this is

■ [REDACTED]

■ [REDACTED]

7 we have an email by Joe Lumpkin.

8 Who was Joe Lumpkin?

9 A. Joe Lumpkin was one of two of our
10 DRAs that we assigned to the Northeast Region.

11 Q. And, now, on November 30, 2012, he
12 sends an email to a large group of people; does he
13 not?

14 A. Yes.

15 Q. And he says, "Northeast Team," right,
16 at the beginning?

17 A. Yes.

18 Q. And he says, "As of December 1,
19 please be aware it is required for any ISMC" -- and
20 that would be the independent small, medium chains;
21 right?

22 A. Yes.

23 Q. He says:

■ [REDACTED]

■ [REDACTED]

[illegible]

16 BY MR. KENNEDY:

17 Q. And these are exactly the things that
18 you told us the DEA said to look out for in 2006;
19 right?

20 MS. HENN: Objection. Lacks foundation.

21 BY MR. KENNEDY:

22 Q. It's now 2012. The DEA said to
23 McKesson in 2006, these are some of the things to
24 look out for?

25 MS. HENN: Same objection.

1 BY MR. KENNEDY:

2 Q. Correct?

3 A. I'm not -- I'm not sure I understand
4 your question, Counsel. The DEA outlined the items
5 such as this in 2006, that is correct.

6 Q. And my point is, sir, it's six years
7 later -- it's 2012 -- and the entire Eastern Region
8 is saying, as of December 1, 2012, six years after
9 these have been outlined by the DEA, we're going to
10 start doing this; correct?

11 MS. HENN: Objection. Mischaracterizes the
12 document. Lack of foundation.

13 THE WITNESS: I wouldn't agree with that
14 statement. We had a number of tools we used
15 throughout the time that we executed CSMP.

16 BY MR. KENNEDY:

17 Q. Sir, other than the dispensing data,
18 where are you going to get the names of the doctors
19 prescribing medications? Where are you getting the
20 names?

21 MS. HENN: Objection to form.

22 BY MR. KENNEDY:

23 Q. Tell us.

24 A. I'm not aware of all the potential
25 sources, but -- that we could get for, you know,

1 doctors prescribing.

2 Q. Other than the dispensing data, where
3 are you going to find out what's getting paid for in
4 cash, sir? Like the DEA said six years earlier you
5 ought to look for, where are you going to find that
6 information without the dispensing data?

7 MS. HENN: Objection to form. Calls for
8 speculation.

9 THE WITNESS: I really don't know. I
10 mean --

11 BY MR. KENNEDY:

12 Q. Tell me, how are you going to run
13 percentages of controlled substances at a particular
14 pharmacy versus total prescriptions without
15 dispensing data, sir? Tell me that. Where are you
16 going to get it?

17 MS. HENN: Objection to form.

18 THE WITNESS: Again, I would -- I would
19 speculate. But I would like to clarify that DEA's
20 guidance in 2006 was percentage of sales of
21 controlled substances to total pharmacy sales.

22 BY MR. KENNEDY:

23 Q. And where are you going to get that
24 information other than dispensing data?

25 A. We would have that information from a

1 sales standpoint.

2 Q. Your sales standpoint, not the total
3 sales; correct? Your sales --

4 MS. HENN: Objection. Calls for
5 speculation.

6 BY MR. KENNEDY:

7 Q. -- but not the total sales of a
8 pharmacy; true?

9 MS. HENN: Calls for speculation.

10 THE WITNESS: Again, we -- we could look at
11 the sales record as a percentage of sales to a given
12 pharmacy.

13 BY MR. KENNEDY:

14 Q. McKesson's data, not the pharmacy's;
15 true?

16 MS. HENN: Objection to form.

17 BY MR. KENNEDY:

18 Q. True?

19 A. This was McKesson's data.

20 Q. Right. You can't do it for the
21 pharmacy because you don't know how many different
22 folks they are buying from; right?

23 MS. HENN: Objection to form. Calls for
24 speculation.

25 ///

1 BY MR. KENNEDY:

2 Q. Correct?

3 A. Again, I don't know that I can answer
4 because there's a number of different tools that we
5 could use to understand if a pharmacy was just our
6 customer.

7 Q. Tell me where in 2012, without the
8 dispensing data, you can find out the total amount of
9 oxycodone being sold by a particular pharmacy? Tell
10 me.

11 MS. HENN: Objection to form. Calls for
12 speculation.

13 THE WITNESS: I don't know.

14 BY MR. KENNEDY:

[illegible]

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

[REDACTED]

20 MS. HENN: I think we are going to have to
21 go off the record.

22 THE VIDEOGRAPHER: We are going off the
23 record. The time is 12:44 p.m.

24 (Lunch recess taken at 12:44 p.m.)

25 --o0o--

1 AFTERNOON SESSION 1:19 P.M.

2 --o0o--

3 THE VIDEOGRAPHER: We are back on the
4 record. The time is 1:19 p.m.

5 BY MR. KENNEDY:

6 Q. All right. Mr. Walker, we've talked
7 a bit about the independents, the small, medium, the
8 smaller chains. I want to switch gears now and talk
9 to you about what McKesson called the RNAs, or the
10 regional national accounts; all right?

11 A. Yes.

12 Q. You're familiar with RNA, regional
13 national account terminology?

14 A. The -- yes, I am. The correct
15 terminology is retail national account.

16 Q. I'm sorry. Those would be the big
17 chains?

18 A. Big chains.

19 Q. The CVS, the Walgreens, the Walmarts,
20 the Rite Aids; correct?

21 A. That size chain, yes.

22 Q. Those are big customers; we agree?
23 The big chains were big customers to McKesson?

24 A. Yes.

25 Q. Probably over a billion dollars worth

1 of business with big -- big national pharmacies?

2 MS. HENN: Objection. Lacks foundation.

3 THE WITNESS: I don't recall the specific
4 sales volume, but they are large -- they were large
5 customers.

6 BY MR. KENNEDY:

7 Q. I mean, would you disagree if I were
8 to say that probably the majority of McKesson's
9 controlled substance sales were being made to the big
10 retail national accounts?

11 MS. HENN: Objection to form. Lacks
12 foundation.

13 THE WITNESS: I actually cannot say because
14 it would be speculative, just due to the business
15 models of particularly some of the hospital accounts.

16 BY MR. KENNEDY:

17 Q. All right. Anyway, the big national
18 accounts made up 16,000-plus individual pharmacies;
19 does that sound right?

20 MS. HENN: Objection to form.

21 THE WITNESS: I don't recall specifically
22 the number of pharmacies that were involved in that
23 segment.

24 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 BY MR. KENNEDY:

14 Q. Now, with respect to threshold
15 increases. We talked about threshold increases in
16 the smaller chains. Let's talk about threshold
17 increases with respect to the big chains.

18 From time to time McKesson would increase
19 thresholds for pharmacies that were part of a large
20 retail account; correct?

21 MS. HENN: Objection to form.

22 THE WITNESS: Yes, we -- we would increase
23 thresholds.

24 BY MR. KENNEDY:

[REDACTED]

Category	Percentage
1	99%
2	95%
3	99%
4	90%
5	95%
6	10%
7	1%
8	99%
9	99%
10	99%
11	95%
12	90%
13	10%
14	99%
15	95%
16	95%
17	90%
18	99%
19	90%
20	95%
21	95%
22	95%
23	99%
24	90%
25	10%
26	10%
27	10%
28	10%
29	99%
30	95%
31	95%
32	95%
33	95%
34	95%
35	95%
36	95%
37	95%
38	95%
39	95%
40	95%
41	95%
42	95%
43	95%
44	95%
45	95%
46	95%
47	95%
48	95%
49	95%
50	95%
51	95%
52	95%
53	95%
54	95%
55	95%
56	95%
57	95%
58	95%
59	95%
60	95%
61	95%
62	95%
63	95%
64	95%
65	95%
66	95%
67	95%
68	95%
69	95%
70	95%
71	95%
72	95%
73	95%
74	95%
75	95%
76	95%
77	95%
78	95%
79	95%
80	95%
81	95%
82	95%
83	95%
84	95%
85	95%
86	95%
87	95%
88	95%
89	95%
90	95%
91	95%
92	95%
93	95%
94	95%
95	95%
96	95%
97	95%
98	95%
99	95%
100	95%

17 Q. Who is Elaine Thomet, if I'm saying
18 that right?

19 A. I'm sorry. Can you spell the last
20 name.

21 Q. T-h-o-m-e-t.

22 A. Thomet.

23 Q. Thomet. I am very sorry. I wasn't
24 even close.

25 Who is she or who was she in this period of

1 '08 to, let's say, '14, 2014?

2 A. My recollection is Elaine and her
3 responsibilities during that time frame, she worked
4 in our retail national account support team. She was
5 a -- as I understood it -- I don't remember her
6 title -- was primarily a liaison, you know, from the
7 retail national account support team into operations
8 and others.

9 Q. Okay. She would liaison into
10 regulatory?

11 A. On occasion, I believe that's
12 correct.

13 MR. KENNEDY: Let's look at Exhibit 677.

14 (Exhibit No. 677 was marked.)

15 MR. KENNEDY: And that is Bates -52132 to
16 -375.

17 Q. I want to look at an email, the top
18 email on the first page, -72.

19 A. I haven't seen this document before.
20 Could I just --

21 Q. Sure.

22 A. -- have a moment to familiarize
23 myself?

24 Q. Please.

25 A. Thank you.

1 (Witness reviewing document.)

2 A. Okay.

3 Q. If you want to look -- look to page
4 -74. That would be the third page in.

5 And you remember, we've had a discussion
6 about dispensing data and whether or not that was
7 required for an increase in a drug threshold for the
8 smaller independent accounts. Do you recall that
9 discussion we had? Correct?

10 A. I'm sorry. Repeat your question.

11 Q. We've -- we've had a discussion --
12 I've asked you about the requirement for dispensing
13 data in -- when increasing the threshold of an
14 independent or smaller chain. You recall that
15 discussion?

16 A. Yes.

17 MS. HENN: Objection to form.

18 BY MR. KENNEDY:

19 Q. So I want to have that discussion now
20 with respect to the regional national accounts.

21 If you look to page -74, down at the bottom,
22 you will see a November 1, 2012, email, it looks like
23 from Perry Anderson, where it says:

24 (Reading) Hi, Dan, quick question.

25 See Frank's email below regarding CSMP

1 threshold adjustments (end of
2 reading).

3 That's Controlled Substance Monitoring
4 Program; right?

5 A. Yes.

6 Q. And they are asking about threshold
7 adjustments. And he says, "Is it common -- common
8 practice in RNA" -- that would be the big chains;
9 right? Right? RNA?

10 A. Yes.

11 Q. (Reading) Is it common practice
12 in RNA to change thresholds without
13 asking for this similar backup, or is
14 it more or less done by RNA support
15 team behind the scenes for RNA
16 accounts (end of reading)?

17 Now, go back to -74. And here seems to be
18 the response. Dan Jeffries responds:

19 (Reading) We do -- we adjust at the
20 request of the customer, but we don't
21 ask for dispense data (end of
22 reading).

23 Do you see that?

24 A. Yes.

25 Q. He's talking about the regional

1 national accounts. Was that the policy -- and it's
2 2012 -- that with respect to increases in the
3 thresholds for pharmacies that were a part of the big
4 chains, you did not ask for dispensing data?

5 MS. HENN: Objection to form.

6 THE WITNESS: Generally we did not ask for
7 any dispensing data from our retail national account
8 pharmacies.

9 BY MR. KENNEDY:

10 Q. Go to page -72, the first page. Now,
11 this is an email from Elaine Thomet on 11-2-12. And
12 she says:

13 (Reading) If it helps, I will add some
14 clarification. What Frank may not
15 understand is that with RNA, the big
16 accounts, we are able to establish the
17 regulatory relationship with their
18 headquarters and not at store level
19 (end of reading).

20 Now, that's what we were talking about. You
21 were addressing the headquarters as opposed to the
22 individual stores when it came to the big national
23 accounts; true?

24 A. We used the headquarters.

25 Q. She then says:

1 (Reading) After their thresholds have
2 been initially set up, based on their
3 required usage data or historical
4 data, if they were a customer back
5 when we implemented the CSMP, then any
6 time they exceed their threshold, we
7 review it and working with their
8 headquarters and our regulatory team,
9 determine if the store should be
10 allowed an increase. If the HQs
11 agreed, then the presumption is made
12 that they have done their due
13 diligence. It also means that we are
14 not talking to the direct purchaser --
15 that's the individual pharmacy -- but,
16 rather, a representative from
17 headquarters, preferably in Regulatory
18 Loss Prevention, Asset Control,
19 et cetera (end of reading).

20 Do you see that?

21 A. Yes.

22 Q. And was that basically then the
23 practice? If headquarters said a threshold increase
24 is okay, there was at least -- in the words of
25 Ms. Thomet, there was a presumption that the

1 headquarters of the national chain had done their due
2 diligence -- had done their due diligence; is that
3 correct?

4 A. It is -- it is correct that we
5 utilized the retail national chains' headquarters
6 regulatory and oversight groups to assist us in
7 ensuring that any threshold increases were
8 appropriate.

9 Q. And you would assume that they did
10 their due diligence when saying a threshold increase
11 is okay, according to -- at least to Elaine Thomet?

12 A. Based -- based on our discussions
13 with headquarters and understanding what their
14 internal procedures were and how they conducted
15 oversight of their pharmacies, yes.

16 Q. No prescribing data was required to
17 grant a threshold increase for the pharmacy at a
18 large chain; correct? We just went through that.
19 True?

20 A. No.

21 MS. HENN: Objection to form.

22 BY MR. KENNEDY:

23 Q. And so McKesson, when increasing the
24 threshold of a pharmacy at a large chain, had no
25 direct knowledge of the physicians who were writing

1 the prescriptions at the pharmacies for the large
2 national accounts; true?

3 A. That is -- that is correct.

4 Q. You weren't able to check to see if
5 any of these physicians had an issue with a medical
6 board in the large national chains, correct, because
7 you didn't have their identity? Couldn't do that;
8 true?

9 MS. HENN: Objection to form. Calls for
10 speculation.

11 BY MR. KENNEDY:

12 Q. Correct?

13 A. It is probably more accurate to state
14 that we did not have the detail of their -- of their
15 prescriptions and the items that would be included in
16 that prescription data.

17 Q. All right. And that would include
18 the identity of the doctor; correct?

19 A. Presumably, yes.

20 Q. It would include the data that would
21 allow you to accurately run percentages on controlled
22 purchases versus non-controlled purchases; correct?

23 MS. HENN: Objection to form.

24 THE WITNESS: We wouldn't have that ability.

25 ///

1	1	1	1
2	2	2	2
3	3	3	3
4	4	4	4
5	5	5	5
6	6	6	6
7	7	7	7
8	8	8	8
9	9	9	9
10	10	10	10
11	11	11	11
12	12	12	12
13	13	13	13
14	14	14	14
15	15	15	15
16	16	16	16
17	17	17	17
18	18	18	18
19	19	19	19
20	20	20	20
21	21	21	21
22	22	22	22
23	23	23	23
24	24	24	24
25	25	25	25
26	26	26	26
27	27	27	27
28	28	28	28
29	29	29	29
30	30	30	30
31	31	31	31
32	32	32	32
33	33	33	33
34	34	34	34
35	35	35	35
36	36	36	36
37	37	37	37
38	38	38	38
39	39	39	39
40	40	40	40
41	41	41	41
42	42	42	42
43	43	43	43
44	44	44	44
45	45	45	45
46	46	46	46
47	47	47	47
48	48	48	48
49	49	49	49
50	50	50	50
51	51	51	51
52	52	52	52
53	53	53	53
54	54	54	54
55	55	55	55
56	56	56	56
57	57	57	57
58	58	58	58
59	59	59	59
60	60	60	60
61	61	61	61
62	62	62	62
63	63	63	63
64	64	64	64
65	65	65	65
66	66	66	66
67	67	67	67
68	68	68	68
69	69	69	69
70	70	70	70
71	71	71	71
72	72	72	72
73	73	73	73
74	74	74	74
75	75	75	75
76	76	76	76
77	77	77	77
78	78	78	78
79	79	79	79
80	80	80	80
81	81	81	81
82	82	82	82
83	83	83	83
84	84	84	84
85	85	85	85
86	86	86	86
87	87	87	87
88	88	88	88
89	89	89	89
90	90	90	90
91	91	91	91
92	92	92	92
93	93	93	93
94	94	94	94
95	95	95	95
96	96	96	96
97	97	97	97
98	98	98	98
99	99	99	99
100	100	100	100

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7 Q. And the DEA had informed McKesson,
8 had they not, that a list of pain clinics were a big
9 problem in our country? They had told you that; had
10 they not?

11 MS. HENN: Objection to form. Lacks
12 foundation.

13 THE WITNESS: In a prior meeting and some
14 communications, the DEA identified pain clinics.

15 MR. KENNEDY: Let me show you Exhibit 752.

16 (Exhibit No. 752 was marked.)

17 MR. KENNEDY: 752 is Bates -498169 to -183.

18 Q. This is an email from you; is it not?

19 A. Yes.

20 Q. Dated May 2nd, 2012; is that right?

21 A. Yes.

22 Q. And it looks like you're sending it
23 out to a variety of the Directors of Regulatory
24 Affairs and folks in somewhat management positions as
25 it relates to Regulatory Affairs; right?

1 MS. HENN: Counsel, let me just ask the
2 videographer, could you please close the door. Thank
3 you.

4 Could you go ahead and repeat that. I'm
5 sorry.

6 MR. KENNEDY: Yes.

7 Q. This email is being sent out by you
8 in 2012, it looks like, to the DRAs, the Directors of
9 Regulatory Affairs, and -- maybe just Directors of
10 Regulatory Affairs; right?

11 A. It appears to be restricted to the
12 regulatory team.

13 Q. And if you want to look at -174.
14 And, again, this is something -- is this a slide,
15 sir, that you would have prepared?

16 A. Yes.

17 Q. And at -174, in your slide show, "How
18 the DEA sees it." Does it state:

■ [REDACTED]
■ [REDACTED]
■ [REDACTED]
■ [REDACTED]
■ [REDACTED]
■ [REDACTED]
■ [REDACTED]

A horizontal bar chart with 20 rows. Each row has a small square icon on the left and a corresponding horizontal bar. The bars vary in length and position, representing different percentages. The categories are not explicitly labeled, but the bars represent the following approximate percentages: 10%, 25%, 15%, 35%, 40%, 55%, 30%, 20%, 75%, 65%, 45%, 30%, 15%, 25%, 35%, 60%, 85%, 45%, 30%, 15%.

Category	Percentage
1	10%
2	25%
3	15%
4	35%
5	40%
6	55%
7	30%
8	20%
9	75%
10	65%
11	45%
12	30%
13	15%
14	25%
15	35%
16	60%
17	85%
18	45%
19	30%
20	15%

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 MS. HENN: Objection. Asked and answered.

7 BY MR. KENNEDY:

8 Q. Is that your slide?

9 A. This is -- this is a slide that I
10 created.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

A horizontal bar chart with 15 rows. Each row consists of a small gray square on the left and a longer gray bar to its right. The bars vary in length and starting position, creating a fragmented, abstract pattern.

15 Q. So the big chain pharmacies represent
16 16,000 individual pharmacies. And I can't remember
17 if we agreed to that number. Does that sound about
18 right, 16,000 individual pharmacies for the big
19 national chains?

20 MS. HENN: Objection to form. Lacks
21 foundation.

22 THE WITNESS: I didn't -- I didn't agree or
23 disagree. I just don't know.

24 BY MR. KENNEDY:

Age Group	Percentage
18-24	10%
25-34	15%
35-44	25%
45-54	35%
55-64	45%
65-74	55%
75-84	65%
85+	75%

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10 BY MR. KENNEDY:

11 Q. Well, let me ask, did McKesson ever
12 think that -- let's say, for example, did they ever
13 think that CVS would report themselves to the DEA?

14 A. I'm not sure I understand that
15 question.

16 Q. Did McKesson ever believe that CVS,
17 for example, CVS headquarters, would report one of
18 their own pharmacies to the DEA?

19 A. I can't answer the question. I
20 don't -- I don't know.

21 Q. I mean, did CVS ever sit there and
22 say, well, we think that CVS headquarters will
23 contact the DEA and tell them we have a pharmacy in
24 West Virginia that is violating the law, and we think
25 you should close them down? Do you think that they

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

12 MR. KENNEDY: Give me 684.

13 (Exhibit No. 684 was marked.)

14 MR. KENNEDY: I am going to show you
15 Exhibit 684, which is McKesson -513746.

16 BY MR. KENNEDY:

17 Q. This is an email from Elaine Thomet.
18 And I believe her title was Director of RNA Support
19 Solutions. Does that sound right?

20 A. Hang on just a moment. Let me take a
21 real quick look.

22 To answer your first question, her title is
23 Director of Business Process.

24 Q. Oh, right. So she would understand
25 the process of what you folks were doing? That's

1 kind of what her job was, the process?

2 A. I believe that she understood our
3 processes.

4 Q. She sends an email on January 2,

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

1	2	3
4	5	6
7	8	9
10	11	12
13	14	15
16	17	18
19	20	21
22	23	24
25	26	27
28	29	30
31	32	33
34	35	36
37	38	39
40	41	42
43	44	45
46	47	48
49	50	51
52	53	54
55	56	57
58	59	60
61	62	63
64	65	66
67	68	69
70	71	72
73	74	75
76	77	78
79	80	81
82	83	84
85	86	87
88	89	90
91	92	93
94	95	96
97	98	99
100	101	102

[illegible]

[illegible]

[illegible]

23 MR. KENNEDY: Let me show you Exhibit 685.

24 (Exhibit No. 685 was marked.)

25 MR. KENNEDY: 685 is Bates -498295 to -307.

1 Q. Do you remember this document?

2 A. Yes, I do.

3 Q. And this is a PowerPoint that was put
4 together for presentation to the DEA; true?

5 A. The date of this document is -- and
6 my understanding of this document, based on the date
7 here, is that it was a document that we put together
8 for a review with various DEA field offices and DEA.

9 Q. Did you prepare this?

10 A. I prepared the original, yes.

11 Q. Go to page -302, if you would. See
12 where it says, "Level 1 Review"?

13 A. Yes.

14 Q. That's what we've been talking about
15 with respect to the large chain pharmacies; right?

16 A. Yes.

[REDACTED]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 MR. KENNEDY: Give me 682.

14 (Exhibit No. 682 was marked.)

15 MR. KENNEDY: Let me show you Exhibit 682.

16 Q. This is a graph of data that we put
17 together, all right? And it is based upon -- I will
18 tell you, it is based upon McKesson's transaction
19 data and sales that they provided to us. All right?

20 And so let me ask you, Rite Aid, was that a
21 big national account, one of the big retail RNA
22 accounts at McKesson?

23 A. Rite Aid was and is a large customer
24 of McKesson.

[REDACTED]

A horizontal bar chart titled 'U.S. should take action to reduce greenhouse gas emissions'. The y-axis lists age groups: 18-29, 30-49, 50-69, 70+, and 'All adults'. The x-axis shows percentages from 0 to 100. For each age group, there are two bars: a blue bar for 'Men' and an orange bar for 'Women'. The data is as follows:

Age Group	Men (%)	Women (%)
18-29	88	85
30-49	85	82
50-69	82	79
70+	79	76
All adults	80	78

[illegible]

[REDACTED]

[REDACTED]

3 MS. HENN: And, Counsel, I will just note
4 for the record that this data is all produced highly
5 confidential, and this should be marked when you
6 create exhibits with that information.

7 So we will ask that the court reporter mark
8 this 682 as highly confidential.

9 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Age Group	All respondents	People who have been vaccinated	People who have not been vaccinated	People who have been vaccinated and are also in a high-risk group	People who have not been vaccinated and are also in a high-risk group
18-24	100%	~45%	~55%	~45%	~55%
25-34	100%	~55%	~45%	~55%	~45%
35-44	100%	~65%	~35%	~65%	~35%
45-54	100%	~75%	~25%	~75%	~25%
55-64	100%	~85%	~15%	~85%	~15%
65-74	100%	~95%	~5%	~95%	~5%
75-84	100%	~98%	~2%	~98%	~2%
85+	100%	~99%	~1%	~99%	~1%

19 MR. KENNEDY: Give me 678.

20 (Exhibit No. 678 was marked.)

21 BY MR. KENNEDY:

22 Q. I am going to show you Exhibit 678,
23 which we don't have Bates numbers on. Let me give
24 you this. It's 445881-4.

25 If you go down to the bottom, this is an

1 email by Elaine Thomet again, July 17, 2014. I want
2 to see if you agree with this. Do you see the second
3 page?

4 A. Hang on just a moment. Let me just
5 take a quick look.

6 Okay. Counsel, you directed me to the
7 second page?

8 Q. Yes. Look at the second page, the
9 big letters. I mean, you just looked at it. She
10 is -- she's talking about setting up informational
11 phone calls; is she not?

12 A. Yes.

[REDACTED]

[REDACTED]

19 BY MR. KENNEDY:

20 Q. Well, let me just -- well, first,
21 tight controls. You understand CVS was fined
22 \$130 million with respect to violations of the
23 Controlled Substances Act, \$130 million fines, as you
24 tell us they had these very, very tight controls?
25 You knew that in your position, didn't you?

1 MS. HENN: Objection to form. Lacks
2 foundation.

3 BY MR. KENNEDY:

4 Q. You knew that; did you not?

5 A. I was aware CVS had paid some
6 penalties. I don't recall the amount nor do I recall
7 the events or the issues.

■ ■ [REDACTED]
■ [REDACTED]
■ [REDACTED] ■
■ [REDACTED]
■ ■ [REDACTED]

13 Q. And proxy means you are giving
14 someone else authority to act for you; is that what
15 it means?

16 MS. HENN: Objection to form. Calls for
17 speculation.

18 THE WITNESS: Generally, I would understand
19 that.

20 BY MR. KENNEDY:

■ ■ [REDACTED]
■ [REDACTED] [REDACTED]
■ [REDACTED]
■ [REDACTED]
■ [REDACTED]

[illegible]

24 Q. It's 2014, all right, when she is
25 saying that. 2014 is the date of this, is it not,

1 for this educational webinar?

2 MS. HENN: Objection to form.

3 BY MR. KENNEDY:

4 Q. Is that right?

5 MS. HENN: Mischaracterizes the document.

6 BY MR. KENNEDY:

7 Q. 2014?

8 A. The document is dated in 2014.

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ ■ [REDACTED]

■ ■ [REDACTED]

■ [REDACTED]

19 Q. And it's eight years after the DEA

20 told McKesson this is what diversion looks like;

21 right? Eight years?

22 MS. HENN: Objection to form. Lacks

23 foundation.

24 BY MR. KENNEDY:

25 Q. Eight years, sir?

1 MS. HENN: Mischaracterizes the document.

2 THE WITNESS: I think better -- a better
3 characterization there is that it was eight years
4 after DEA identified issues with Internet pharmacies.
5 They didn't reveal all of this -- these issues.

6 And, frankly, as we evolved our program and
7 gained additional information and additional
8 knowledge and ability to utilize data, we expanded
9 our enforcement and -- well, not enforcement, but our
10 oversight effort in every way that we could.

11 BY MR. KENNEDY:

[REDACTED]

23 BY MR. KENNEDY:

24 Q. And it took you eight years?

25 MS. HENN: Same objection.

1 BY MR. KENNEDY:

2 Q. Eight years to modify your program
3 after being told by the DEA this is important
4 information to have in identifying suspicious orders
5 and diversion; correct?

6 MS. HENN: Objection. Lacks foundation.
7 Mischaracterizes the documents.

8 BY MR. KENNEDY:

9 Q. Is that right, sir, eight years to
10 develop it?

11 A. It is eight years between 2006 and
12 2014. But it is not correct that DEA identified all
13 the issues and all the information that we have
14 discussed in terms of prescription data. And during
15 that time frame, prescription data resources and
16 capabilities increased significantly with technology.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 BY MR. KENNEDY:

14 Q. Sir, let me ask you this. You're
15 familiar with the Controlled Substance Act of 1970;
16 is that right?

17 A. Yes.

18 Q. And then the regulations we've talked
19 about after that relating to suspicious order
20 monitoring that came into effect, I think, in 1971?
21 We spoke about that regulation; true?

22 A. Yes, I'm familiar with that.

23 Q. Did the United States Congress ever
24 say that McKesson could give the pharmacies and the
25 big national accounts their proxy and allow them to

1 monitor themselves? Did Congress ever state that?

2 MS. HENN: Objection to form. Calls for
3 speculation.

4 THE WITNESS: Ask the question again,
5 Counsel. I'm not sure I understand what you're
6 asking.

7 BY MR. KENNEDY:

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED]

25 ///

1 BY MR. KENNEDY:

2 Q. Sir, a pharmacy is not a distributor;
3 correct?

4 MS. HENN: Objection to form.

5 BY MR. KENNEDY:

6 Q. With respect to what we're talking
7 about, some of the pharmacies would distribute to
8 themselves. But outside of that, what we're talking
9 about is, let's say, pharmacies that are not
10 self-warehousing, they have a duty and a
11 responsibility under the law as a pharmacy; correct?

12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. Is that right?

15 MS. HENN: Lacks foundation.

16 THE WITNESS: I'm not familiar with pharmacy
17 legal requirements. I understand distributor.

18 BY MR. KENNEDY:

19 Q. All right. But didn't you just tell
20 us you, as a distributor, were relying upon the
21 pharmacy and what they were required to do under the
22 law?

23 MS. HENN: Same objections.

24 BY MR. KENNEDY:

25 Q. And now you don't know what their

1 requirements are?

2 A. What I was answering was the chains
3 that we're discussing were self-warehousing chains
4 and had a distributor registration as well as a
5 pharmacy registration.

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

16 BY MR. KENNEDY:

17 Q. You understand that the
18 responsibilities under the law for a pharmacy to
19 prevent a diversion is different than the
20 responsibilities under the law of a distributor?
21 They are different; correct?

22 A. I don't understand specifically the
23 regulations associated with pharmacy. I've never
24 reviewed them. But generally I understand that they
25 are different.

1 Q. Right. And the way Congress set this
2 up, because they did not want a crisis, is they gave
3 responsibilities to the distributors, and they gave a
4 separate responsibility to the pharmacies, a belt and
5 a suspenders? It wasn't one or the other. Congress
6 wanted both to have responsibilities to prevent the
7 diversion of dangerous drugs into the communities;
8 right? A separate set of responsibilities for each;
9 correct?

10 MS. HENN: Objection to form.

11 THE WITNESS: Again, I -- I don't know what
12 Congress's intent necessarily was. I understand the
13 regulation.

14 BY MR. KENNEDY:

15 Q. And you understand the regulation
16 gave a responsibility and a set of responsibilities
17 to the two different entities? Distributors, you've
18 got your jobs, and pharmacies, you have your job;
19 correct?

20 A. I understand the distributor
21 responsibilities.

22 Q. Nowhere did it ever say that if the
23 pharmacy has responsibility, us as distributors, we
24 don't have any responsibility to prevent diversion?
25 That has never been stated anywhere; correct?

1 MS. HENN: Objection to form.

2 THE WITNESS: Again, I -- the regulations
3 are very clear what our responsibilities are.

4 MS. HENN: Counsel, is this another good
5 time for a break? It's been an hour.

6 MR. KENNEDY: Give me five minutes.

7 MS. HENN: Are you comfortable going five
8 minutes?

9 THE WITNESS: That's fine.

10 MR. KENNEDY: Let me show you Exhibit 674,
11 if I could.

12 MS. HENN: Thank you.

13 (Exhibit No. 674 was marked.)

14 BY MR. KENNEDY:

15 Q. This is Bates -507218 to -507220.

16 This is an email from Michael Oriente, if you look at
17 the top. Who is Michael Oriente?

18 A. Michael Oriente was -- was and is the
19 Director of Regulatory Affairs for the East Region --
20 Northeast Region.

21 Q. So a big responsibility. He's one of
22 four/six people; correct?

23 A. Yes, at that point in time.

24 Q. And at this point in time, he is also
25 responsible for managing and monitoring some of the

1 large national chains; true?

2 A. Yes.

3 Q. And this is April of 2011. And does
4 he state, "Dave" -- and he's sending an email to Dave
5 Gustin, who is another Regulatory Affairs person;
6 right? He's in the Midwest; right?

7 A. Yes.

8 Q. He also has some responsibility for
9 these big national chains; right?

10 A. Yes.

11 Q. And does he state, "Dave, can you ask
12 RNA" -- and that's the regional national account
13 portion of McKesson; right?

14 A. Yes.

[REDACTED]

A horizontal bar chart titled "Percentage of respondents who believe that the current government is responsible for the economic crisis in the United States". The chart displays data for two main categories: "Age" and "Gender". Each category is further divided into sub-groups, with the percentage of respondents in each sub-group who believe the current government is responsible for the economic crisis. The bars are colored in shades of gray.

Category	Sub-category	Percentage
Age	18-29	45%
	30-49	55%
	50-69	60%
	70+	60%
	18-29	55%
	30-49	50%
	50-69	55%
	70+	65%
	18-29	55%
	30-49	60%
Gender	Male	50%
	Female	55%
	Male	55%
	Female	60%

█ [REDACTED]

█ [REDACTED] █ [REDACTED]

█ [REDACTED] █ [REDACTED]

█ [REDACTED]

5 Q. And do you know he was responsible
6 for CVS for a certain portion of time; did you know
7 that?

8 A. I don't recall.

9 Q. He was in charge of Rite Aid for a
10 certain portion of time; do you know that?

11 A. I do recall he had responsibility for
12 Rite Aid.

13 Q. Kroger's?

14 A. Again, I don't remember all the ones
15 that he had.

16 Q. Costco; do you remember that?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 THE WITNESS: Again, I don't -- I don't
20 recall specifically.

21 BY MR. KENNEDY:

█ [REDACTED] █ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

16 BY MR. KENNEDY:

17 Q. Well, at this point in time -- maybe
18 there's been change, maybe people are moving around,
19 but this man, in charge of CVS and Rite Aid and
20 Costco and Krogers, he doesn't even know who to call;
21 right?

22 MS. HENN: Objection.

23 BY MR. KENNEDY:

24 Q. At this point he doesn't even know
25 who to call?

1 MS. HENN: Objection to form. Lacks
2 foundation.

3 BY MR. KENNEDY:

4 Q. Isn't that what this is saying at
5 this moment in time?

6 A. No, that's not accurate. I don't
7 believe that this is that at all. I think he is
8 ensuring that he has right information.

9 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. Well, not so much interaction that
10 Mr. Oriente even knows who to call; right?

11 MS. HENN: Objection to form.

12 THE WITNESS: Again, I think it's simply, as
13 I read this and understand the question, is more of
14 an update and clarification of who the contact people
15 are.

16 MS. HENN: Go off the record.

17 THE VIDEOGRAPHER: We are going off the
18 record. The time is 2:29 p.m.

19 (Recess taken.)

20 THE VIDEOGRAPHER: We are back on the
21 record. The time is 2:46 p.m.

22 BY MR. KENNEDY:

23 Q. Mr. Walker, we have been talking
24 about the large national --

25 THE VIDEOGRAPHER: Sorry, Counsel, your

1 microphone.

2 MR. KENNEDY: Oh, yeah.

3 Q. All right. Let me start all over.

4 Mr. Walker, we have been talking about the large
5 national accounts, and I want to talk specifically
6 about CVS; all right?

7 A. Okay.

8 Q. CVS was a large national account;
9 were they not?

10 A. CVS is a large national retail chain.

11 Q. More than that, CVS, certainly while
12 you were at McKesson, was -- they were McKesson's
13 largest customer; were they not?

14 MS. HENN: Objection to form. Lacks
15 foundation.

16 THE WITNESS: I don't recall specifically
17 where they were. They were a large customer, but we
18 were not the sole supplier. So I don't know exactly
19 what their position was in our business.

20 BY MR. KENNEDY:

21 Q. Well, you know that in the 2010,
22 2012, 2014 era, they were a customer purchasing in
23 excess of \$10 billion --

24 MS. HENN: Objection to form. Lacks
25 foundation.

1 BY MR. KENNEDY:

2 Q. -- from McKesson? Did you know that?

3 \$10 billion?

4 A. I don't have any specific knowledge
5 of what their sales volume was then.

The diagram consists of 20 horizontal gray bars of varying lengths and positions, arranged in a staggered fashion. The bars are organized into four groups of five, each group separated by a vertical dashed line. The first group of five bars starts at the left edge. The second group of five bars is indented from the left edge. The third group of five bars is also indented from the left edge. The fourth group of five bars is indented from the left edge. The bars vary in length, with some extending across most of the width and others being shorter. The bars are arranged in a way that suggests a sequence of events or a timeline, with the bars in each group appearing to be related to each other.

[illegible]

[REDACTED]

19 MR. KENNEDY: We will go through the
20 refusals. We will do that at one at a time.

21 Let's start with 698. Let's start in 2008
22 and your discussions with CVS and trying to get them
23 involved with your monitoring program.

24 (Exhibit No. 698 was marked.)

25 MR. KENNEDY: -627161 to -162.

1 THE WITNESS: Can I have a minute to review.

2 I just --

3 MR. KENNEDY: Please. Please.

4 THE WITNESS: -- haven't seen the document
5 before.

6 (Witness reviewing document.)

7 THE WITNESS: Okay.

8 BY MR. KENNEDY:

9 Q. All right. Let's start at the
10 bottom. That's the first email in time. This is
11 from Michael Oriente, an email; correct?

12 A. Yes.

13 Q. And he was one of the Directors of
14 Regulatory Affairs, who at that time was monitoring
15 the CVS stores; would that be accurate?

16 A. I believe that's correct.

17 Q. And it's April 24, 2008. This is
18 about the time that you're beginning the
19 implementation of the monitoring program at McKesson;
20 true?

21 A. Yes, we were implementing.

22 Q. And this is an email to you; right?

23 A. It's addressed to me.

24 Q. And he is recapping a call with CVS
25 on that day; right?

1 A. Yes.

2 Q. And he starts off, "Don" -- and
3 that's you. And he states:

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

[illegible]

[illegible]

A horizontal bar chart with 20 rows. Each row has a small square icon on the left and a corresponding horizontal bar. The bars vary in length, representing percentages. The categories are not explicitly labeled, but the bars represent data for each row.

Category	Percentage
1	45%
2	55%
3	65%
4	75%
5	85%
6	25%
7	65%
8	100%
9	35%
10	15%
11	45%
12	85%
13	65%
14	75%
15	55%
16	15%
17	25%
18	85%
19	65%
20	75%
21	100%
22	100%
23	95%
24	100%
25	85%

A horizontal bar chart with 20 rows. Each row consists of a small square icon on the left and a horizontal bar of varying length extending to the right. The bars are gray, and the background is white. The lengths of the bars vary significantly, representing different percentages for each category. The bars are arranged in a descending order of length from top to bottom.

Category	Percentage
1	15%
2	25%
3	85%
4	95%
5	90%
6	88%
7	88%
8	50%
9	30%
10	30%
11	25%
12	25%
13	90%
14	40%
15	40%
16	95%
17	80%
18	88%
19	82%
20	98%
21	40%
22	30%
23	90%
24	90%
25	80%
26	30%
27	30%
28	30%

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

Row	Bar Length (approx. % of total width)
1	100
2	95
3	90
4	35
5	25
6	95
7	100
8	55
9	35
10	85
11	35
12	25
13	95
14	95
15	90
16	85
17	55
18	35
19	95
20	100
21	90
22	85
23	55
24	95
25	90

25

Q. And, sir, you were -- you were in

1 charge of all the regulatory during this period, were
2 you not, 2010, 2011, and 2012? You were in charge --

3 A. Yes.

4 Q. -- correct?

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED] [REDACTED] [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

24 MR. KENNEDY: We were talking about CVS, I
25 believe, in April of '08. Let's go four months

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7 Q. Well, let me ask you this. What do
8 you think Viper was monitoring? Was it monitoring
9 controlled substances?

10 MS. HENN: Objection. Calls for
11 speculation.

12 BY MR. KENNEDY:

13 Q. Or you just don't have any idea?

14 A. I can't speculate, because I just
15 don't know.

16 Q. Well, this whole email is about the
17 Controlled Substances Monitoring Program; isn't it?

18 A. Yes, it is.

19 Q. And it says that CVS has got a
20 monitoring program. Do you think they are monitoring
21 something other than controlled substances?

22 A. Again, I don't have any -- any
23 specific knowledge or -- other than to speculate that
24 that's about controlled substances.

25 Q. So you think that they're talking

1 about monitoring toothbrushes?

2 MS. HENN: Objection to form. Asked and
3 answered. Calls for speculation.

4 THE WITNESS: Counsel, I'm trying to be
5 clear that I did not and do not understand what Viper
6 monitored, and, therefore, I can't answer your
7 question specifically whether it did or did not
8 include anything other than controlled substances or
9 whether -- you know, what it oversaw.

10 BY MR. KENNEDY:

11 Q. Well, let me -- this is an email to
12 you. You're in charge of Regulatory, which relates
13 to controlled substances; right?

14 A. Yes.

15 Q. The topic -- or the subject of the
16 email is your Controlled Substances Monitoring
17 Program; correct? Correct?

18 A. Yes.

19 Q. They are talking about thresholds and
20 Threshold Change Requests relating to controlled
21 substances; are they not?

22 A. Yes.

23 Q. Right? They are talking about
24 thresholds in relationship to controlled substances;
25 are they not?

[illegible]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5 MR. KENNEDY: Mark this, please.

6 THE REPORTER: 803.

7 (Exhibit No. 803 was marked.)

8 MR. KENNEDY: I show you Exhibit 700.

9 (Exhibit No. 700 was marked.)

10 BY MR. KENNEDY:

11 Q. I show you Exhibit 700, which is
12 -555948 to -950.

13 (Witness reviewing document.)

14 Q. You get an email from Elaine Thomet,
15 August 26, '08. We're still talking about CVS, and
16 it is -- you are copied on this email; are you not?

17 A. Yes, I am.

18 Q. And it says:

19 (Reading) Team, here's the recap from
20 our meeting with Don this morning (end
21 of reading).

22 And Don is you; right?

23 A. Yes.

24 Q. And it says:

[REDACTED]

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

A horizontal bar chart with 20 rows. Each row has a small square marker on the left and a corresponding horizontal bar. The bars vary in length and position, representing percentages. The categories are not explicitly labeled, but the bars represent data points for each category.

Category	Percentage
1	85%
2	95%
3	70%
4	85%
5	80%
6	75%
7	95%
8	80%
9	85%
10	85%
11	85%
12	45%
13	80%
14	95%
15	95%
16	85%
17	90%
18	10%
19	55%
20	65%
21	80%
22	25%
23	85%
24	25%
25	85%

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

12 MR. KENNEDY: All right. Let's go forward,
13 then, a couple months into this, in November of '08,
14 and look at 701.

15 (Exhibit No. 701 was marked.)

16 BY MR. KENNEDY:

17 Q. I'm looking at the Elaine Thomet's
18 email, November 12 of 2008, to you and others. But
19 it's sent to you.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

10 BY MR. KENNEDY:

11 Q. And you don't know what Viper is;

12 right?

13 A. I don't remember what Viper is.

14 Q. Did anybody ever know what Viper was?

15 A. I don't know.

16 Q. You don't know.

17 Would you be surprised to know that Viper is

18 not a Controlled Substance Monitoring Program for any

19 controlled substances that CVS purchased from

20 McKesson?

21 MS. HENN: Objection to form. Lack --

22 BY MR. KENNEDY:

23 Q. Would that be surprising to you?

24 MS. HENN: Objection to form. Lacks

25 foundation.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11 MR. KENNEDY: Let's go to Exhibit 702.

12 (Exhibit No. 702 was marked.)

13 MS. HENN: Thank you.

14 MR. KENNEDY: This is an email from Ned.

15 MS. URQUHART: Could we get the Bates
16 number, please.

17 MR. KENNEDY: -627150 to -158.

18 Q. This is from Ned McKenna of McKesson;
19 correct?

20 A. Yes.

21 Q. And it's being sent to CVS; correct?

22 A. Yes.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

4 MR. KENNEDY: Let's look how that worked,
5 all right? Give me 703, please.

6 (Exhibit No. 703 was marked.)

7 MR. KENNEDY: This is Exhibit 703, -535756
8 to -901.

9 Q. I'm going to start with the bottom
10 email. That's from Dave Gustin. All right?

11 A. Okay.

12 Q. And the subject is, "Hydrocodone
13 Increase." We know what hydrocodone is, right, a
14 controlled substance? Right?

15 A. Yes.

16 Q. And it says:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

23 What does that stand for?

24 A. I don't know.

25 Q. That's related to the hydrocodone;

1 right? So you're going to increase the hydrocodone

2 THD for WM. Is that Walmart?

3 A. I believe so.

█

█

█

█

█

█

█

█

█

█

█ █

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

[REDACTED]

20 Now we're two years later with CVS; all right?

21 Exhibit 704.

22 (Exhibit No. 704 was marked.)

23 MR. KENNEDY: -512900 to -01 and then -02.

24 Q. If you will go to page -- the first
25 page, -900, Exhibit 704, the bottom email. That's

1 from Rhonda Fargo, that bottom email?

2 A. The bottom of -900?

3 Q. Yes.

4 A. Yes.

5 Q. And now it's February of 2010, two
6 years after the CSMP has been put into place. And
7 she's sending an email to different directors in
8 Regulatory Affairs; correct?

9 A. Yes.

10 Q. She says:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 MS. HENN: Objection to form. Lacks
7 foundation.

8 Counsel, we're over an hour. Take a five-,
9 ten-minute break.

10 THE VIDEOGRAPHER: We are going off the
11 record. The time is 3:51 p.m.

12 (Recess taken.)

13 THE VIDEOGRAPHER: We are back on the
14 record. The time is 4:07 p.m.

15 MR. KENNEDY: I show you Exhibit 713, which
16 is Bates -627066.

17 (Exhibit No. 713 was marked.)

18 BY MR. KENNEDY:

19 Q. Do you see that email? I just wanted
20 to look at the last sentence in that email.

21 A. I see the email there.

22 Q. You're right. Do you see that
23 last --

24 A. The last sentence at the bottom?

25 Q. Yes. Ned is from -- Ned is from

1 McKesson?

2 A. Ned is from McKesson.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1 Q. And does that email -- and it's CVS
2 Action Plans. That's the subject; true? Do you see
3 that?

4 A. Yes.

5 Q. And it states:

[REDACTED]

[illegible]

[REDACTED]

10 Q. This is 2010, two years after the
11 original CSMP; is it not, sir?

12 A. Two years after we implemented.

[REDACTED]

20 MR. KENNEDY: Let's look at the CVS program
21 and where it led to; all right? Give me Exhibit 708,
22 please.

23 (Exhibit No. 708 was marked.)

24 BY MR. KENNEDY:

25 Q. The metadata indicates that this is

11 MR. KENNEDY: That's 2010. Let's go two
12 years forward and look at CVS and see how the
13 threshold system was working.

14 Let's go to 2012, Exhibit 709.

15 (Exhibit No. 709 was marked.)

16 BY MR. KENNEDY:

17 Q. This is from Tom McDonald. Tom
18 McDonald, at this point in time, he was the Director
19 of Regulatory Affairs and was responsible for CVS;
20 was he not?

21 MS. HENN: Objection to form. Lacks
22 foundation.

23 BY MR. KENNEDY:

24 Q. 2012.

25 A. I believe in 2012 Tom McDonald was --

A horizontal bar chart consisting of 20 rows. Each row begins with a small, solid black square marker. The bars themselves are horizontal rectangles of varying lengths and positions, extending to the right from the markers. The bars are distributed across the rows as follows:

- Row 1: A long bar extending almost to the right edge.
- Row 2: A long bar extending almost to the right edge.
- Row 3: A short bar extending about one-third of the way across.
- Row 4: Two bars, one starting at the second marker and another starting at the fourth marker.
- Row 5: A long bar extending almost to the right edge.
- Row 6: A long bar extending almost to the right edge.
- Row 7: A short bar extending about one-third of the way across.
- Row 8: Two bars, one starting at the second marker and another starting at the fourth marker.
- Row 9: A short bar extending about one-third of the way across.
- Row 10: Two bars, one starting at the second marker and another starting at the fourth marker.
- Row 11: A short bar extending about one-third of the way across.
- Row 12: Two bars, one starting at the second marker and another starting at the fourth marker.
- Row 13: A long bar extending almost to the right edge.
- Row 14: A short bar extending about one-third of the way across.
- Row 15: A short bar extending about one-third of the way across.
- Row 16: Two bars, one starting at the second marker and another starting at the fourth marker.
- Row 17: A long bar extending almost to the right edge.
- Row 18: A short bar extending about one-third of the way across.
- Row 19: A short bar extending about one-third of the way across.
- Row 20: Two bars, one starting at the second marker and another starting at the fourth marker.

23 Q. And oxycodone, sir, was at the center
24 of the opioid crisis in this country by 2012; was it
25 not?

[illegible]

[REDACTED]

18 Q. And, sir, the law says you stop
19 shipping until you do your due diligence; isn't that
20 what the law says?

21 MS. HENN: Objection to form. Lack of
22 foundation.

23 BY MR. KENNEDY:

24 Q. Right?

25 A. No, that --

1 Q. This is 2012.

2 A. Can I finish, Counsel.

3 MS. HENN: Yes, you can.

4 BY MR. KENNEDY:

5 Q. My question is --

6 MS. HENN: Counsel, he would like to finish
7 his answer.

8 MR. KENNEDY: I didn't finish my question.

9 Q. Isn't that the law in 2012, you don't
10 ship if you have a concern?

11 MS. HENN: Mr. Walker, do you need the prior
12 question back so you can answer?

13 MR. KENNEDY: It's the same question.

14 THE WITNESS: I think I can answer the
15 question.

16 MS. HENN: Okay.

17 THE WITNESS: Counsel, there is no
18 regulation to stop shipping controlled substances.
19 The regulation requires that we report suspicious
20 orders.

21 MR. KENNEDY: We're going to write this one
22 down.

23 Q. How long has that been your view? In
24 2007 -- let's start with 2007 -- was McKesson
25 required to not ship until it did its due diligence

1 on potentially suspicious orders? Was that required
2 in 2007?

3 MS. HENN: Objection to form.

4 BY MR. KENNEDY:

5 Q. Don't ship until we do our due
6 diligence?

7 MS. HENN: Objection to form. Lack of
8 foundation.

9 BY MR. KENNEDY:

10 Q. Was that required of McKesson in
11 2007, do not ship until we do our due diligence?

12 MS. HENN: Same objection.

13 THE WITNESS: There is no regulatory
14 requirement to not ship. There is a regulatory
15 requirement to report.

16 BY MR. KENNEDY:

17 Q. All right. And did the DEA tell you
18 in 2006 that you are required not to ship until you
19 do your due diligence on a potentially suspicious
20 order? Did they tell you that in '06 in a letter to
21 McKesson?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 BY MR. KENNEDY:

25 Q. Did they tell you that in '06 in a

[illegible]

25

MR. KENNEDY: I show you 707.

1 (Exhibit No. 707 was marked.)

2 BY MR. KENNEDY:

3 Q. A PowerPoint prepared by you?

4 MS. URQUHART: Could we get the Bates
5 number, please?

6 MR. KENNEDY: Pardon me?

7 MS. URQUHART: Could we get the Bates
8 number, please?

9 MR. KENNEDY: Just don't interrupt my
10 question, and I will be right back with you,
11 all right?

12 Q. 707, Exhibit 707, is a PowerPoint,
13 "CVS - Regulatory PowerPoint"; is it not?

14 THE WITNESS: This is a -- appears to be a
15 PowerPoint presentation from McKesson to CVS.

16 BY MR. KENNEDY:

17 Q. So my answer is, "Yes"? Is the
18 answer to my question, "Yes"?

19 MS. HENN: Objection to form.

20 THE WITNESS: It's a McKesson PowerPoint.
21 You asked if it was a CVS PowerPoint. It's a
22 McKesson PowerPoint.

23 BY MR. KENNEDY:

24 Q. Does it say, "CVS - Regulatory
25 Review"?

1 A. It's a CVS regulatory review.

2 Q. Prepared by you?

3 A. Yes.

4 Q. Bates No. -497980 to -89. This is
5 March of 2012? Is that correct?

6 A. Yes, that's the date on the document.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

18 Q. And the DEA had been talking to you
19 about this being important since 2006; right?

20 MS. HENN: Objection to form. Lack of
21 foundation.

22 THE WITNESS: The DEA had identified
23 prescribing doctors as an area of focus.

24 BY MR. KENNEDY:

[illegible]

[illegible]

A horizontal bar chart consisting of 25 rows. Each row begins with a small, dark gray square icon. To the right of each icon is a horizontal gray bar. The length of each bar varies, representing a quantitative value for each row. The bars are arranged in a descending order of length from top to bottom, starting with a bar that is nearly the full width of the chart area and ending with a very short bar. The background of the chart is a light gray, and the bars themselves are a darker gray.

[REDACTED]

19 Q. And -- and the DEA had been telling
20 you since 2006, this is important information to have
21 to identify diversion; correct?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 BY MR. KENNEDY:

25 Q. It's six years later.

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

19 BY MR. KENNEDY:

20 Q. Let's switch topics. We will talk
21 about sales, McKesson, sales and promotion as it
22 related to the Controlled Substances Monitoring
23 Program.

24 Can we agree that sales should have nothing
25 to do with the Controlled Substances Monitoring

1 Program, should not have anything to do with it? Do
2 you agree with that?

3 A. Can I clarify, Counsel. Are you
4 referring to our sales force?

5 Q. Your sales force, your sales
6 strategy, your sales goal should have nothing to do
7 with your job as the head of Regulatory to monitor
8 controlled substances?

9 MS. HENN: Objection to form. Compound.

10 THE WITNESS: I would not agree that our
11 sales force should not be involved in the Controlled
12 Substance Monitoring Program. I would agree that
13 sales never influenced our decisions around our
14 regulatory responsibilities.

15 BY MR. KENNEDY:

16 Q. Okay. Well, let's look at that.
17 Let's look at that.

18 First of all, how many sales reps -- did you
19 know how many national sales reps McKesson had,
20 regional sales manager? Hundreds?

21 A. I'm going to -- it would be a guess
22 that we had -- it would probably be less -- you know,
23 150 or less. I really don't remember exactly.

24 Q. And the First Service -- the sales
25 assistants, the First Service folks that were located

1 down in Texas, I think I've read there were a hundred
2 sales assistants down in Texas; do you recall that?
3 First Service.

4 MS. HENN: Objection. Objection to form.

5 THE WITNESS: Counsel, our -- it's called
6 Service First.

7 MR. KENNEDY: I'm sorry.

8 THE WITNESS: Our Service First organization
9 was not just a sales support organization. It was
10 really a customer -- customer service call center.

11 BY MR. KENNEDY:

12 Q. You had the Regional Sales Managers.
13 How many District sales folks above the -- above the
14 Regional Sales Managers were there? If there's 100
15 to 150 Sales Managers, how many District sales folks
16 were above them?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 THE WITNESS: I don't remember specifically
20 how many there were.

21 BY MR. KENNEDY:

22 Q. How many marketing folks were there,
23 people that had put together the marketing sales
24 programs above the -- let's say the District Sales
25 Manager? How many were those in that department,

1 let's say, nationally?

2 MS. HENN: Objection to form.

3 THE WITNESS: Our marketing group was not
4 based in the field. We had a marketing group that
5 was headquartered. I don't remember what the
6 specific number of marketing people we had. I
7 would -- I would estimate, and it would be a pure
8 estimation, it was probably 35.

9 BY MR. KENNEDY:

10 Q. So you maybe have 150 Sales Managers
11 across the country, and you've got District Sales
12 Managers above them. McKesson has got 35 people
13 working in marketing. Is that in San Francisco?
14 Would that be here?

15 A. Yes. All the marketing at the time
16 was at our headquarters in San Francisco.

17 Q. And you've got a hundred customer
18 service reps sitting at a call center. They were
19 down in Texas; right?

20 MS. HENN: Objection to form. Lacks
21 foundation.

22 THE WITNESS: Our Service First organization
23 was based in Texas, and we also had a satellite --
24 and at that time I think we had a satellite in
25 Phoenix that, again, I can't remember specifically

1 how many people were there.

2 BY MR. KENNEDY:

3 Q. And I'm -- I'm -- for what we've
4 said, I'm counting up close to -- close to 300 people
5 in marketing and sales at McKesson; would that be
6 about right?

7 MS. HENN: Objection to form. Lacks
8 foundation.

9 THE WITNESS: Again, I'm concerned about
10 guessing on the numbers.

11 MR. KENNEDY: All right.

12 THE WITNESS: But it's --

13 BY MR. KENNEDY:

14 Q. Well, one thing you're not guessing
15 on back in 2006 or '7, in Regulatory, watching
16 opioids, there was three; right? Three people?

17 MS. HENN: Objection to form. Lacks
18 foundation.

19 BY MR. KENNEDY:

20 Q. Three?

21 A. That -- that's not accurate because
22 our Field Operations Team, our Distribution Center
23 Managers, and their second in command were also very
24 heavily involved in regulatory compliance.

25 Q. Five hours ago didn't we look at a

1 slide you presented to the DEA and said, prior to
2 2008 our regulatory team had three people?

3 MS. HENN: Objection to form.

4 BY MR. KENNEDY:

5 Q. You, Mr. Hilliard, and another
6 gentleman. Isn't that the representation to the DEA
7 on the slide that we looked at six hours ago?

8 MS. HENN: Objection to form.
9 Mischaracterizing the document.

10 THE WITNESS: What I was representing in
11 that document was what our Regulatory Affairs staff
12 group was. Again, we very strongly utilized our
13 Field Operations Teams in terms of our regulatory
14 compliance, and ensured that at a local level we had
15 oversight.

16 BY MR. KENNEDY:

17 Q. Sir, McKesson paid a \$13 million fine
18 in 2008; correct?

19 A. We paid -- as a result of the
20 agreement, we paid a penalty of \$13 million.

21 Q. So the answer would be "Yes"; right?

22 MS. HENN: Objection to form. Asked and
23 answered.

24 BY MR. KENNEDY:

25 Q. Would the answer be "Yes"?

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, which supports the hypothesis that was tested.

4. The fourth part of the document discusses the implications of the findings for future research and practice. It suggests that the results could be used to inform policy decisions and to guide the development of new programs and initiatives.

5. The fifth part of the document provides a conclusion and a summary of the key points. It reiterates the importance of the study and the need for continued research in this area.

6. The sixth part of the document includes a list of references to the sources used in the study. It also includes a list of appendices that provide additional information and data.

7. The seventh part of the document is a glossary of terms that are used throughout the document. It defines the key concepts and provides a clear understanding of the terminology used.

8. The eighth part of the document is a list of figures and tables that are included in the study. It provides a clear overview of the data presented and allows for easy comparison and analysis.

9. The ninth part of the document is a list of footnotes that provide additional information and references. It includes a list of sources that were consulted during the research process.

10. The tenth part of the document is a list of acknowledgments that thank the individuals and organizations that provided support and assistance during the study.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 MR. KENNEDY: Give me 722, please.

14 (Exhibit No. 722 was marked.)

15 BY MR. KENNEDY:

16 Q. You have seen this document before;

17 haven't you, sir?

18 A. Give me a minute. I don't think

19 I've -- certainly, if it's an email that I generated.

20 But I don't remember having seen it.

21 Q. Bates No. -543914 to -16.

22 A. Okay.

23 Q. Go to the last page, -916, because

24 this is where this exchange begins.

25 Okay. You see the email from Gary Hilliard?

1 And this is October 23, 2006. This is during the
2 period when you're trying to put together your
3 monitoring program; correct?

4 A. Yes, this would be during the time
5 frame we were creating the IT development for --

6 Q. And Gary Hilliard --

7 MS. HENN: Did you finish your answer, sir?

8 THE WITNESS: The IT development program for
9 the CSMP.

10 MS. HENN: Thank you.

11 BY MR. KENNEDY:

12 Q. Gary Hilliard, at that point he is
13 the Director of Regulatory Affairs; right?

14 A. I believe Gary's title at the time
15 was Regulatory. He's on the Regulatory staff, and I
16 believe that title is correct.

17 Q. He states in this email -- do you
18 know Sharon Mackarness? Who that is?

19 A. I'm familiar with the name. Sharon
20 Mackarness was one of our -- the McKesson I.T.
21 associates who was responsible for pieces of
22 development and interface with CSMP.

23 Q. This is a year-and-a-half before your
24 monitoring program goes into place; true?

25 MS. HENN: Objection to form.

1 Mischaracterizes the evidence.

2 THE WITNESS: October 2006. We implemented

3 in the spring of 2008. So roughly that time frame.

4 BY MR. KENNEDY:

5 Q. It states:



12 MS. HENN: Objection to form.

13 BY MR. KENNEDY:

14 Q. That's basically what she's saying?
15 She's responding, and she's asking some I.T.
16 questions about the establishment of the program?

17 A. It appears that she is asking
18 questions to get the information she needs for system
19 design.

20 Q. And she is -- again, she's
21 referencing a meeting that occurred that morning,
22 October 26, 2006; right?

23 A. Yes.

24 Q. And go to the earlier page, -15. The
25 same day Sharon McGinnis -- Mackarness, excuse me,

1 from I.T. at McKesson, she writes an email to Gary
2 Hilliard; correct?

3 A. At the bottom of the page, yes.

4 Q. And she copies two other folks.

5 VanderWerf; correct?

6 A. Yes.

7 Q. And she says, "Gary," right? Gary?

8 A. Yes.

9 Q. In the second paragraph she says,
10 "JD," and that's probably referencing Jean-Dou up
11 ahead? Up above, JD?

12 A. Yes.

13 Q. Do you know JD, who he was?

14 A. Another I.T. individual.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

[illegible]

Highly Confidential - Subject to Further Confidentiality Review

■	[REDACTED]
■	■ [REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED] [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]

Row	Bar Start (%)	Bar End (%)
1	0	100
2	0	75
3	0	100
4	0	90
5	0	25
6	0	95
7	0	50
8	0	20
9	25	100
10	0	85
11	0	90
12	25	100
13	0	55
14	25	40
15	25	75
16	25	40
17	25	90
18	0	85
19	0	85
20	0	20
21	0	35
22	25	100
23	0	85
24	0	100
25	0	95
26	0	60

23 MS. HENN: Objection to form. Lacks

24 foundation.

25 ///

1 BY MR. KENNEDY:

2 Q. Isn't that true, sir?

3 A. I'm not sure I understand the
4 question as asked.

5 Q. Well, we will go through some detail,
6 then.

7 First of all, you knew and understood that
8 the salespeople at McKesson were paid on commission;
9 did you not?

10 A. Our sales force was -- has a
11 portion -- my understanding is a portion of their
12 compensation, there was variable compensation
13 associated with various programs.

14 Q. The more they sold, the more money
15 they made, very simple; isn't that true?

16 MS. HENN: Objection to form. Lacks
17 foundation.

18 THE WITNESS: To my knowledge, that's not
19 accurate. It wasn't -- it's not that simple of a
20 calculation or process.

21 BY MR. KENNEDY:

22 Q. In fact, didn't you know and
23 understand that a salesperson could double, could
24 double their annual income based upon sales?

25 A. I don't have any specific knowledge

1 on what the percentages or the proportions were.

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

17 BY MR. KENNEDY:

18 Q. All right. Salespeople also got paid
19 if they brought in a new pharmacy, a new customer
20 into McKesson; didn't they? They also got paid if
21 they did that; true?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 THE WITNESS: Again, I don't have any
25 specific knowledge of what they were paid. But I

1 believe there was compensation associated with new
2 business.

3 BY MR. KENNEDY:

4 Q. And, sir, before McKesson -- under
5 their 2008 program, before McKesson would sell
6 opioids to a pharmacy, they went through an
7 on-boarding process; did they not?

8 A. Yes.

[REDACTED]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7 Q. And McKesson knew and you knew and
8 the salespeople knew that if we bring in a new
9 customer, number one, I'm going to get a bonus as a
10 salesperson for bringing in a new customer, and,
11 number two, my sales are going to increase if I get a
12 new customer, and I'm going to make more money; you
13 all knew that, right?

14 MS. HENN: Objection to form.

15 BY MR. KENNEDY:

16 Q. You knew that?

17 A. Again, I think that's oversimplifying
18 the sales force compensation.

19 Q. Now, also built right into your
20 program for the salespeople, you told us -- we've

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

A horizontal bar chart with 15 rows. Each row consists of a small square on the left and a gray bar of varying length. The bars are arranged in a pattern that suggests a sequence or flow, with some bars starting at different horizontal positions.

19 MR. KENNEDY: Let's look at Exhibit 730.

20 I'm going to withdraw that exhibit. Give me
21 732, please.

22 (Exhibit No. 732 was marked.)

23 BY MR. KENNEDY:

24 Q. Do you see this email? This is from
25 you dated 9-17-13; do you see that?

1 A. Yes.

2 Q. And the next page says, "Controlled
3 Substances Regulatory Org Structure." Do you see
4 that?

5 A. Yes.

6 Q. This is created by you?

7 A. Yes.

8 Q. And this is 2013. And if you go to
9 page -500. Do you see that? Look at the second
10 bullet point. Do you see that second bullet point?

11 A. Yes.

12 Q. In 2013 you write:

Figure 1. The effect of the number of trials on the number of correct responses.

Response	Percentage
Yes, the current system is the best way to run the country	55%
No, the current system is not the best way to run the country	45%



Response	Percentage
Yes, the U.S. should take action to reduce global warming	85%
No, the U.S. should not take action to reduce global warming	15%

Figure 6

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8 BY MR. KENNEDY:

9 Q. And, sir, over and above these
10 salespeople that we're talking about, you had -- you
11 had marketing people at McKesson; did you not? We
12 have talked about them.

13 MS. HENN: Objection to forms. Lacks
14 foundation.

15 BY MR. KENNEDY:

16 Q. There were marketing people at
17 McKesson; were there not?

18 A. Yes, there was a marketing
19 department.

20 Q. And while you were trying to control
21 the flow of opioids into the communities and the
22 pharmacy, the marketing people were trying to sell
23 more opioids; were they not?

24 MS. HENN: Objection to form. Lacks
25 foundation.

1 THE WITNESS: No, that's not accurate.

2 MR. KENNEDY: 720.

3 (Exhibit No. 720 was marked.)

4 BY MR. KENNEDY:

5 Q. The first email in time is number one
6 at the bottom. That's where it starts in time.
7 -543462 to -63.

8 This is an email from Scott Mooney, and this
9 is to you, January 16 of 2008, importance high. It
10 states:

[REDACTED]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

11 Q. Now I want to go to two months later.

12 Tell the jury what fentanyl is?

13 A. Fentanyl is a Schedule 2 narcotic.

14 Q. And is it the most powerful,

15 dangerous of all the narcotics you sell?

16 MS. HENN: Objection to form. Lacks

17 foundation.

18 BY MR. KENNEDY:

19 Q. Is that true, sir?

20 A. I do not know. I know it's a very

21 powerful pain control narcotic.

22 MR. KENNEDY: 714.

23 (Exhibit No. 714 was marked.)

24 BY MR. KENNEDY:

25 Q. There's an email down at the bottom.

1 Kenneth Ball. And this is two years after you're
2 saying we've got to discuss promos. And he states:

[illegible]

[illegible]

■ [REDACTED]

■ [REDACTED] ■ [REDACTED]

3 Q. Let's look to 2012, two years later,
4 two years after that 7-19.

5 A. Again, Counsel, we would not have
6 changed any thresholds on any of our customers in
7 support of any promotions.

8 Q. Mr. Walker, you got fined
9 \$150 million in 2018 for changing thresholds; didn't
10 you?

11 MS. HENN: Objection to form. Lacks
12 foundation.

13 BY MR. KENNEDY:

14 Q. Is that true? Did you get fined
15 \$150 million in 2018, McKesson?

16 A. I wasn't with McKesson at the time.
17 I understand that McKesson paid \$150 million.

18 (Exhibit No. 719 was marked.)

19 BY MR. KENNEDY:

20 Q. Let's go to 719. We're still on

■ [REDACTED] [REDACTED]

■ [REDACTED] [REDACTED] [REDACTED]

■ [REDACTED] [REDACTED] [REDACTED]

■ [REDACTED]

■ [REDACTED] [REDACTED]

1	1	1	1
2	2	2	2
3	3	3	3
4	4	4	4
5	5	5	5
6	6	6	6
7	7	7	7
8	8	8	8
9	9	9	9
10	10	10	10
11	11	11	11
12	12	12	12
13	13	13	13
14	14	14	14
15	15	15	15
16	16	16	16
17	17	17	17
18	18	18	18
19	19	19	19
20	20	20	20
21	21	21	21
22	22	22	22
23	23	23	23
24	24	24	24
25	25	25	25
26	26	26	26
27	27	27	27
28	28	28	28
29	29	29	29
30	30	30	30
31	31	31	31
32	32	32	32
33	33	33	33
34	34	34	34
35	35	35	35
36	36	36	36
37	37	37	37
38	38	38	38
39	39	39	39
40	40	40	40
41	41	41	41
42	42	42	42
43	43	43	43
44	44	44	44
45	45	45	45
46	46	46	46
47	47	47	47
48	48	48	48
49	49	49	49
50	50	50	50
51	51	51	51
52	52	52	52
53	53	53	53
54	54	54	54
55	55	55	55
56	56	56	56
57	57	57	57
58	58	58	58
59	59	59	59
60	60	60	60
61	61	61	61
62	62	62	62
63	63	63	63
64	64	64	64
65	65	65	65
66	66	66	66
67	67	67	67
68	68	68	68
69	69	69	69
70	70	70	70
71	71	71	71
72	72	72	72
73	73	73	73
74	74	74	74
75	75	75	75
76	76	76	76
77	77	77	77
78	78	78	78
79	79	79	79
80	80	80	80
81	81	81	81
82	82	82	82
83	83	83	83
84	84	84	84
85	85	85	85
86	86	86	86
87	87	87	87
88	88	88	88
89	89	89	89
90	90	90	90
91	91	91	91
92	92	92	92
93	93	93	93
94	94	94	94
95	95	95	95
96	96	96	96
97	97	97	97
98	98	98	98
99	99	99	99
100	100	100	100

1 THE VIDEOGRAPHER: I think it is ten minutes
2 left.

3 MS. HENN: Okay.

4 (Exhibit No. 721 was marked.)

5 BY MR. KENNEDY:

6 Q. Let's go to the next. It's 2013.

The diagram consists of a vertical list of 20 items on the left, each represented by a small square. To the right of each item is a horizontal bar of varying length. The bars are arranged in a staggered, cascading fashion, with some items having multiple bars. The bars are gray and the background is white.

Item	Bar 1 Length (approx. %)	Bar 2 Length (approx. %)
1	95	
2		95
3	20	
4		45
5		95
6	60	100
7	85	
8	25	
9		65
10		90
11		85
12		95
13		90
14		95
15		90
16		85
17		40
18		50
19		95
20	90	

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5 Q. Do you know how many people
6 hydrocodone was killing a year at the time of this --
7 of this promotion in 2013? Do you know that?

8 A. No, I don't have any specific
9 information on that.

10 MR. KENNEDY: Let's look at 718. We are
11 still in 2013.

12 (Exhibit No. 718 was marked.)

13 BY MR. KENNEDY:

14 Q. This is Exhibit 718, -546932 to -34.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

A horizontal bar chart consisting of 25 rows. Each row features a small, solid gray square on the left side, followed by a gray bar of varying length. The bars are distributed across the rows in a non-sequential manner, with some rows having bars that span the entire width of the chart area, while others have bars that are significantly shorter. The overall pattern of the bars is irregular and non-repeating.

[illegible]

■ [REDACTED]
■ [REDACTED]
■ [REDACTED]

4 BY MR. KENNEDY:

5 Q. And, sir, when you say you are not
6 going to change thresholds without justification, let
7 me ask you very clearly, isn't it true that McKesson
8 got fined \$150 million in a 2018 agreement based upon
9 conduct, increasing thresholds without
10 documentations, during this very time period, 2012,
11 2013, 2014?

12 MS. HENN: Objection to form. Lacks
13 foundation.

14 BY MR. KENNEDY:

15 Q. Do you recall that?

16 A. Counsel, as I -- as I answered, the
17 agreement or document of 2014 or '15, whatever it
18 was, I was not with the company. I have no specific
19 knowledge of the settlement.

20 I do know that McKesson paid 150. I do not
21 understand or have reviewed the details of that
22 settlement.

23 MS. HENN: Counsel, I think we're about at
24 time, if you want to ask your last question.

25 MR. KENNEDY: All done.

1 MS. HENN: Great. So I guess we will go off
2 the record.

3 THE VIDEOGRAPHER: We are going off the
4 record. The time is 5:34 p.m.

5 (Recess taken.)

6 THE VIDEOGRAPHER: We are back on the
7 record. The time is 5:54 p.m.

8 EXAMINATION

9 BY MS. HENN:

10 Q. Good evening, Mr. Walker.

11 A. Good evening.

12 Q. Mr. Walker, you testified earlier
13 today that you joined McKesson in 1987; is that
14 correct?

15 A. That is correct.

16 Q. Before joining McKesson, where did
17 you work?

18 A. Prior to -- immediately prior to
19 working for McKesson, I worked for a grocery
20 wholesale distributor, a trucking company. And then
21 prior to that, I spent ten years in law enforcement.

22 Q. What roles did you play in law
23 enforcement?

24 A. I was a city police officer in a city
25 in the East Bay of San Francisco.

1 Q. Back to your time at McKesson. Could
2 you describe for the jury the various positions you
3 held at McKesson beginning in 1987.

4 A. 1987 I joined the company with a
5 subsidiary company in the transportation group,
6 transportation and warehousing. And that company
7 transitioned to the McKesson Drug Company in roughly
8 1991. Was in a staff role for a short period of
9 time, a staff role in transportation.

10 Then I became the Distribution Center
11 Manager in Sacramento, promoted to the Vice President
12 of Distribution Operations for the Western Region.
13 It was a newly-created position.

14 And subsequently, in roughly 1996, I was
15 promoted to the Senior Vice President of Distribution
16 for McKesson Pharmaceutical.

17 Q. And when did you become Senior Vice
18 President of Distribution for McKesson
19 Pharmaceutical?

20 A. It was 1996. I don't remember
21 exactly when in '96.

22 Q. And that was also the position you
23 held when you retired from McKesson; is that correct?

24 A. Yes, it was.

25 Q. When did you retire?

1 A. June of 2015.

2 Q. You've mentioned today that your
3 former employer, McKesson, is a wholesale distributor
4 of pharmaceuticals. Can you describe how that
5 business operates at a high level?

6 A. At a high level, McKesson, as the
7 other major distributors operate, we purchase
8 pharmaceuticals and medicines from the manufacturers.
9 We virtually warehoused all of the various
10 medications of manufacturers in our warehouses.

11 And on a daily basis, we supplied those
12 pharmaceuticals to pharmacies. And the major groups
13 of pharmacies that we had were -- are independent
14 pharmacies, single owner; or generally our retail
15 national account customers, which were the large
16 chains, like Rite Aid, and CVS and Walmart; our
17 hospital group; and then the federal government.

18 Q. And briefly, what were your job
19 responsibilities as Senior Vice President of
20 distribution operations at McKesson?

21 A. I was the senior staff operations
22 person for McKesson. I had the overall
23 responsibility for the distribution network.

24 On my staff I had a support team made up of
25 a Transportation Group, an I.T. Support Group, our

1 Regulatory Affairs Group was in there, and I had a
2 group that was responsible for construction and
3 building of our distribution centers.

4 Q. You mentioned Regulatory Affairs.
5 What kind of regulatory affairs matters were you
6 responsible for as Senior Vice President of
7 operations -- distribution operations, I should say?

8 A. McKesson, and the wholesalers as an
9 industry, are highly regulated. We have
10 responsibilities for a number of regulatory
11 requirements. The FAA, the Department of
12 Transportation, DOT, OSHA. We had hazardous material
13 requirements. Certainly we had responsibility for
14 compliance with DEA regulations. And various state
15 and local regulations as well.

Row	Start	End
1	0	100
2	0	70
3	25	95
4	0	85
5	0	100
6	0	95
7	0	95
8	0	25
9	25	95
10	0	100

A horizontal bar chart titled 'Percentage of respondents who believe that the current government is responsible for the economic crisis in the United States'. The chart displays two data series: 'Current government' and 'Previous government'. The 'Current government' series shows a value of 80%, represented by a dark blue bar. The 'Previous government' series shows a value of 20%, represented by a light blue bar. The bars are positioned side-by-side, with the 'Current government' bar on the left and the 'Previous government' bar on the right. The x-axis represents the percentage of respondents, ranging from 0% to 100%.

Government	Percentage
Current government	80%
Previous government	20%

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. And you described earlier to
10 Mr. Kennedy that you had a five-year period, I think
11 it was, when you ran McKesson's Six Sigma program; is
12 that correct?

13 A. That's correct. Roughly, in 2000 to
14 2005 I was not the Senior Vice President of
15 Operations, Distribution Operations, and did not have
16 responsibility for Regulatory during that time frame,
17 but was responsible for our Six Sigma process
18 improvement.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

[illegible]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13 MS. HENN: I'd like to show you an exhibit.

14 Let's get this marked as 84.

15 THE REPORTER: 804.

16 MS. HENN: 804. Thank you.

17 (Exhibit No. 804 was marked.)

18 BY MS. HENN:

19 Q. Mr. Walker, the court reporter handed
20 you an Exhibit No. -- that's been marked 804. The
21 Bates number is -571361 through -65.

22 MR. KENNEDY: Counsel, 804, is this a
23 defense exhibit?

24 MS. HENN: It is.

25 MR. KENNEDY: Okay. Defense Exhibit 804.

1 THE REPORTER: I just continued, if that's
2 okay, on the sequence.

3 MR. KENNEDY: Oh, okay.

4 BY MS. HENN:

5 Q. Mr. Walker, do you recognize
6 Exhibit 804?

7 A. Yes, I do.

8 Q. What is Exhibit 804?

Profession	Male (%)	Female (%)	Both (%)
1. Teacher	100	0	0
2. Doctor	100	0	0
3. Engineer	100	0	0
4. Scientist	100	0	0
5. Lawyer	100	0	0
6. Artist	100	0	0
7. Businessman	100	0	0
8. Politician	100	0	0
9. Journalist	100	0	0
10. Farmer	100	0	0
11. Chef	100	0	0
12. Nurse	0	100	0
13. Social Worker	0	100	0
14. Retailer	0	100	0
15. Freelancer	0	100	0

[illegible]

A horizontal bar chart titled "U.S. should take action to reduce greenhouse gas emissions." The y-axis lists age groups: 18-29, 30-49, 50-69, 70+, and "Don't know." The x-axis shows percentages from 0 to 100. For each age group, there are two bars: a blue bar for "Men" and an orange bar for "Women." The data is as follows:

Age Group	Men (%)	Women (%)
18-29	85	85
30-49	85	85
50-69	85	85
70+	85	85
Don't know	85	85

[illegible]

[illegible]

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

20 Q. Mr. Kennedy had a lot of questions
21 for you earlier today about a 2008 Settlement
22 Agreement between McKesson and the DEA. Do you
23 recall those questions?

24 A. Yes.

[REDACTED]

█ [REDACTED]

█ [REDACTED] █ [REDACTED]

█ [REDACTED]

█ █ [REDACTED]

5 Q. Did the 2008 Settlement Agreement
6 have provisions in it about what was to replace the
7 DU45 reporting?

8 A. Specifically in the Settlement
9 Agreement, it was agreed that there would be a
10 significant change in suspicious order reporting.
11 That at an agreed-upon time, we would cease providing
12 them a -- the DU45 suspicious order reporting, and we
13 would replace it with a format that was mutually
14 agreed upon between the two parties.

15 And probably the most significant change was
16 that we would no longer report suspicious orders to
17 field offices, as stated in the regulation because,
18 in fact, that we would be reporting directly to DEA
19 headquarters. And from that, we recognized that
20 there would be a mutual effort from the two I.T.
21 groups, being DEA and McKesson, to develop the
22 system's interface to execute the suspicious order
23 reporting.

24 MS. HENN: I'd like to mark as Exhibit 805,
25 Defense Exhibit 805, a copy of the Settlement and

1 Release Agreement from 2008.

2 (Exhibit No. 805 was marked.)

3 BY MS. HENN:

4 Q. Mr. Walker, do you recognize
5 Exhibit 805? The Bates number is -516360.

6 A. Yes, I do.

7 Q. Were you involved -- or let me just
8 ask you, what was your involvement in the process
9 that led to this 2008 Settlement Agreement with the
10 DEA?

11 MR. KENNEDY: Okay. Just to interrupt.
12 This has already been marked, do you understand? So
13 you have -- this exhibit will be marked twice?

14 MS. HENN: I'm not sure it's the same Bates
15 numbered version, but --

16 MR. KENNEDY: All right.

17 MS. HENN: -- that's fine.

18 Q. Did you want me to repeat the
19 question?

20 A. No. I think I remember your
21 question.

22 Q. Okay.

23 A. My -- my role in the overall
24 Settlement Agreement was to provide feedback to
25 counsel, who was interacting with DEA counsel, and to

1 primarily focus on operationalizing the commitments
2 that we were negotiating, making in the -- in the
3 agreement.

4 Q. And in the agreement you mentioned
5 there were provisions dealing with suspicious order
6 reporting. Could you point us to those provisions
7 that you were referring to?

8 A. Well, the first is -- is under "Terms
9 and Conditions" on page 3, 1(a), Obligations of
10 McKesson to -- Obligations of McKesson. And (a) --
11 do you want me to read this, Counsel, or --

12 Q. Yes, please.

13 A. (Reading) McKesson agrees to
14 maintain a compliance program designed
15 to detect and prevent diversion of
16 controlled substances as required
17 under the CSA and applicable DEA
18 regulations. This program shall
19 include procedures for -- to review
20 orders for controlled substances.
21 Orders that exceed established
22 thresholds and criteria will be
23 reviewed by a McKesson employee
24 trained to detect suspicious orders
25 for the purposes of determining

1 whether such orders should not be
2 filled and reported to the DEA or,
3 based on a detailed review, the order
4 is for a legitimate purpose and the
5 controlled substances are not likely
6 to be diverted into other than
7 legitimate medical, scientific, and
8 industrial channels. Orders
9 identified as suspicious will be
10 reported to the DEA as discussed in
11 subsection II (end of reading).

12 Do you want me to continue?

13 This compliance program shall apply --

14 Q. Actually, Mr. Walker, I would like to
15 stick on the subject of suspicious orders. So let's
16 continue to that cross-reference.

17 A. Okay. II.1(c). II.1(c):
18 (Reading) McKesson shall inform DEA of
19 suspicious orders as required by 21
20 C.F.R in a format mutually and
21 responsibly agreed upon by the
22 parties, except that contrary to DEA
23 regulations, McKesson shall inform DEA
24 headquarters rather than the local
25 field office of suspicious orders,

█ [REDACTED]

2 You have described the Lifestyle Drug
3 Monitoring Program. Earlier today Mr. Kennedy asked
4 you a lot of questions about the next program that
5 McKesson developed. That was called what?

6 A. The Controlled Substance Monitoring
7 Program, or CSMP.

█ █ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ █ [REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED]

█ [REDACTED]

Highly Confidential - Subject to Further Confidentiality Review

■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]

█ [REDACTED] [REDACTED]

█ [REDACTED]

3 MS. HENN: Let's mark another exhibit,
4 No. -- Defense Exhibit 806.

5 (Exhibit No. 806 was marked.)

6 BY MS. HENN:

7 Q. Mr. Walker, you've been handed
8 Defense Exhibit 806, which is Bates
9 No. McKesson-WVA-167.

10 Do you recognize this document?

11 A. Yes, I do.

12 Q. What is this?

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

█ [REDACTED]

[REDACTED]

[REDACTED]

3 MS. HENN: Let's take a look at another
4 exhibit, which I will mark -- ask the court reporter
5 to mark as 807, Defense Exhibit 807.

6 (Exhibit No. 807 was marked.)

7 BY MS. HENN:

8 Q. Mr. Walker, you've been handed
9 Defense Exhibit 807, which is a Bates No. MCK-WVA-88.

10 Do you recognize this document?

11 A. Yes, I do.

12 Q. What is it?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

[illegible]

24 MS. HENN: I'd like to mark another exhibit,
25 ask the court reporter to mark this as Defense

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 MS. HENN: Let's take a look at another
7 exhibit. This is internal No. 6. And I'm going to
8 have the court reporter mark this one as Defense
9 Exhibit 80?

10 THE REPORTER: 809.

11 (Exhibit No. 809 was marked.)

12 BY MS. HENN:

13 Q. Mr. Walker, you've been handed a
14 document marked Defense Exhibit 809, Bates
15 No. MCK-WVA-163.

16 Do you recognize Exhibit 809?

17 A. Yes, I do.

18 Q. What is it?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9 Q. Who is Maureen O'Keefe?

10 A. I don't -- she's staff coordinator,
11 according to the memo from Kyle. She was on the
12 diversion staff.

13 MS. HENN: Okay. And let's mark another
14 exhibit. This will be -- I will ask that this be
15 marked Defense Exhibit 810, please.

16 (Exhibit No. 810 was marked.)

17 BY MS. HENN:

18 Q. You've been handed Defense
19 Exhibit 810 Bates No. MCK-WVA-187.

20 Do you recognize this document, Mr. Walker?

21 A. Yes, I do.

22 Q. What is it?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11 MS. HENN: I will show you one more example.

12 We will mark this exhibit as Defense Exhibit 811,
13 please.

14 (Exhibit No. 811 was marked.)

15 BY MS. HENN:

16 Q. Mr. Walker, you've been handed
17 Defense Exhibit 811. And I don't think we have a
18 Bates number, but I will try to find out what that
19 is. Oh, actually, I know what it is, but it's not
20 appearing on the document. The Bates number is
21 -534479.

22 Mr. Walker, do you recognize Exhibit 811?

23 A. Yes, I do.

24 Q. What is it?

[REDACTED]

[REDACTED]

20 MS. HENN: Okay. I'd like to mark this
21 exhibit as 812, Defense Exhibit 812, please. But
22 Counsel, a similar document was marked, but this is
23 different, a different version.

24 (Exhibit No. 812 was marked.)

25 ///

1 BY MS. HENN:

2 Q. Mr. Walker, you've been handed
3 Defense Exhibit 812. And the Bates number, again, is
4 not appearing on the document you have, but it's
5 -542494. Or maybe it is on yours, not on mine.

6 A. I got it.

7 Q. What is Exhibit 812, if you recognize
8 it?

[REDACTED]

1	1	1	1
2	2	2	2
3	3	3	3
4	4	4	4
5	5	5	5
6	6	6	6
7	7	7	7
8	8	8	8
9	9	9	9
10	10	10	10
11	11	11	11
12	12	12	12
13	13	13	13
14	14	14	14
15	15	15	15
16	16	16	16
17	17	17	17
18	18	18	18
19	19	19	19
20	20	20	20
21	21	21	21
22	22	22	22
23	23	23	23
24	24	24	24
25	25	25	25
26	26	26	26
27	27	27	27
28	28	28	28
29	29	29	29
30	30	30	30
31	31	31	31
32	32	32	32
33	33	33	33
34	34	34	34
35	35	35	35
36	36	36	36
37	37	37	37
38	38	38	38
39	39	39	39
40	40	40	40
41	41	41	41
42	42	42	42
43	43	43	43
44	44	44	44
45	45	45	45
46	46	46	46
47	47	47	47
48	48	48	48
49	49	49	49
50	50	50	50
51	51	51	51
52	52	52	52
53	53	53	53
54	54	54	54
55	55	55	55
56	56	56	56
57	57	57	57
58	58	58	58
59	59	59	59
60	60	60	60
61	61	61	61
62	62	62	62
63	63	63	63
64	64	64	64
65	65	65	65
66	66	66	66
67	67	67	67
68	68	68	68
69	69	69	69
70	70	70	70
71	71	71	71
72	72	72	72
73	73	73	73
74	74	74	74
75	75	75	75
76	76	76	76
77	77	77	77
78	78	78	78
79	79	79	79
80	80	80	80
81	81	81	81
82	82	82	82
83	83	83	83
84	84	84	84
85	85	85	85
86	86	86	86
87	87	87	87
88	88	88	88
89	89	89	89
90	90	90	90
91	91	91	91
92	92	92	92
93	93	93	93
94	94	94	94
95	95	95	95
96	96	96	96
97	97	97	97
98	98	98	98
99	99	99	99
100	100	100	100

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

Row	Bar Length (approx. %)
1	95
2	92
3	25
4	98
5	100
6	90
7	93
8	40
9	99
10	96
11	70
12	97
13	94
14	95
15	96
16	93
17	94
18	95
19	96
20	97
21	75 10
22	98
23	100
24	90
25	80
26	93
27	95
28	50 98

A horizontal bar chart with 20 rows. Each row has a small square icon on the left and a gray bar representing a percentage. The bars vary in length and position, with some starting at the left margin and others being indented. The bars represent the following approximate percentages: 85%, 90%, 95%, 30%, 75%, 80%, 70%, 95%, 45%, 70%, 60%, 85%, 95%, 80%, 95%, 85%, 95%, 80%, 20%, 75%, 95%, 85%, 70%, 95%, 90%.

Category	Percentage
1	85%
2	90%
3	95%
4	30%
5	75%
6	80%
7	70%
8	95%
9	45%
10	70%
11	60%
12	85%
13	95%
14	80%
15	95%
16	85%
17	95%
18	80%
19	20%
20	75%
21	95%
22	85%
23	70%
24	95%
25	90%

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

16 MS. HENN: Let's just mark quickly another
17 exhibit, defense Exhibit 812.

18 THE REPORTER: 813.

19 MS. HENN: 813, thank you.

20 (Exhibit No. 813 was marked.)

21 BY MS. HENN:

22 Q. Mr. Walker, I hand you Defense
23 Exhibit 813, Bates No. MCK-WVA-230.

24 Do you recognize that document?

25 A. Yes, I do.

1 Q. What is it?

[illegible]

[illegible]

12 MS. HENN: Thank you very much, Mr. Walker.

13 I have no further questions.

14 Do you mind if we take a break? It's been a
15 long time. Let's go off the record, please.

16 THE VIDEOGRAPHER: We are going off the
17 record. The time is 7:14 p.m.

18 (Recess taken.)

19 THE VIDEOGRAPHER: We are back on the
20 record. The time is 7:38 p.m.

21 FURTHER EXAMINATION

22 BY MR. KENNEDY:

23 Q. Mr. Walker, this is Eric Kennedy.

24 I'm allowed to ask you some questions in response to
25 the questions that your lawyer asked you a few

1 moments ago; all right?

2 A. I understand that.

3 Q. And I'm going to try to keep it brief
4 because I know it's late in the day.

5 One of the things that you were shown by
6 McKesson's lawyer was Defense Exhibit 804. And that
7 was a January 18, 2006, letter written by a gentleman
8 at McKesson to the DEA. It was written by Paul
9 Julian. Do you remember that? Do you remember
10 talking about that?

11 A. Yes.

[REDACTED]

24 BY MR. KENNEDY:

25 Q. All right. And you -- actually, I

1 think you read a footnote on page -1362 of the letter
2 written to the DEA. Do you remember reading that
3 footnote?

4 MS. HENN: Objection to form.

5 BY MR. KENNEDY:

6 Q. Sir, do you remember reading that
7 footnote?

8 A. Counselor, I remember describing the
9 content of the footnote. I don't remember that -- I
10 don't recall that I read it specifically. I just
11 want to be clear.

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8 MR. KENNEDY: Could you give me 686,
9 Exhibit 686.

10 Q. And this is the Settlement Agreement
11 with respect to the Internet pharmacy dosages; right?

12 I'm going to pull it up so we can look at
13 it.

14 MS. HENN: Well, he may want it.

15 BY MR. KENNEDY:

16 Q. If you will go to the second page of
17 that Settlement Agreement.

18 A. I got it.

19 MS. HENN: Great.

20 BY MR. KENNEDY:

21 Q. And so the DEA, the conduct that they
22 were talking about was three million dosages to
23 Maryland; right? In Maryland, three million doses.
24 2.1 million into Florida. 2.6 million into Texas.
25 824,000 into Utah. Right?

1 I mean, that's what this DEA settlement was
2 all about for conduct in '04, '05, and '06; right?
3 Correct?

4 A. This settlement covered the
5 allegations that DEA made. So yes.

[REDACTED]

1	2	3	4
5	6	7	8
9	10	11	12
13	14	15	16
17	18	19	20
21	22	23	24
25	26	27	28
29	30	31	32
33	34	35	36
37	38	39	40
41	42	43	44
45	46	47	48
49	50	51	52
53	54	55	56
57	58	59	60
61	62	63	64
65	66	67	68
69	70	71	72
73	74	75	76
77	78	79	80
81	82	83	84
85	86	87	88
89	90	91	92
93	94	95	96
97	98	99	100
101	102	103	104
105	106	107	108
109	110	111	112
113	114	115	116
117	118	119	120
121	122	123	124
125	126	127	128
129	130	131	132
133	134	135	136
137	138	139	140
141	142	143	144
145	146	147	148
149	150	151	152
153	154	155	156
157	158	159	160
161	162	163	164
165	166	167	168
169	170	171	172
173	174	175	176
177	178	179	180
181	182	183	184
185	186	187	188
189	190	191	192
193	194	195	196
197	198	199	200
201	202	203	204
205	206	207	208
209	210	211	212
213	214	215	216
217	218	219	220
221	222	223	224
225	226	227	228
229	230	231	232
233	234	235	236
237	238	239	240
241	242	243	244
245	246	247	248
249	250	251	252
253	254	255	256
257	258	259	260
261	262	263	264
265	266	267	268
269	270	271	272
273	274	275	276
277	278	279	280
281	282	283	284
285	286	287	288
289	290	291	292
293	294	295	296
297	298	299	300
301	302	303	304
305	306	307	308
309	310	311	312
313	314	315	316
317	318	319	320
321	322	323	324
325	326	327	328
329	330	331	332
333	334	335	336
337	338	339	340
341	342	343	344
345	346	347	348
349	350	351	352
353	354	355	356
357	358	359	360
361	362	363	364
365	366	367	368
369	370	371	372
373	374	375	376
377	378	379	380
381	382	383	384
385	386	387	388
389	390	391	392
393	394	395	396
397	398	399	400
401	402	403	404
405	406	407	408
409	410	411	412
413	414	415	416
417	418	419	420
421	422	423	424
425	426	427	428
429	430	431	432
433	434	435	436
437	438	439	440

1 BY MR. KENNEDY:

2 Q. Between 2000 and 2005, you said you
3 were out of Regulatory for that period of time, and
4 what was your job?

5 A. I was -- I can't remember my specific
6 title, but I was the Senior Vice President overseeing
7 Six Sigma.

8 Q. And what did that involve? Did that
9 involve regulation of controlled substances?

10 A. Not at all.

11 Q. Not at all.

12 How many meetings with the DEA did you go to
13 between 2000 and 2005?

14 A. None.

15 Q. How many DEA seminars did you go to
16 between 2000 and 2005?

17 A. None that I remember.

18 Q. How many regulatory meetings did you
19 go to at McKesson between 2000 and 2005 with respect
20 to controlled substances?

21 A. I don't recall going to any.

■ ■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

Highly Confidential - Subject to Further Confidentiality Review

[REDACTED]

[illegible]

Responsibility	Percentage
Current government	85%
Previous government	10%
No government	5%

4 MS. HENN: Counsel, I'm going -- we're going
5 to need to go off the record so the court reporter
6 can get her car out of the garage.

7 THE VIDEOGRAPHER: We are going off the
8 record. The time is 7:50 p.m.

9 (Off the record.)

10 THE VIDEOGRAPHER: We are back on the
11 record. The time is 7:58 p.m.

12 BY MR. KENNEDY:

The diagram consists of 14 horizontal gray bars of varying lengths and positions, arranged vertically. The bars represent a sequence of events or a timeline. The first bar is short and positioned on the left. The second bar is long and spans most of the width. The third bar is long and spans most of the width. The fourth bar is long and spans most of the width. The fifth bar is long and spans most of the width. The sixth bar is long and spans most of the width. The seventh bar is long and spans most of the width. The eighth bar is long and spans most of the width. The ninth bar is long and spans most of the width. The tenth bar is long and spans most of the width. The eleventh bar is long and spans most of the width. The twelfth bar is long and spans most of the width. The thirteenth bar is long and spans most of the width. The fourteenth bar is long and spans most of the width.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10 BY MR. KENNEDY:

11 Q. Let's look at how diligent you were
12 in executing, then. Let's look at Exhibit 730, if we
13 could.

14 MR. ASQUITH: It's a new one.

15 MS. HENN: Do you have a copy? That's the
16 only copy.

17 Oh, this is an exhibit you withdrew. There
18 you go.

19 (Exhibit No. 730 was marked.)

20 BY MR. KENNEDY:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

15 BY MR. KENNEDY:

16 Q. Exhibit 730 is an audit done by
17 McKesson in March of 2011. Is that what it says on
18 the cover page, March of 2011 Audit Report?

19 A. Yes.

20 Q. If you go to page -498069. Do you
21 see that? "Level 1 Forms," do you see that title?
22 Level 1 Forms.

23 A. Yes.

24 Q. Delran, what is that? Is that one of
25 your distribution centers?

1 A. Delran, New Jersey was one of our
2 distribution centers.

[illegible]

1 Q. Now, New Castle. This is another
2 distribution center; right?

3 A. Yes.

4 Q. Under that one it says:

14 Q. Washington Court House, is that
15 another distribution center?

16 A. Yes, it is.

17 Q. Does that say:

25 Q. Conroe, on the next page. That's

1 another distribution center; is it not?

2 A. Yes, it is.

3 Q. Does that state:

Government	Percentage
Current government	85%
Previous government	15%

Response	Percentage
Yes, the U.S. should take action to reduce greenhouse gas emissions	92%
No, the U.S. should not take action to reduce greenhouse gas emissions	8%

[illegible]

10 of 10

Highly Confidential - Subject to Further Confidentiality Review

■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED] [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED] ■
■	[REDACTED]
■	■ [REDACTED] [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	[REDACTED]
■	■ [REDACTED]
■	■ [REDACTED]
■	[REDACTED] [REDACTED] [REDACTED] [REDACTED]
■	[REDACTED]
■	■ [REDACTED] [REDACTED] ■
■	■ [REDACTED] ■
■	[REDACTED]
■	■ [REDACTED]

[illegible]

[illegible]

24 BY MR. KENNEDY:

25 Q. Is Landover one of your distribution

1 centers, sir?

2 A. Landover was one of our distribution
3 centers. It closed in 2012, I believe.

4 Q. And this comes from the DEA, so you
5 should be aware of this.

[REDACTED]

23 BY MR. KENNEDY:

24 Q. Livonia, is that a distribution
25 center of McKesson?

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7 BY MR. KENNEDY:

8 Q. Metheun, Massachusetts, is that
9 another distribution center?

10 A. Yes, it is.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

25 Q. Sir, didn't McKesson get fined

1 \$150 million by the DEA because of their failures
2 with respect to the 2008 program, leading all the way
3 up from 2008 and '09, '10, '11, '12, '13, '14, '15,
4 '16, and '17? \$150 million.

5 MS. HENN: Objection to form.

6 BY MR. KENNEDY:

7 Q. Do you recall that, sir?

8 MS. HENN: Objection to form. Lacks
9 foundation. Mischaracterizes.

10 THE WITNESS: All that I'm aware of is
11 that -- and because it was public information, is
12 that McKesson paid \$150 million. I don't understand
13 any of the details of the settlement, of the
14 documentation, because all of it occurred after I
15 left the company.

16 BY MR. KENNEDY:

17 Q. When did you leave the company?

18 A. In June of 2015.

19 Q. And the DEA fine of \$150 million
20 involved conduct from '08 to '15, while you were the
21 head of Regulatory; do you understand that?

22 MS. HENN: Objection to form. Lacks
23 foundation.

24 THE WITNESS: Again, Counsel, I was not here
25 when they -- all of that was finalized and completed.

1 So I don't understand what was in the allegations
2 presented by the DEA.

3 MR. KENNEDY: Give me P.88, please. This is
4 Exhibit 814.

5 (Exhibit No. 814 was marked.)

6 BY MR. KENNEDY:

7 Q. If you will look at that very last
8 page. Do you see that this is dated 1-5-17, at least
9 the signatures, one of the signatures? 1-5-17, it's
10 on the back cover.

11 A. Yes.

12 Q. If you look at the front cover, the
13 front page, is this titled, "Administrative
14 Memorandum Agreement?

15 A. Yes, it is.

16 Q. And does the first paragraph say:
17 (Reading) The Administrative
18 Memorandum Agreement is entered into
19 by and between the United States
20 Department of Justice, Drug
21 Enforcement Administration, and
22 McKesson Corporation (end of reading)?

23 Is that what it says?

24 A. Yes.

25 Q. And if you'll go to page 88.3 up at

1 the -- up at the top. And look at No. 2. Does No. 2
2 say, "Acceptance of Responsibility"?

3 A. Yes.

4 Q. That's acceptance of responsibility
5 by McKesson; isn't it, sir?

6 MS. HENN: Objection to form.

7 BY MR. KENNEDY:

8 Q. Is that what that means?

9 MS. HENN: Objection to form.

10 THE WITNESS: That's what it says, Counsel.
11 Quite honestly, I don't know under the legal terms of
12 a settlement agreement what that means. I don't have
13 the legal expertise.

14 BY MR. KENNEDY:

15 Q. Well, so what I'm -- can you explain
16 to me how you can come in here and tell us that
17 McKesson was diligent and aggressive in following and
18 implementing its 2008 agreement, and you haven't read
19 the settlement covering that same period of time with
20 respect to the implementation of that program? How
21 can you -- how can you not have read this?

22 MS. HENN: Objection to form.

23 THE WITNESS: Counsel, I wasn't with the
24 company when -- to my knowledge, when this document
25 was -- was generated.

1 BY MR. KENNEDY:

2 Q. How many hours have you spent with
3 McKesson's lawyer prior to today reviewing documents
4 and other materials in preparation for today's
5 testimony? How many hours, sir?

6 A. A number of them.

7 Q. How many, sir?

8 A. Five or six.

9 Q. And how many different days, sir?

10 A. How many different days?

11 Q. Yes.

12 A. Five or six.

13 Q. Five or six days?

14 A. Yes.

15 Q. And they never showed you this
16 document before you came in here to testify that
17 McKesson was aggressive and diligent in implementing
18 its policies? You were never shown this?

19 A. In reviewing this document, I think
20 it was shown. This document, I believe, we did not
21 cover in detail.

22 Q. Well, under "Acceptance and
23 Responsibility," go down about four or five lines
24 down in the middle where the sentence starts with,
25 "McKesson."

1 Does it state:

2 (Reading) McKesson acknowledges that,
3 at various times during the period
4 from January 1, 2009, up through and
5 including the effective date of this
6 agreement (the covered period of
7 time), it did not identify or report
8 to DEA certain orders placed by
9 certain pharmacies which should have
10 been detected by McKesson as
11 suspicious based upon the guidance
12 contained in the DEA letters about the
13 requirements set forth in 21 C.F.R
14 1301.74(b) and 21 U.S.C 842(a)(5)
15 (end of reading)?

16 Do you see where it states that McKesson
17 acknowledged those failures; sir? Is that what it
18 states?

19 MS. HENN: Objection to form.

20 THE WITNESS: That's what the document
21 states.

22 BY MR. KENNEDY:

23 Q. Look down to the next paragraph, if
24 you would. About five lines down it starts with
25 "McKesson." Do you see that?

1 A. Yes.

2 Q. Does it state, again:

3 (Reading) McKesson acknowledges that,
4 at various times during the covered
5 time period, it did not identify or
6 report to DEA certain orders placed by
7 certain pharmacies which should have
8 been detected by McKesson as
9 suspicious in a manner fully
10 consistent with requirements set forth
11 in the 2008 Memorandum of
12 Understanding (end of reading)?

13 Is that what it states?

14 A. That's -- yes, that's what it states.

15 Q. Covered conduct, No. 3, A. Does it
16 state:

17 (Reading) McKesson failed to maintain
18 effective controls against diversion
19 of particular controlled substances
20 into other than legitimate medical,
21 scientific, and industrial channels by
22 sales to certain of its customers in
23 violation of the Controlled Substance
24 Act and the Controlled Substance Act's
25 implementing regulations (end of

1 reading)?

2 Does it say that?

3 A. Yes.

4 Q. And then does it outline the
5 different distribution centers where these failures
6 occurred, sir?

7 MS. HENN: Objection to form.
8 Mischaracterizing the document.

9 BY MR. KENNEDY:

10 Q. Does it outline the distribution
11 centers where this conduct occurred?

12 MS. HENN: Same objection.

13 BY MR. KENNEDY:

14 Q. Does it, sir?

15 A. Just a minute.

16 What I -- what I read is that the
17 distribution centers listed there -- it said at
18 McKesson -- at the distribution centers, including
19 the following, with the list of distribution centers
20 that are down below.

21 Q. Right. Distribution center --
22 McKesson Distribution Center in Colorado, Illinois,
23 New Jersey, Wisconsin, Florida, Maryland, Nebraska,
24 Michigan, Massachusetts, and California; correct?

25 A. That's what's written in the

1 document.

7 Q. Let's look to the next page. If we
8 look at C, this was specific to what you've been
9 telling us. Does it state on C:

10 (Reading) McKesson failed to follow
11 the procedures and policies set forth
12 in the McKesson CSMP to detect and
13 disclose suspicious orders of
14 controlled substances (end of
15 reading)?

16 Is that what it states, sir?

17 A. Yes, that's what the document states.

18 Q. Does it next state:

19 (Reading) Among other things, McKesson
20 failed to conduct adequate due
21 diligence of its customers, failed to
22 keep complete and accurate records of
23 the CSMP files maintained for many of
24 its customers, and bypassed suspicious
25 order reporting procedures set forth

1 in McKesson's CSMP (end of reading)?

2 Did I read that right?

3 A. You read that correctly.

4 Q. And, sir, could we agree -- and I'm
5 only going to ask you one more time. Could we agree
6 that writing a policy, putting it on paper, meeting
7 with the FDA [sic] and saying these are our policies,
8 that doesn't do anybody any good unless you follow
9 your own policies?

10 MS. HENN: Objection to form.

11 BY MR. KENNEDY:

12 Q. Could we agree to that, sir?

13 A. I don't agree with that statement. I
14 strongly believe that we were executing and doing
15 everything in our capability that we could to manage
16 our Controlled Substance Monitoring Program.

17 Q. And the FDA [sic] disagreed when they
18 fined you \$150 million; correct?

19 MS. HENN: Objection to form.

20 THE WITNESS: Again, I'm not going to
21 speculate, because I wasn't involved in the process
22 of how that was negotiated and reached.

23 MR. KENNEDY: I have nothing further. Thank
24 you, sir.

25 MS. HENN: We have no further questions

1 either.

2 We have just two things to note. We would
3 request that the transcript be designated highly
4 confidential pending review and further designations.

5 And we request that the witness have the
6 opportunity to read and sign.

7 Thank you very much.

8 THE VIDEOGRAPHER: This concludes the video
9 deposition of Donald Walker, consisting of eight
10 media.

11 The time is 8:23 p.m. We are off the
12 record.

13 (The deposition was concluded at 8:23 p.m.)

14 --o0o--

15

16

17

18

19

20

21

22

23

24

25

1 Please be advised I have read the foregoing
2 deposition, and I state there are:

3 (Check one) _____NO CORRECTIONS

4 _____CORRECTIONS PER ATTACHED

5

6

7

8 _____
DONALD WALKER

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 DEPONENT'S CHANGES OR CORRECTIONS

2 Note: If you are adding to your testimony, print the
3 exact words you want to add. If you are deleting from
4 your testimony, print the exact words you want to
5 delete. Specify with "Add" or "Delete" and sign this
6 form.

7 DEPOSITION OF: DONALD WALKER

8 CASE: IN RE NATIONAL PRESCRIPTION OPIATE LITIGATION

9 DATE OF DEPOSITION: JANUARY 10, 2019

10	PAGE	LINE	CHANGE/ADD/DELETE/REASON
11	_____	_____	_____
12	_____	_____	_____
13	_____	_____	_____
14	_____	_____	_____
15	_____	_____	_____
16	_____	_____	_____
17	_____	_____	_____
18	_____	_____	_____
19	_____	_____	_____
20	_____	_____	_____
21	_____	_____	_____
22	_____	_____	_____
23	_____	_____	_____

24 DEPONENT'S SIGNATURE _____

25 DATE _____

1 CERTIFICATE OF REPORTER

2 I, SANDRA BUNCH VANDER POL, a Certified
3 Shorthand Reporter, hereby certify that the witness in
4 the foregoing deposition was by me duly sworn to tell
5 the truth, the whole truth and nothing but the truth
6 in the within-entitled cause;

7 That said deposition was taken down in shorthand
8 by me, a disinterested person, at the time and place
9 therein stated, and that the testimony of the said
10 witness was thereafter reduced to typewriting, by
11 computer, under my direction and supervision;

12 That before completion of the deposition, review
13 of the transcript was requested. If requested, any
14 changes made by the deponent (and provided to the
15 reporter) during the period allowed are appended
16 hereto.

17 I further certify that I am not of counsel or
18 attorney for either or any of the parties to the said
19 deposition, nor in any way interested in the event of
20 this cause, and that I am not related to any of the
21 parties thereto.

22 DATED: JANUARY 14, 2019

23

SANDRA BUNCH VANDER POL, CSR 3032

24

25